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Abstract 
The importance of active drug transport in determining chemical fate is becoming increasingly 
clear, with efflux transporters such as MDR1, MRP2 and BCRP recognised as key determinants 
of drug action. The impact have been shown to impact compound bioavailability through first-
pass effects; determine target site drug concentrations through affecting drug distribution; and 
drive drug resistance through their up-regulation following chronic drug exposure. While the 
role of these transporters is well established, less is known about transporters such as MRP3 
and MRP4, which act to move chemicals back into the systemic circulation rather than target 
them for elimination. In this thesis the hypothesis examined states, “transport and metabolism 
processes are balanced to allow for efficient handling of both endogenous and xenobiotics 
substrates into the excreta and systemic circulation”.  
To examine this hypothesis a portion of the molecular interaction network of active drug 
transporters, passive transport and drug metabolising enzymes that determines the biological 
fate of 17β-estradiol in the liver was reconstructed. The model was parameterised using 
experimentally-derived kinetic and abundance values where available, or biologically realistic 
estimates. The behaviour of the model was validated against in vitro measurement of estradiol 
fate in primary human hepatocytes. As such the model represents, to the best of our knowledge, 
the situation occurring in the liver.  
Under steady-state conditions and physiologically relevant concentrations of 17β-estradiol 
robust network behaviour was predicted, with network flux predominantly via passive 
processes. To examine the role of dietary constituents on network behaviour, the impact of the 
flavonoid compounds hesperidin and naringin on MRP3 and MRP4-dependent transport was 
determined experimentally.  Inhibitory constants were then applied to the in silico model of 
estradiol metabolism, predicting a complete loss of basolateral efflux by MRP4 and redirection 
of estradiol glucuronide transport via apical transporters. 
In summary, we present a computational approach to examine the relative input of network 
components in determining drug fate, and the impact of food chemical interactions. Such 
computational approaches provide novel systems to examine the impact of genetic variation or 
transporter-specific inhibitors on drug fate and, hence, efficacy.  
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1.0  Introduction 
In a little over a century life expectancy has increased by approximately sixty per cent, largely 
due to better quality public health and increased knowledge of both medical conditions and our 
ability to treat them.  Drugs such as antibiotics and statins have radically changed the healthcare 
front, however globally the pharmaceutical industry is faced with unprecedented challenges of 
a globally ageing population, and this provides an ever increasing need for the development of 
new therapies against diseases such as Alzheimer’s and cancer, along with the growing issues 
such as antibiotic resistance and HIV therapies (Kola and Landis, 2004).   
In no other industry does it cost so much, or take so long, to bring a product to market as it 
does within the pharmaceutical industry. Progress in all of the aforementioned areas have been 
slowed by low numbers of new chemical entities (NCEs) being approved for further drug 
development and fewer passing through the entirety of the drug development pipeline.  The 
average success for compounds that made it through the development process, and got to 
approval by the regulatory authorities during the period 1991-2000, was only one in nine 
compounds, approximately eleven per cent. These success rates are also shown in Figure 1.1 
to vary between therapeutic areas, with the most successful drug approval seen in 
cardiovascular disease with twenty per cent passed and the poorest seen in central nervous 
system (CNS) disorders and oncology with eight and five per cent (Kola and Landis, 2004, Yu 
and Adedoyin, 2003). To highlight the obstacles faced by drug companies when bringing new 
compounds to market I will discuss the different phases to the drug development pipeline and 
the issues that arise. 
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Figure 1.1. The success rates of different therapeutic classes of NCEs from Phase I clinical 
trials up to approval and registration by the drug authority. Data from 1991-2000 of ten 
of the biggest drug companies was analysed for their overall success from the first clinical trial 
to registration, showing that overall in the industry only 11% of compounds were successful 
with the largest successes seen in cardiovascular disease and the poorest in oncology and 
women’s health (Kola and Landis, 2004). 
There are two clear stages to the drug approval process, as shown in the drug development 
pipeline (figure 1.2) which all pharmaceutical products go through; the first is pre-clinical with 
drug discovery and screening in animal models and the second is clinical analysis of the drug 
compound with human studies. In the pre-clinical phase large numbers of NCEs are identified 
in the lab and these are often structurally similar. Any promising candidates are selected and 
tested using in vitro models that aid the examination of their binding to receptors, effects on 
enzyme activities, toxic effects, or other in vitro pharmacologic parameters. Candidates that 
have not exhibited favourable characteristics are terminated from further development; those 
that are not rejected are then prepared for in vivo studies, in multiple animal species, where 
they can be tested for their efficacy and safety in a biological system. This allows identification 
of any longer term and system toxicity issues which would not be detected in in vitro studies.  
The compound with the best characteristics from these studies is selected and the obtained data 
is submitted as an investigational new drug (IND) application to the drug authority to allow 
progression to clinical trials (Savers, 2006, Kola and Landis, 2004).  Although data gathered 
from the preclinical trials is valuable to the decision of which drug candidates undergo further 
development, this data cannot be extrapolated so as to predict exactly what will happen in 
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humans, and therefore many drugs can fail in any of the clinical phases due to unexpected 
interactions and side effects (Roses, 2008).  
 
Figure 1.2. The drug development pipeline; The first stage is Pre-clinical where new 
compounds are tested in in vitro and in vivo studies and clinical where a new compound is 
tested in human trials to check for adverse reactions. Both stages required for market approval. 
 
Clinical testing of the drug investigates both the safety and efficacy of a drug in the human 
population and these studies can take up to six years to complete before approval to market the 
drug. Phase I uses a small number of healthy volunteers, twenty to eighty people, and these 
studies are designed to verify the safety and tolerability of the candidate drug in humans, which 
can take approximately six to nine months. Candidates are observed all the time and careful 
documentation of how the drug acts in the body is made allowing assessment of the dosing 
range and appropriate dosing for therapeutic use can be identified along with the effect of food 
consumption on the drug absorption by the body. Phase II trials commence once patient safety 
has been established through healthy volunteer Phase I trials (Roses, 2008).  
Phase II trials are carried out in patients with the disease the drug is targeted to treat and the 
safety and efficacy in these compromised patients is assessed. This trial can take anywhere 
from three months to three years, using twenty to three hundred candidates in a randomized 
trial of the drug.  In a randomized trial, one cohort receives the drug and the other cohort 
receives a placebo; indeed, most trials are double blinded such that both the patients and 
researchers conducting the trial do not know who is receiving what drug to avoid bias in the 
results. On completion of the trial data is analysed and the therapeutic benefit of the drug is 
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assessed and if deemed suitable it is carried on to Phase III.  However drugs can be identified 
to have poor therapeutic effect or negative side effects in these ill patients and development 
can be terminated at this stage (Roses, 2008). 
Phase III testing is similar to phase II, measuring both the safety and efficacy of the drug in ill 
patients between different populations and hundreds to thousands of patients, taking up to four 
years to complete. It is usually required for there to be at least two successful trials carried out 
before the drug receives approval from the necessary authorities, European Medicines Agency 
(Europe) Food and Drug Administration (USA). Reasons to terminate a drugs development can 
also be found at this late stage, with evidence of toxicity in populations or side effects not seen 
before, which ultimately sees the whole cost of a drugs development footed by the company, 
without the opportunity to recoup the cost (Roses, 2008, Kola and Landis, 2004).  
Successful compounds that do reach approval and are marketed are sometimes removed later 
due to toxicities not discovered during these extensive testing stages and the most common 
reason for a drugs removal from the market is the occurrence of drug induced liver toxicity 
(Liu et al., 2011). This can be somewhat attributed to the nature under which the pre-clinical 
and clinical studies are run with the use of homogenous animal models and specific cohorts of 
people whom fall within certain characteristics; i.e. defined by BMI, age and sex.  This cannot 
possibly represent the general population with respect to factors such as genetics and 
metabolism, which are so varied across the population. It is therefore unlikely that all these 
differences are highly, if at all, represented within the clinical studies and for this reason any 
potentially sensitive sub-populations may well be missed during these studies and only arise as 
an issue once marketed and supplied to large numbers of people.  Drug authorities may restrict 
use of the drug or withdraw from the market if they deem an alternative drug to be a safer 
option (Chen and Kodell, 2010, Ma and Lu, 2011, Lu and Klaassen, 2008).   
With the discovery and subsequent development of new drugs being such a long and expensive 
process, along with poor compound success as discussed before, it is important for the industry 
to develop a better understanding of why these drugs are failing and where possible prevent 
later drug withdrawal due to unpredicted toxicities. Key factors to take into consideration, when 
designing these new compounds, are the absorption, distribution, metabolism and excretion 
(ADME) properties. By studying these components of a drug we can predict the 
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pharmacological activity and potential success of the compound and make the drug discovery 
process more cost effective. 
1.1 Absorption, Distribution, Metabolism and Excretion (ADME) 
The phases of ADME describe the interactions between a drug and the body, together 
determining the disposition of a compound within an organism, and impacting on both drug 
pharmacokinetics and pharmacodynamics (Li, 2001). To begin with I will outline the major 
factors for each of the phases of ADME, and how these can affect drug action. 
1.1.1 Drug Absorption  
The absorption of compounds into the systemic circulation, such as drugs, occurs at three main 
sites; the skin, lungs and the gastrointestinal (GI) tract.  The general process of drug absorption 
and distribution will be covered further down; first I will consider the role of these three 
absorption routes and their unique properties.  
The skin is constantly exposed to xenobiotics due to its location as the external face of the 
body. However, its structure is designed to reduce absorption and protect the body from 
unwanted exposures. The skin is composed of the epidermis (stratum basale and stratum 
corneum), the dermis and underlying fatty tissue, with hair follicles crossing the dermis and 
epidermis as shown in Figure 1.1.1A. The upper epidermal cells (stratum corneum) are dead, 
and act as a barrier between the environment and the vasculature, reducing absorption. Drug 
exposure to the skin can occur through two deliberate routes: First, a number of skin conditions 
such as eczema or fungal infections like athletes foot require topical treatments.  These 
treatments include the application of ointments, creams or powders to the skin such as 
corticosteroids or ketoconazole.  In such cases, the minimal absorption through the skin is 
actually beneficial, allowing the use of drugs that would be systemically toxic, such as 
polymixins.  Second, transdermal patches can be used to bypass the barrier of the skin, 
delivering active ingredients across the skin into the underlying vasculature.  This provides the 
drug a means to avoid first pass metabolism and the fluctuations in plasma levels of a drug 
when administered orally (Martinho et al., 2011, Timbrell, 2001).  
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Figure 1.1.1. Drug absorption into the systemic circulation across the skin and aveolar 
barriers. (A) The different layers which make up the skin defence protecting the body from 
absorbing and exposing the systemic circulation to unwanted xenobiotics. (B) The basic 
alveolar structure, which is surrounded with a two cell thick membrane coated with surfactants 
and cilliary hair to capture and aid the removal of unwanted microbes and xenobiotics from 
entering the systemic circulation (Martinho et al., 2011) 
(http://embryology.med.unsw.edu.au/embryology/). 
 
The lungs represent an ideal site for drugs and other foreign substances to be absorbed into the 
circulation. As a consequence of their major biological role of absorbing oxygen, they possess 
a large blood flow around the alveoli of the lungs, and the cell barrier between the air in the 
lungs and the blood is only up to two cells thick as shown in Figure 1.1.1.B. Hence, particulate, 
vapour and gaseous substances in the air may be rapidly absorbed via this route (Timbrell, 
2002).  However, the mucosal layers of the airways do provide some protection, with both 
mucus and cilliary hair trapping and removing any foreign substances from the airway, 
reducing absorption into the alveoli cells.   
The GI tract is considered the most common route of entry for foreign substances, due to the 
physiological adaptations to aid absorption of food and fluids, and the high exposure achievable 
through tablet formulations.  The GI tract has a plentiful supply of blood, allowing the rapid 
and efficient absorption of nutrients from the lumen, and this facilitates the uptake of foreign 
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substances into the systemic circulation.  In addition to these general adaptations to optimise 
absorption, the GI tract can be divided into several sections, each with varying pH levels, 
enterocyte composition and enzyme expression, ensuring optimal absorption conditions for a 
wide range of different chemical species at some point within the GI tract. This importance of 
the gut microbiome is becoming increasingly recognised, providing a means of processing both 
nutrients and xenobiotics, potentially altering their absorption characteristics (Nicholson et al., 
2005).  
With many drugs given orally to increase both patient convenience and compliance, there is a 
need to design a drug (and drug formulations) that can not only traverse the plethora of 
obstacles before absorption can occur, but can also take advantage of them. In order to do this, 
drug discovery requires a good understanding of gut biological and molecular physiology, 
leading to therapeutic interventions that ensure sufficient drug can pass through the GI tract 
and be absorbed into the systemic circulation so as to be effective for the patient.   On its 
journey through the GI tract drug will be degraded due to changes in luminal pH and bacterial 
enzymes.  As such, it is important to contain drugs within formulations that minimise loss due 
to these effects.  For example, bacterial content increases down the GI tract, meaning that more 
drugs would be lost due to bacterial metabolism in the colon compared to the duodenum; due 
to this, the majority of drug absorption occurs higher in the GI tract, before significant 
quantities of active ingredient are lost through metabolism (Silverthorn et al., 2009, Gibson 
and Skett, 2001, Timbrell, 2001). 
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Figure 1.1.2. A Schematic of the first pass metabolism effect. This figure shows a basic 
schematic of different routes of drug administration and its absorption into the systemic 
circulation.  A drug is often given orally for patient compliance however large drug loss is seen 
in the passage of the drug through the GI tract and liver before it reaches the systemic 
circulation, often requiring large doses being prescribed to get the desired therapeutic dose.  
Some drugs such as morphine are very susceptible to this effect and this can be bypassed 
through intravenous injection of drug. 
 
Even when drug has been absorbed from the gut lumen into the enterocytes systemic absorption 
is not assured due to the process of first pass metabolism which is shown in Figure 1.1.2. This 
is contributed to by enzymes present in the gut walls, and everything that is absorbed from the 
GI tract is taken directly to the liver via the hepatic portal vein, where hepatic enzymes will 
also metabolise drugs, creating metabolites with increased water solubility suitable for 
excretion out of the liver via the canalicular membrane into the bile.  In addition to enzyme 
metabolism, drug absorption can also be limited by transport back into the gut lumen by efflux 
proteins present in both the intestinal enterocytes and liver hepatocytes.  All these factors 
contribute to the first pass metabolism effect, reducing the availability of drug for the systemic 
circulation (Gibson and Skett, 2001, Pond and Tozer, 1984).     
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It is possible to directly bypass the absorption phase through the injection of drugs, which is 
administration of a drug by parenteral injection, either intravenously (directly into the 
circulation) or intramuscularly (into the muscle). Administration of a drug by injection may be 
preferred as an alternate route of exposure where the oral route is not possible, either due to 
poor absorption or a significant first pass effect.  This is an important route of administration 
for drugs such as adrenaline, which are administered in cases of anaphylactic shock or cardiac 
arrest, where the drug is required immediately by the target tissue (Coleman, 2005).  The use 
of the injection route must be weighed against the negative impact upon patient 
convenience/compliance, plus the risk of injection site inflammation. As such, it is usually 
restricted to either patient groups that are highly trained (e.g type I diabetics) or limited to 
administration by trained medical professionals. 
1.1.2 Cell Membranes 
Cell membranes define the boundaries between cells protecting and regulating what can enter 
the interior of the cell, and the converse. These membranes share a common general structure, 
being composed mainly of phospholipids arranged as a bilayer with proteins dispersed 
throughout, as shown in Figure 1.1.13. The types and number of proteins integrated in the 
membrane varies depending on the cell type, and these may be structural or possess a specific 
function, such as acting as sensors of external signals allowing a cell to adapt and respond to 
the environmental signal (Quinn, 2010, Alberts et al., 2005).  Small molecules including drugs 
can cross a membrane in several ways, although this can be divided into two general categories; 
Passive, facilitated and active transport, which all involve movement of molecules across the 
membrane and will be specifically discussed here, whereas phago/pinocytosis and paracellular 
transport utilise alternate mechanisms (Timbrell, 2002).  The preferred route of transport for a 
small molecule is primarily defined by its physio-chemical properties: Passive transport needs 
a concentration gradient across the membrane with the compound transported being lipid 
soluble; facilitated transport requires a specific membrane carrier, may transport polar and non-
polar molecules, and requires a concentration gradient; although no energy expenditure is 
required for either of these forms of transport. Pinocytosis and phagocytosis both use 
invagination of the membrane around a particle allowing for the movement in and out of the 
cell, respectively.  Active transport uses a specific membrane carrier that requires energy 
expenditure to transport polar and non-polar molecules against a concentration gradient 
(Gibson, 2001).   
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For several years drug design has worked on the assumption that the majority of cellular uptake 
of molecules is through passive diffusion, with drugs being designed based on Lipinskis rule 
of five, a set of parameters a compound must fulfil to be considered as likely to undergo 
efficient passive diffusion into cells (Lipinski et al., 2001). However, this paradigm is 
becoming increasingly challenged, with Dobson and Kell, (2008) arguing that the role of 
protein transporters in cellular uptake should be considered the rule rather than being the 
exception to passive diffusion. This argument is supported by the fact drugs can accumulate 
within particular tissues and do not just leak out into the surrounding areas, which would be 
expected if it were just passive diffusion responsible for drug movement. There are also many 
drugs currently consumed which fall outside this traditional rule of five approach, such as 
antibiotics and antifungals, and have structural features that allow them to act as substrates for 
 
Figure 1.1.3. The common structure of biological membranes. The above is a lipid 
matrix model showing the different phospholipids (Phophatidylcholine (PC) and 
Phosphatidylethanolamine (PE)) and transmembrane proteins which make up a 
complex membrane structure, allowing control of movement in and out of the internal 
cell environment (Quinn, 2010). 
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naturally occurring transporters and this highlights the important role that transporters play in 
the distribution of drug. 
 
1.1.3 Drug Distribution 
The distribution of a drug around the body is an important part of drug action as it determines 
the concentration of drug in each organ. It is mediated through the systemic circulation, with 
well perfused organs such as the lungs and heart receiving an increased exposure to any drug 
within the circulation, compared to tissues such as bone and teeth, which have minimal blood 
supply and therefore less drug exposure. Therefore the target tissue has to be of consideration 
when prescribing a dose, both to ensure efficacy in the target tissue and prevent toxicity in 
secondary organs. 
Blood perfusion to organs is not the only determinant of drug distribution: Non-specific binding 
within the body, such as sequestration of lipophillic drugs in adipose tissue, can also be a major 
determinant. While adipose tissue has only a relatively low level of blood perfusion, the design 
of most drugs (lipophilic) means that they are often ‘trapped’ within adipose tissue (Lipinski 
et al., 2001). Given that the percentage of adipose tissue can vary greatly within a population, 
from over 50% in morbidly obese individuals to less than 8% in individuals with eating 
disorders, as well as being different between ethnicities this factor must be accounted for in 
determining the drug exposure for an individual (Park et al., 2001). Finally distribution can 
also be affected by membrane barriers such as the blood brain barrier and the placenta, which 
are designed to prevent drugs, xenobiotics and other toxins from crossing into the brain or 
foetus and causing damage.  These barriers are full of active transport proteins which help 
provide this protective role through active exclusion of drugs from the CNS and developing 
foetus (Gibson, 2001). 
Figure 1.1.4 shows the ways in which transport of different compounds are mediated across 
the cellular membrane.  In all membranes there are ion channels and aquaporins present along 
with transporter proteins responsible for the regulation of influx and efflux of compounds, such 
as drugs, from the cell. Ion channels are responsible for controlling the flow of ions across 
secretory and epithelial cells, as well as regulating the cell volume and regulating membrane 
potentials. Unlike the solute carrier (SLC) proteins, responsible for regulation of both influx 
and efflux, these channels are hydrophobic pores across the membrane, which regulate the ions 
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that pass through by their charge and size. Aquaporins regulate the movement of water 
molecules in and out of a cell allowing, when required, a rapid and organised uptake of water, 
also controlling the cell volume along with the ion channels (Kruse et al., 2006). This is 
supportive of (Dobson and Kell, 2008) argument that majority of uptake into a cell is a 
mediated process.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.4. Solute Carrier (SLC) and ATP binding cassette (ABC) and channels present 
in the plasma membrane, allowing for the transport and movement of substance both in 
and out of the cell across the cell membrane.  The SLCs mediate cellular uptake and efflux 
and ABCs mediate cellular efflux. Ion channels allow for bidirectional transport of ions and 
aquaporins selectively conduct water molecules in and out of the cell. Adapted from (Petzinger 
and Geyer, 2006). 
The transporter proteins, SLCs and ABC, are also present within these membranes and are the 
key regulators of influx and efflux of drugs, as well as endogenous solutes such as amino acids, 
glucose and urea. The expression and function of these transporters within a cell can vary from 
Passive Diffusion 
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tissue to tissue and all have broad substrate specificity requiring binding of the substrate to 
stimulate translocation across the membrane (Petzinger and Geyer, 2006).  The roles and 
mechanisms of these proteins will be discussed in further detail later, but it is important to note 
that these play a key role as gate keepers to the cell and put further weight to the notion that 
movement in and out of a cell is a mediated and controlled process. 
Absorption and distribution determine what drugs or compounds make it into the systemic and 
which organs they are distributed to. However once in the systemic circulation it is important 
that these compounds can be removed to prevent any damaging action in places they are not 
needed.  This is where the role of the liver and its key role in metabolism take centre stage, as 
I shall discuss next. 
1.1.4 Drug metabolism 
Drugs are designed with lipophilic properties to promote efficient absorption into the systemic 
circulation; however once in the circulation these properties also make excretion of the 
compound unfavourable.  This is when the role of drug metabolism becomes vital, with a broad 
range of enzymes designed to alter the chemical structures of the compound, increasing 
solubility and ultimately making excretion favourable.  These enzymes are present in varying 
levels in tissues throughout the body, with the primary site of drug metabolism occurring in the 
liver. 
The liver is the largest internal organ of the human body, and also the largest gland playing an 
important role in the biotransformation of drugs and xenobiotics. With this significant role in 
metabolism it is unsurprising that liver diseases are some of the most life threatening issues 
worldwide (Sun et al., 2009, Chu et al., 2013b).  The basic structure of the liver is shown in 
Figure 1.1.5 and shows a cross section of a lobule and its supply of blood from both the hepatic 
artery, flowing from the aorta, and the portal vein that carries digested nutrients from both the 
small intestine and descending colon. Eighty percent of the liver volume is made up of the 
parenchymal cells, hepatocytes, which are organised into lobules with blood vessels branching 
among the hepatocytes forming sinusoids into which blood flows. Seventy percent of the 
hepatocytes surface area faces the sinusoid increasing the exchange of chemicals between 
blood and cells and fifteen percent of the cell surface area faces the bile canaliculi which allows 
the excretion of parent and drug metabolites into the bile channels for excretion (Silverthorn, 
2006).     
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Figure 1.1.5. A cross section the structure of a hepatic lobule (Chu et al., 2013b) 
Transporter Consortium). 
The structure of the liver enables it to play its key role in the clearance of toxins and xenobiotics 
within the body and it is the primary site for biotransformation reactions. The hepatocytes are 
characterized by their functionally different plasma membrane which allows the formation of 
sinusoidal and cannalicular membranes and they are responsible for hepatic metabolism and 
biliary excretion of waste products (Watanabe et al., 2010). This system provides protection in 
the event of an increased concentration of high lipophillic threats such as drugs, toxins and 
hormone ‘mimics’, aiming to make the target into more water soluble secondary metabolites 
which can be easily excreted from the body (Coleman, 2005).  This process of metabolism is 
often treated as a two phase process simply called phase I and Phase II metabolism. 
In addition to its important role in drug metabolism, the liver is responsible for synthesis, 
degradation and storage of a large number of endogenous chemicals: albumin production, 
glycogen synthesis and storage, production and secretion of bile to aid emulsification of lipids 
in the gut along with the synthesis of key signalling molecules such as cAMP and steroid 
hormones. 
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1.1.4.1 Phase I Metabolism 
Phase I metabolism is made up of biotransformation reactions which are used to add or expose 
functional groups, such as hydroxyl groups, to a drug with the aim being to increase the 
compounds polarity and making it better suited for excretion from the body. Although Phase I 
drug metabolism occurs in most tissues, the primary site of metabolism occurs with the liver, 
with additional metabolism occurring in the gastrointestinal epithelial, renal, skin, and lung 
tissues.  Phase I metabolism is activated when hepatocytes detect the presence of particular 
persistent lipophilic drugs or toxins. Detection of these chemicals is translated to chemical 
signals within the cell to instigate the appropriate metabolic system to allow clearance of the 
drug as quickly as possible. Phase I reactions are grouped into three categories, oxidation, 
reduction, and hydrolysis. Typically, oxidation is the most common phase I reaction with the 
cytochrome (CYP) P 450 system being the most important in phase I oxidation (Gibson and 
Skett, 2001, Plant, 2007). 
Both CYPs and Flavin-containing monooxygenases (FMOs) act by adding molecular oxygen 
to lipophilic compounds in the presence of NADPH and oxygen, albeit fundamentally different 
catalytic cycles.  FMOs as a rule tend to produce increased polarity molecules with reduced 
pharmacological activity however there are few physiological substrates compared to CYPs 
which are responsible for metabolism of a broad range of drugs and chemicals. CYPs are often 
implicated in producing more polar but reactive metabolites which can be pharmacologically 
active and be causal of toxicities seen from a drug (Cashman, 2005, Furge and Guengerich, 
2006).  
The CYPs form a superfamily of enzymes defined by their ability to absorb UV light at 450 
nm when reduced and bound to carbon monoxide.  Their main role is the oxidation of 
chemicals, both xenobiotics and endogenous in nature, leading to increased polarity and, 
ultimately, excretion. There have been 18 families of CYPs identified in humans, encoding a 
total of 57 specific enzymes, allowing this family to possess a wide variety of metabolic 
activities essential to homeostasis. CYPs are found in virtually every tissue within the human 
body with each CYP designed to metabolize particular groups of chemical structures (Furge 
and Guengerich, 2006).  CYPs are found in their highest concentrations within the gut and 
liver, where the highest volumes of biotransformational reactions are required.  As discussed 
earlier, toxins can enter the body not only via the diet (orally) but also through other routes 
such as via the skin and lungs.  For this reason CYPs are present in reasonable levels within 
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the lungs and skin to deal with these specific absorption routes. However, there is little 
contribution from these sites to the overall clearance of the majority of drugs, due to of the 
limited absorption through these alternate exposure routes.  These non-hepatic, non-intestinal 
CYPs can, however, contribute to the formation of toxic species from xenobiotics (Furge and 
Guengerich, 2006, Plant, 2007). 
While CYP enzymes are numerically the major contributor to Phase I metabolism, a significant 
contribution (Table 1.1.1) is also mediated by other enzymes most notably Flavin-containing 
monooxygenases (FMOs).  These enzymes are found in many tissues but are expressed at their 
highest levels within the liver, again enforcing the important role of this organ in drug 
metabolism. The FMO family consists of five enzymes, with FMO 1 and 3 being the major 
enzymes within humans. Their most common substrates are sulphur- and nitrogen- containing 
xenobiotics, with FMOs catalysing the oxygenation of these nucleophilic compounds (Gibson, 
2001, Krueger and Williams, 2005).   
Reductive reactions are less common than the oxidation reactions but are important in the 
reduction of azo- and nitro-compounds, as well as compounds with hetrocyclic rings and 
halogenated hydrocarbons.  These reactions are seen to occur in in vitro systems within hepatic 
microsomes in the presence of NADPH and are inhibited by oxygen. Hydrolytic reactions 
differ as they do not need to involve the hepatic microsomal enzymes and can occur within the 
plasma with enzymes such as esterases and amidases acting upon ester and amide bonds present 
within the drugs chemical structure (Gibson, 2001). 
The net effect of all of these enzymes is to increase the compounds water solubility by 
providing reactive centres for the action of phase II metabolic enzymes which ultimately act 
upon the drug compound to make it water soluble and more suited for excretion. 
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Table 1.1.1. Enzyme classes involved in phase I metabolism, their main catalytic role 
and example substrates (Gibson, 2001). 
 
Phase I Enzyme Type of reaction Example Substrates 
Cytochrome P450s Oxidation Therapeutic Drugs 
Flavin containing Monoxygenases Oxidation Thiourea 
Reductases Reduction Hetrocyclic ring 
containing compounds 
Esterase and Amidases Hydrolysis Esters, amides 
 
1.1.4.2 Phase II Metabolism 
Phase II metabolism, generally, uses the reactive centres generated from phase I reactions to 
further transform the chemical in to a metabolite with high water solubility; for chemicals that 
already possess such reactive centres (e.g. paracetamol), phase I metabolism may not be 
required and phase II can proceed directly (Coleman, 2005).  Phase II enzymes also share a 
similar distribution pattern to Phase I enzymes, but preferentially expressed in entry/exit organs 
such as the liver, lungs, skin and kidneys. 
Unlike Phase I metabolism, where one superfamily (CYPs) encodes >75% of the metabolic 
enzymes, phase II reactions are divided between a number of transferase enzyme groups.  
Amongst these groups, the UDP-glucoronsyltransferases (UGT) enzymes are considered to be 
key, and represent approximately 25% of all Phase II enzymes. They catalyse the addition of a 
glucuronic acid moiety producing a product that is again more polar and therefore more readily 
excreted (Gibson, 2001). Due to the ready availability of the conjugate and ubiquitous 
expression of UGT enzymes, the majority of both endogenous compounds and xenobiotics can 
be substrates for glucoroindation. Beyond UGT-mediated Phase II reactions, several other 
routes of conjugation that are biologically important for the safe excretion of drugs exist (Table 
1.1.2).  Sulphation is a major conjugation pathway for phenols, alcohols, amines and thiols, 
and occurs through the interaction of 3’ phosphoadenosine 5’-phosphosulfate (PAPs) in the 
presence of sulfotransferases. In general, most compounds that are subject to sulpho-
conjugation are also substrates for glucuronidation, with the latter becoming predominant at 
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higher substrate concentrations due to sulphation being limiting due to conjugate depletion 
and/or catalytic efficiency of the sulphotransferase enzymes (Timbrell, 2001).  
Table 1.1.2. Enzyme classes involved in phase II metabolism, the conjugate they add to 
drugs plus an example substrate (Gibson, 2001).      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Phase II Enzyme Type of Conjugate Example Substrates 
UGT Glucuronide Broad range of drug 
Sulphotransferases Sulphur Phenols and Alcohols 
Methyltransferases Methyl Nicotinamide 
Aminotransferases Amino acids Aspartate 
Acetyltransferases Acetyl Arylamide 
Glutathione-s-Transferase Glutathione  Broad range of drugs 
 
Both glucuronidation and sulphation are considered class I Phase II reactions, utilising high 
energy conjugates, formed through the incorporation of phosphate, to react with low- to mid-
energy reactive centres.  In contrast, the glutathione S-transferase (GST) enzymes are a family 
of enzymes present in both eukaryotes and prokaryotes that catalyse class II Phase II reactions, 
utilising a low energy conjugate, glutathione. As glutathione is of minimal chemical reactivity, 
it is unable to react with the majority of reactive centres, which are low- to medium- reactivity.  
Rather, glutathione is reserved for conjugation reactions with high-energy metabolites, such as 
halides or epoxides. As compounds containing these groups are likely to be toxic, as they will 
spontaneously react with endogenous macromolecules forming adducts, GST-mediated 
reactions are crucial for mitigating this toxic liability GSTs are present in both the cytosol and 
microsomes of liver, kidney and gut cells, allowing them to undertake their protective role 
regardless of the sub-cellular localisation of the potentially toxic substrate. Once the compound 
has been made more water soluble it needs to be excreted from the body either via biliary or 
urinary excretion (Rang et al., 2003, Gibson and Skett, 2001). 
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In summary, the body has in place a metabolic network that allows the efficient removal of 
compounds by ensuring that they are readily soluble in the water-based excretion media. These 
enzymes work in a coordinated fashion, altering levels of both Phase I and II enzymes to most 
efficiently remove each compound. In addition, their substrate promiscuity is such that they 
are able to deal with the large chemical space of compounds that the body is exposed to, 
although this does raise the potential for drug-drug interactions as will be discussed later.   
1.1.5 Excretion  
The process of metabolism results in highly water soluble metabolites, which are suitable for 
excretion in water-based media such as urine and faeces. As discussed previously, active 
transporters are a major determinant of drug distribution, and this is also true with regard to 
distribution of metabolites for excretion. Efflux pumps present within the main excretion 
organs (liver and kidneys) are used to drive these chemicals toward excretion efficiently and 
rapidly, even against a concentration gradient. It is important that removal of these potentially 
toxic metabolites is rapid, so that they don’t accumulate in the aqueous areas of the cells where 
they may interact with cellular macromolecules and elicit toxicity (Rang et al., 2003, Gibson 
and Skett, 2001).  
The main route of excretion for many compounds is via the biliary route of excretion, with 
transport from the liver hepatocytes into the bile caniculi for excretion via the faeces. A major 
determinant of biliary excretion is one of compound size, as the secondary excretion route 
(kidneys and urine) is dependent on an initial size filtration. Metabolites that are small (less 
than 100KDa) and water soluble can also be excreted by the kidneys and removed from the 
body in urine.  The role of the efflux transporters is often referred to as the third phase of the 
detoxification system, as they prevent inhibition of the phase II part of the detoxification system 
(Toyoda et al., 2008). 
Having a system with multiple parts for removing drugs/xenobiotics from the body is very 
effective as many drugs need to undergo significant structural alterations to ensure efficient 
excretion.  In addition, the complexity of the ADME systems ensure that it is able to handle 
the wide variety of chemical structures that it is exposed to, including novel drugs and 
chemicals that the body may not have seen before. These metabolic processes usually greatly 
diminish or remove the pharmacological action of a drug; however, the drug may retain some 
pharmacological effect, or indeed be administered as a pro-drug that requires metabolism 
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before it is pharmacologically active (Coleman, 2005). I will now go on to discuss the different 
transporters and their role within the ADME process.  
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1.2 Membrane Transporters and their role in ADME 
The traditional view of drug metabolism has only truly considered the effect of phase I and II 
metabolism, as the major determinant of drug fate.  Recently, a greater emphasis has been 
placed on furthering our understanding into the role of drug transporters within the ADME 
process and their effect on the pharmacokinetics and pharmacodynamics of a drug.  For several 
years drug design has worked on the assumption that the majority of the cellular uptake of 
molecules is through passive diffusion, with drugs being designed following the  Lipinski rule 
of five (Lipinski et al., 2001), or its derivative the rule of three. Both these rules set out series 
of design features (number of hydrogen bond donors/acceptors, molecular mass and 
octanol:water partition coefficient) to optimise lipid solubility. However, this paradigm is 
becoming increasingly challenged, with Dobson and Kell, (2008) arguing that the role of 
protein transporters in cellular uptake should be considered the rule rather than being the 
exception to passive diffusion. 
A review by  Petzinger and Geyer, (2006) proposed that the process of drug metabolism can 
be considered as a five phase model, from absorption of the drug to its excretion from the body 
as shown in Figure 1.2.1.  Phase 0 is the extraction of the drug from the blood via an uptake 
process across the basolateral membrane into the proximal tubule of the kidneys, into the 
hepatocytes or enterocytes of the GI lumen.  This process is mediated by active transport 
proteins such as the organic anion transporter proteins.  Phase I and II are the traditional steps 
of biotransformation of a parent drug, carried out by the detoxification enzymes within cells as 
discussed in the previous section 1.1.2.  Phase III is the intracellular transport of xenobiotics 
and their metabolites within cells, providing access for lipophillic compounds to aqueous 
compartments of the cells.  This requires intracellular carrier proteins, such as the fatty acid 
binding protein family members that facilitate the movement of lipophilic drugs through the 
hydrophilic cytosol, and movement of metabolites from the ER to the secretory sites of the cell 
membrane.   
Phase IV is considered to be the final steps which lead to excretion of the drug from the cell, 
and ultimately the body.  In the liver, this can either occur through the cannalicular (luminal) 
membrane, with excretion into the bile, or through the basolateral membrane, where the 
compound re-enters the systemic circulation, allowing excretion via (for example) the kidneys. 
Both these processes are each mediated by active transport proteins to a larger or lesser extent, 
with passive diffusion being a relatively minor component for many drug molecules. 
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Figure 1.2.1. Representation of the different phases and transporters involved in drug 
clearance; Phase 0 is the uptake transport of substances from the circulation, Phase 1 and 2 
are the two phases of metabolism making the substance more water soluble and readily 
excreted.  Phase 3 is the transport of substrate within the cell by carrier proteins and Phase 4 
substrate is removed from the cell out into the bile or urine for elimination from the body 
(Petzinger and Geyer, 2006). 
 
The model presented by Petzinger and Geyer, hence, emphasizes the importance of transporters 
in drug clearance, with three of the five phases concerning the transport of a compound, 
whereas only two phases are concerned with metabolism.   
1.2.1 Transporter Proteins 
There are two main classes of transporters that have an influence on drug ADME, Solute 
carriers (SLCs) and ATP binding cassette transporters (ABCs). These multi-gene families 
encode specialized proteins that span the cell membrane and mediate the translocation of 
chemicals into and out of the cell, acting as gate keepers to the cell as shown in Figure 1.2.2. 
There are two key differences between the SLC and ABC transport proteins, their energy 
source and the transport they regulate. SLCs are a diverse superfamily of transporters that can 
act as both efflux and uptake transporters, capable of moving substrates both with and against 
a concentration gradient, using electrochemical gradients of co-transported molecules to 
facilitate the latter scenario. In contrast, ABC transporters utilise the hydrolysis of ATP to ADP 
to fuel the transport of substrates against their concentration gradients and are only responsible 
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for mediating efflux of chemicals in eukaryotes (Nakanishi and Tamai, 2011). Therefore, both 
work in tandem to determine the fate of a chemical. 
 
Figure 1.2.2. Canalicular and sinusoidal transporters of a hepatocyte: The canalicular 
ABC transporters; Bile Salt Export Protein (BSEP), Multidrug Resistance Protein 2 (MRP2), 
Breast Cancer Resistance Protein (BCRP), P-gp also known as Multidrug Resistance Protein 1 
and sinusoidal transporters; Sodium-taurocholate cotransporting polypeptide (NTCP), Organic 
Cation Transporter 1 (OCT1), Organic Anion Transporting Protein 1B1 (OATP1B1) and 1B3 
(OATP1B3), Multidrug Resistance Protein 3 (MRP3) and 4 (MRP4).  These control the 
directional transport of drug compounds and their metabolites in and out of the hepatocyte 
(Watanabe et al., 2010).  
1.2.2 Solute Carrier (SLC) Transport Proteins 
The human solute carrier gene superfamily consists of 55 gene families that encode 
approximately 360 transport proteins in humans.  As mentioned above, a central feature of SLC 
transporters is that they do not hydrolyse ATP to provide the energy required for transport. 
Rather, they use the concentration gradient of compounds to drive transport through the 
associated electrochemical gradient. These solute carriers are typically formed of a single 
domain that consists of 10-14 transmembrane alpha helices and are found on the sinusoidal 
membranes of hepatocytes and apical membranes of intestinal cells. There are three key types 
of SLC transporter uniporters, symporters and anti-porters. 
Classically SLC transporters act as passive transporters, where they transport only a single 
compound at a time down its concentration gradient (uniporters). An example of a uniporter is 
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the GLUT2 transporter, which provides a glucose sensing function within hepatocytes and 
releases the glucose from the hepatocyte gluconeogenesis into the blood.  An important sub-
set of SLC transporters are able to move compounds against their concentration gradient 
through the simultaneous transport of a second compound down its concentration gradient. 
These symporters transport both compounds across the membrane in the same direction, 
SGLT1 is such an example, being a high affinity glucose transporter allowing uptake into cells 
such as hepatocytes. Antiporters transport compounds across the membrane in opposite 
directions and these transporters are key in the exchange processes of the cells such as the AE1 
transporter which is key in transport of CO2 out of cells (Zhao and Keating, 2007b, Lodish, 
2008) 
SLC transporters are able to undertake a broad range of substrate transport in and out of a cell, 
including amino acids, sugars, inorganic cations and anions, as well as cell signalling factors 
(Zhao and Keating, 2007a).  From within this superfamily, there are some subfamilies that are 
of particular note with regard to drug ADME; the organic anion transporter polypeptides 
(OATP) and the organic cation transporters (OCT), which both modulate the uptake of a wide 
range of drugs (Hagenbuch, 2009, Kalliokoski and Niemi, 2009, Leuthold et al., 2009), 
(Nakanishi and Tamai, 2011).  These transporters are known by many names due to changes 
in nomenclature over recent years, with nomenclature often used interchangeably. It is 
important to note that the SLC name actually refers to the gene encoding the transporter, while 
the common name (e.g. OATPx or OATx) refers to the actual protein transporter. Table 1.2.1 
gives the subfamilies of the solute carrier transporter family and their gene prefix and number 
of members. In addition, it is not clear if the correct orthologues have been determined between 
humans and pre-clinical species, as OATPs in both species have broad and overlapping 
substrate range allows for hepatic uptake of a large number of xenobiotics and drugs (Faber et 
al., 2003). As such, direct read across between species at the level of nomenclature should be 
taken with caution, while general behaviours are generally well conserved. 
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Table 1.2.1. The solute carrier transporter subfamilies (Hediger et al., 2004) 
Subfamily Gene Prefix 
Number of 
Members 
The high-affinity glutamate and neutral amino acid transporter family SLC1 7 
The facilitative GLUT transporter family SLC2 14 
The heavy subunits of the heteromeric amino acid transporters SLC3 2 
The bicarbonate transporter family  SLC4 10 
The sodium glucose cotransporter family  SLC5 8 
The sodium- and chloride-dependent neurotransmitter transporter family SLC6 16 
The cationic amino acid transporter/glycoprotein-associated amino-acid 
transporter family SLC7 14 
The Na+/Ca2+ exchanger family  SLC8 3 
The Na+/H+ exchanger family  SLC9 8 
The sodium bile salt cotransport family  SLC10 6 
The proton coupled metal ion transporter family SLC11 2 
The electroneutral cation-Cl cotransporter family SLC12 9 
The human Na+-sulfate/carboxylate cotransporter family SLC13 5 
The urea transporter family SLC14 2 
The proton oligopeptide cotransporter family  SLC15 4 
The monocarboxylate transporter family  SLC16 14 
The vesicular glutamate transporter family  SLC17 8 
The vesicular amine transporter family  SLC18 3 
The folate/thiamine transporter family  SLC19 3 
The type-III Na+-phosphate cotransporter family  SLC20 2 
The organic anion transporting family  SLC21/SLCO 11 
The organic cation/anion/zwitterion transporter family SLC22 18 
The Na+-dependent ascorbic acid transporter family  SLC23 4 
The Na+/(Ca2+-K+) exchanger family  SLC24 5 
The mitochondrial carrier family SLC25 27 
The multifunctional anion exchanger family SLC26 10 
The fatty acid transport protein family  SLC27 6 
 The Na+-coupled nucleoside transport family  SLC28 3 
The facilitative nucleoside transporter family  SLC29  4 
The zinc efflux family  SLC30  9 
 The copper transporter family  SLC31 2 
The vesicular inhibitory amino acid transporter family SLC32  1 
The acetyl-CoA transporter family  SLC33 1 
The type-II Na+-phosphate cotransporter family  SLC34  3 
The nucleoside-sugar transporter family  SLC35  17 
The proton-coupled amino acid transporter family  SLC36 4 
The sugar-phosphate/phosphate exchanger family  SLC37  4 
The System A and N, sodium-coupled neutral amino acid transporter family SLC38  6 
The metal ion transporter family SLC39 14 
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The basolateral iron transporter family  SLC40  1 
The MgtE-like magnesium transporter family  SLC41  3 
The Rh ammonium transporter family (pending) 3 SLC42 3 
The Na+-independent, system-L-like amino acid transporter family SLC43  2 
Total  298 
 
  
  
  
  
There are nine human OATPs, which are expressed in many tissues, three of these transporters 
show preferential expression within ADME essential tissues such as the liver; OATP1B1, 
OATP1B3 and OATP2B1.  These three transporters are located within the sinusoidal 
membrane of the hepatocytes where they regulate the liver uptake of a broad range of 
substrates. In vitro these transporters have been shown to transport endogenous substrates such 
as conjugated and un-conjugated bilirubin, bile acids and conjugated steroids.  In addition, they 
can facilitate the liver uptake of a number of important drugs, such as the type 2 diabetic (T2D) 
drugs repaglinide and naleglinide, anticancer agents and lipophillic statins such as pravastatin. 
It is important to note that, as with any protein-mediated process, OATP-mediated drug 
transport can be saturated, raising the potential for competitive inhibition and drug-drug 
interactions. For example, cyclosporin, is a substrate for OATP1B1, with a known drug-drug 
interaction with atorvastatin and pitavastain. Due to the narrow therapeutic window of 
cyclosporin, such DDIs can result in toxicity or lack of efficacy (Hagenbuch and Meier, 2003, 
Kalliokoski and Niemi, 2009).  A counterpoint to this, is that the substrate specificity of these 
transporters, encompassing hydrophilic therapeutic compounds, means that these transporters 
represent potential drug targets to improve drug efficacy through altered/improved drug 
distribution.  
There are several organic cation transporters (OCTs) expressed in humans: OCT1 and OCT2 
are expressed in the liver, intestine, kidney, while OCT3 is distributed within the brain. These 
transporters are responsible for the elimination of monoamines and cationic xenobiotics, and 
are important in the regulation of drugs such as metformin and verapamil, playing a key role 
in the renal elimination of chemotherapeutics. In addition, the OCTN1 transporter known as 
the antioxidant, ergothioneine transporter, and the OCTN2 transporter are responsible for the 
transport of carnitine both in and out of cells. Polymorphisms in these OCTN genes has been 
linked with conditions such as Crohns disease and rheumatoid arthritis (Nakamura et al., 2008). 
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It is important to note that the ability of these influx transporters to work efficiently depends 
on the ability of the rest of the biological system to cope with the substrate load.  SLC 
transporters work through the use of concentration gradients across the lipid membrane. Hence, 
it is crucial that the subsequent metabolism and excretion of substrates is efficient to maintain 
the concentration gradient across the sinusoidal membrane and ensure safe levels of a substrate 
within the cell. For symports and antiports, such a concept also applies to the co-transported 
solute.  If the ability of metabolism and excretion within the cell is impeded then some of the 
OATP transporters with bi-directional capabilities will switch from a hepatic uptake function 
to hepatic efflux, allowing the quick reduction of substrate concentration within the hepatocyte 
(Faber et al., 2003, He et al., 2009, Sissung et al., 2010).  Such a process can be critical to 
ensure the safe handling of a compound within the target cell, but will have the disadvantage 
that it will alter cellular concentrations in other tissues.  Hence, this process is of great 
importance when considering the elimination of drug from the body, as if there is an altered 
level of OATP expression in tissues, or its directionality of transport, this can lead to altered 
drug uptake and elimination, impacting upon both pharmacokinetics and pharmacodynamics 
of the drug. 
1.2.3 ATP Binding Cassette (ABC) transport proteins 
The ABC superfamily consists of 48 genes, divided into 7 sub-families, named ABCA through 
to G. Although smaller than both CYP and SLC super families, this still represents one of the 
largest protein families encoded within the human genome.  As seen with the SLC transporters, 
the nomenclature for members of this superfamily is inconsistent, with interchangeable names 
often used in the literature including MRPs/BCRPs/MDRs and ABCs; however, as seen with 
the SLC superfamily, such variance is incorrect, with use of the terminology as ABC-X 
referring to the gene name, while MRP and others refer to their functional encoded proteins 
(Toyoda et al., 2008). The subfamilies and their transporters gene names an alias’s are shown 
in Table 1.2.2. 
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Table 1.2.2.  The ATP binding cassestte (ABC) transporter subfamilies. 
Subfamily Gene Name Alias Function 
A 
ABCA1 ABC1 cholesterol efflux 
ABCA2 ABC2 macrophage lipid metabolism, neural development, LDL trafficking 
ABCA3 
ABC3, 
ABCC secretion of surfacants 
ABCA4 ABCR N-retinylidiene-PE-efflux 
ABCA5   
ABCA6  implicated in macrophage lipid homeostasis  
ABCA7  role in clearance of apoptotic cells 
ABCA8   
ABCA9  macrophage lipid homeostasis 
ABCA10  macrophage lipid homeostasis 
ABCA12  lipid metabolism 
ABCA13  implicated in Shwachman-Diamond syndrome and cancers of the CNS 
B 
ABCB1 
PGY1, 
MDR efflux of xenobiotics 
ABCB2 TAP1 peptide transport 
ABCB3 TAP2 peptide transport 
ABCB4 PGY3 phophatidylcholine transport, 
ABCB5   membrane potential and regulator of cell fusion in skin progenitor cells 
ABCB6 MTABC3 heme transport and biosynthesis 
ABCB7 ABC7 role in hematopoiesis 
ABCB8 MABC1  
ABCB9  peptide transport 
ABCB10 MTABC2 heme biosynthesis 
ABCB11 SPGP bile salt transport 
C 
ABCC1 MRP1 organic anion efflux 
ABCC2 MRP2 organic anion efflux including bile salts 
ABCC3 MRP3 organic anion efflux including bile salts 
ABCC4 MRP4 organic anion efflux including bile salts 
ABCC5 MRP5 organic anion efflux 
ABCC6 MRP6  
ABCC7 CFTR chloride ion channel 
ABCC8 SUR1 receptor 
ABCC9 SUR2 modulator of ATP sensitive K+ channels 
ABCC10 MRP7 
E217BG transport, steroid sulfates, glutathione conjugates and monoionic bile 
acids 
ABCC11   
ABCC12   
D 
ABCD1 ALD VLCFA transport regulation 
ABCD2 
ALDL1, 
ALDR  
ABCD3 
PXMP1, 
PMP70 peroxisome biogenesis 
ABCD4 
PMP69, 
P70R  
E 
ABCE1 
OABP, 
RNS41 inhibition of Rnase I 
 
F 
ABCF1 ABC50 mRNA translation 
ABCF2  mRNA translation 
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ABCF3  mRNA translation 
G 
ABCG1 
ABC8, 
White cholesterol efflux 
ABCG2 
ABCP, 
MXR, 
BCRP riboflavin pump, heme efflux 
ABCG4 White2 cholesterol efflux 
ABCG5 White3 sterol transport 
ABCG8  sterol 2 transport 
 
As noted previously, ABC genes encode only efflux transporters in eukaryotic cells, but they 
can act as both importers and exporters in prokaryote cells (Rees et al., 2009), demonstrating a 
specialisation of function in more complex organisms.  For the purpose of this work, only 
mammalian efflux transporters will be considered. The presence of efflux transporters is 
necessary as the resulting conjugates of metabolism are often too hydrophilic or too large to 
diffuse through the cell membrane unaided, and therefore require dedicated transporters to 
assist their removal from the cell and continue the process of excretion.  In addition, a system 
that utilises the hydrolysis of ATP to ADP to drive transport means that the transport is highly 
efficient, as it does not have to rely on maintaining a concentration gradient to provide the 
electromotive force.  This highly efficient system is important because accumulation of drugs, 
either parent or metabolite, within the cell can cause both a decrease in the detoxification 
activity of the phase I and II system and cause cellular toxicity (Toyoda et al., 2008).   
The importance of the ABC superfamily in biological functioning can be seen from the fact 
that mutation of ABC genes has significant impact on human health and wellbeing, including 
disease causation. For example, mutation of ABCC7, which encoders the chloride ion channel 
CFTR, is causative of cystic fibrosis.  This mutation prevents anion flow through the channel, 
which is essential to normal function of epithelial cells which line the airways.  Without this 
anion flow, the mucus that is produced in the lung to trap antigens, becomes dehydrated and 
collects within the lungs. This results in a suitable environment for the development of serious 
bacterial infections, a common issue in CF patient care (Gadsby et al., 2006).  
In addition to their established role in disease causation, a number of the ABC proteins are 
named after their association with the development of multidrug resistance phenotype; for 
example, Multidrug resistance 1 (MDR1), Multidrug resistance associated protein (MRP) and 
breast cancer resistance protein (BCRP).  In total, 15 of the 48 human ABC transporters have 
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been implicated in multiple drug resistance, demonstrating their importance in this 
phenomenon. This is perhaps not surprising given that ABC transporters have a major role in 
removing important therapeutic drugs, and thus their over-expression may lead to cellular 
resistance.  This over-expression may be as a result of genetic polymorphisms or, more 
commonly, as an adaptive response to chronic drug exposure.  As such, they are considered a 
negative prognostic marker of disease such as cancer and targeted down regulation of these 
transporter genes, by means of antisense interfering RNA, could be a potential co-drug to use 
during therapy and help improve the patient’s response to treatment.  It would also enable 
companies to modify and design novel drugs which could evade the transporter mediated efflux 
while retaining their activity in the target tissues (Liu et al., 2010).  
1.2.3.1 ABC Transporter Structure 
The primary structure of ABC proteins has a common template, although they differ 
significantly to accommodate altered substrate specificities.  The common features of all ABC 
proteins are the membrane spanning domains (MSD) and the nucleotide binding domains, 
which will be discussed in more detail below. A functional ABC protein consists of two MSDs, 
with each typically containing 6 transmembrane (TM) helices, although this can vary from five 
to ten. These TMs contain the specific drug binding sites, which are thought to be located 
within a flexible internal chamber large enough to accommodate its broad range of substrates 
(Deeley et al., 2006, Russel et al., 2008).  Each ABC protein also contains two NBDs and these 
have the Walker A and B motifs within them. The Walker domains are conserved between all 
transporters, and are essential in the binding and hydrolysis of ATP used to fuel the transport 
of substrate across a membrane.  The NBDs also contain a ‘C-signature’ motif, sometimes 
referred to as Walker C, which also plays a role in nucleotide binding (Deeley et al., 2006, 
Toyoda et al., 2008).  A major variance within the ABC superfamily is that some of the ABC 
transporter genes encode half transporters, with only have a single MSD and NBD (Klaassen 
and Aleksunes, 2010).  In the case of half-transporters, homo or hetrodimerization of proteins 
is required to create a functional transporter protein (Figure 1.2.3). 
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Figure 1.2.3. The Minimal Functional Unit required to create a functional transporter, 
made up of ATP Binding Domains (ABD) and Transmembrane (TM) Domains; Full 
transporters have all required domains and half transporters require Homo or Hetrodimerisation 
of units to create a functional transporter. 
Manchester university group (Robert C. Ford ISSX 2012) have been analysing the structures 
of ABC transporters to see how they function to move drug out of the cell.  It is likely that an 
ATP molecule is permanently bound to each NBD domain in the transporter, but that this 
binding alone is not enough to allow transport. In addition, there is a requirement for movement 
of the transporter from an inward to an outward facing orientation to allow the substrate to 
locate into the internal chamber: As the transmembrane free energy is much higher than the 
NBD free energy this holds the transporter in its fixed position until both ATP and substrate 
are bound.  Upon substrate binding, the confirmation changes and allows the drug/substrate to 
detach and be released out of the cell.  The two ATP molecules are reduced, allowing the NBD 
to reconfigure into its inward facing position, upon which the ADP is replaced with new ATP 
molecules, keeping the transporter ready for its next transport function.  
1.2.3.2 ABCB1 
ABCB1 encodes the MDR1 protein, also known as Pgp, which plays a key defensive role in 
the body. It acts to limit the entry of xenobiotics with high expression levels in the gut, liver 
and kidney; in addition, it is present in high numbers at the blood brain barrier (BBB) and in 
placental trophoblasts to protect the brain and developing foetus, respectively. The MDR1 
protein has been extensively studied for its inhibitory effect on delivery of many drugs to target 
tissues, and its limiting effect on the oral bioavailability of many drugs.  For example, the anti-
cancer drug Taxol has to be given intravenously as it’s a very good MDR1 substrate, meaning 
that oral bioavailability is limited to approximately 11% (Borst and Elferink, 2002a).   
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MDR1 can be considered the archetypal ABC transporter, upon which highly conserved 
elements such as the Walker B motif are defined. In addition, much of our understanding of 
the role of active transport proteins in drug resistance is based upon findings from MDR1. For 
example, proteins with similar drug profiles were identified in the small cell lung cancer cell 
line H69AR, with a drug resistance profile similar to MDR1, but where MDR1 could not be 
detected.  After identification of highly expressed mRNAs following drug selection, 
overlapping cDNA clones were obtained to correspond to an mRNA open reading frame (ORF) 
and it was predicted to have the presence of multiple TM helices and 2 NBDs as shown with 
the typical general ABC structure, later named MRP1.  This discovery through shared activity 
is all the more important given that there is only minimal structural identity, being 19% 
between MRP1 and MDR1 (Deeley et al., 2006). As such, this work represented the 
identification of not only another drug resistance-associated transporter, but also a distinct 
family of ABC transporter, as defined by the limited sequence identity.  
1.2.3.3 ABCC 
The ABCC subfamily consists of 12 genes in humans, of which 9 have been implicated in the 
development of MDR.  The encoded proteins can be categorised into two types short and long 
(Figure 1.2.4).  The short ABCCs encode typical full transporters, with two MSDs and two 
NBDs and this group consists of MRP4, 5, 8 and 9. In contrast, long ABCCs have an additional 
MSD region called MSD0 and consist of four to six TMs: MRP1, 2, 3, 6 and 7 are members of 
this group.  The long ABCCs also have an additional extracellular N2H terminal region that is 
comprised of approximately 200 amino acids and is attached to the MSD0.  This is then 
attached to the MSD1 region by a cytoplasmic loop known as CL3 (figure 1.2.4). (Deeley et 
al., 2006) reviewed evidence that the MSD0 region functions to enable the apical and vacuolar 
localization of MRP2 or MRP1. This hypothesis was supported by work with MRP1 
demonstrating that partial or complete removal of MSD0 resulted in a loss of LTC4 transport, 
and this has been based upon the presence of a partially redundant trafficking signal called the 
CL3 sequence resulting in a reduction of MRP1 taken to the membrane for movement of its 
substrates (Deeley et al., 2006).   
In comparison to the ABCB (MDR) subfamily of transporters, which primarily transport parent 
compound, ABCC (MRP) subfamily members are, generally, responsible for the transport of 
drug conjugates. Hence, ABCB and ABCC encoded proteins work in concert to ensure the 
rapid excretion of drugs, as either the parent or metabolites, from the cell.  
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Figure 1.2.4. The structure of the ATP Binding Cassette subfamily C (ABCC) 
transporters and the structural differences which categorise them into two groups within 
the subfamily; long ABCCs (MRP1, 2, 3, 6 and 7) and short ABCCs (MRP4, 5, 8 and 9). 
Adapted from (Deeley et al., 2006). 
 
1.2.3.3.1 MRP1   
MRP1 is widely expressed in normal tissues and is expressed on the basolateral membrane of 
polarised cells such as hepatocytes and enterocytes. It has a significant overlap in substrate 
specificity with MDR1, with conjugates derived from the majority of chemotherapeutic drugs 
being substrates.  Increased expression of MRP1 is taken as a negative prognostic marker for 
cancers such as leukemia colorectal and breast cancer, as it has been shown MRP1 is able to 
confer resistance to anthracyclines, vinca alkaloids, epipodophyllotoxins, camptothecins and 
Short ABCCs 
Long ABCCs 
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methotrexate. MRP1 also has a particularly high affinity for the inflammatory mediator LTC4 
(Kruh et al., 2007, Toyoda et al., 2008).   
1.2.3.3.2 MRP2 
MRP2 is expressed at critical sites of elimination of xenobiotics, mainly the liver and kidneys. 
It is localized to the apical surface of these cells and in these tissues plays a key role in 
hepatobiliary and urinary excretion of its substrates.  It is also expressed in the gut epithelial 
cells, where it acts to remove drug conjugates formed directly in the intestinal epithelia, back 
into the GI lumen.  The importance of MRP2 for normal cellular functioning can be seen in its 
handling of bile components. Bilirubin glucuronide is a high affinity endogenous substrate for 
MRP2, but this transport is reduced in Dubin-Johnson syndrome patients who have a hereditary 
autosomal recessive deficiency of MRP2. It is mostly an asymptomatic disorder whose 
principal manifestation is jaundice and is also accompanied by defects in the hepatobiliary 
excretion of a variety of other anionic compounds. Some neonates may present with cholestasis 
and the use of hormonal contraceptives and pregnancy in adult hood may lead to overt jaundice, 
yellowing of the eyes and skin (Deeley et al., 2006, Faber et al., 2003).  
 
There are animal models which are used in the lab to replicate the human syndrome; the Eisa 
Hyperbilurinemic Rat (EHBR) and the transport deficiency rat (TR-/-).  These models are 
created through a one nucleotide substitution and sequence mutation of the ABCC2 gene, 
causing a frame shift respectively and these sequence alterations create a new stop codon, 
truncating the sequence and preventing functional protein from being produced. In these 
models reduced levels of glucuronide conjugates are observed in the bile. MRP2 is similar to 
MRP1 in that it mediates and confers resistance to cancer therapies, such as the efflux of 
anthracyclines, vinca alkaloids epipodophyllotoxins and camptothecins. (Kruh et al., 2007, 
Deeley et al., 2006, Faber et al., 2003) .  
1.2.3.3.3 MRP3 and MRP4 
The transport proteins MRP3 and MRP4 are both present in the basolateral membrane of 
hepatocytes facilitating efflux of chemicals into the systemic circulation.  MRP3 is expressed 
at very low levels in human and rat hepatocytes, with higher expression in the ducts of the gall 
bladder (Chu et al., 2006).  It is also found in the gut epithelium, where it is thought to aid in 
the reclaim of bile acids in the gut lumen (Kruh et al., 2007).  MRP3 transports a similar 
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substrate profile as MRP2 and MRP1, again suggesting that MRP proteins coordinate transport 
to balance transfer into the excreta and systemic circulation. We also see that MRP3 expression 
is induced in the livers of human and rat during cholestatic conditions, a condition in which 
substances which would normally be eliminated via the bile are retained within the cell. This 
results in increasing intracellular bile acid concentrations, which triggers increased MRP3 
expression through an accumulative response. It is believed that this increase is part of the 
cellular adaptive response, helping to eliminate the substrates normally excreted via the 
canalicular membrane out into the circulation and thus reduce hepatotoxicity. Transport by 
MRP3 of some substrates such as E217βG can also be limited by the concentration of the 
substrate itself within the hepatocyte; therefore the higher the concentration E217βG resulted 
in inhibition of its transport out of the cell by MRP3 (Borst and Elferink, 2002b, Kool et al., 
1999).   
MRP4 is very different to the other MRPs discussed as it can transport not only glucuronide 
and sulphate conjugates of steroids such as E217βG and DHEAS but also a large number of 
unconjugated endogenous substrates, including cyclic nucleotides such as cAMP and cGMP 
(Kruh et al., 2007). In addition, MRP4 has an important role in the inflammatory response as 
it facilitates the release of prostaglandins into circulation and has been shown to be a target for 
reducing inflammation as its transporting function is inhibited by nonsteroidal anti-
inflammatory drugs (NSAIDs) (Reid et al., 2003). Another important difference between 
MRP4 and the other MRPs, is that depending on the cell type its subcellular localization can 
alter: it can be localised to the basolateral membrane, as in the liver, or the apical membrane as 
seen in the renal proximal tubules and the blood brain barrier.  (Leggas et al., 2004). This shows 
it plays a key role in protecting these critical areas sensitive to chemical and toxic imbalances.    
1.2.3.3.4 Other MRPs 
There are seven MRP transporters identified so far, those previously discussed (MRP1-4) have 
been subject to greater study than MRP5 (ABCC5) MRP6 (ABCC6) and MRP7 (ABCC10). 
MRP 5 and 7 have both been identified as playing a role in resistance to anticancer drugs and 
MRP5 also plays a role in HIV drug resistance. MRP6 deficiency has been linked with 
connective tissue disorders with reduced calcein transport observed (Deeley, 2006). 
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1.2.3.4 ABCG2 
The ABCG2 gene encodes for the transporter Breast Cancer Resistance Protein (BCRP). In 
contrast to ABCB and ABCC family members, the ABCG2 gene encodes a half transporter 
that must homodimerise to form a functional transporter.  In common with MDR and MRP 
proteins, overexpression of BCRP has been associated with multidrug resistance, with BCRP 
playing a significant role in the multidrug resistance profile of MCF 7 human breast cancer 
cells (Doyle et al., 1998). Like MDR1 and MRP2, this protein transporter is present in the 
apical membrane of the hepatocyte, kidney and enterocyte cells.   
1.2.3.5 Summary 
It is clear that the net intracellular concentration for any given molecule is dependent upon the 
coordinated action of metabolic and transport enzymes. In addition, the antagonistic action of 
apical versus basolateral transporters is central in determining the fate of chemicals from liver 
metabolism, facilitating either systemic circulation or body excretion as a fate. It is hence 
important to understand the interaction of drug transporters in determining a chemicals ultimate 
fate. This is demonstratred in MRP2-deficient mice which present with increased levels of 
bilirubin, in both serum and urine and reduced elimination via the bile canaliculus, a result due 
to the utilisation of MRP3 and MRP4 to compensate for the loss of MRP2. Loss of MRP2 has 
shown to lead to increased transport across the sinusoidal membrane of the heaptocyte, and 
subsequent elimination through the urine, due to induction of MRP3 and MRP4 protein levels 
in these MRP2 deficient mice (Chu et al., 2006, Kruh et al., 2007). 
It is well accepted that ADME plays a key role in the fate of endogenous and exogenous 
compounds and work carried out so far shows that transporters play an important role in this 
process. There are a broad range of both uptake and efflux transporters and these transporters 
work together to control the movement and elimination of endogenous and xenobiotic 
compounds and their conjugates, into both the excreta and systemic circulation. The apical 
placed transporters MDR1 and MRP2 have been highly studied and more emphasis is now 
being put on the role that the basolateral transporters, such as MRP3 and MRP4, play in 
maintaining the chemical balance within the cell.  The aim of this project is to understand the 
inter-relationship between apical and basolateral expression of ABC transporters, allowing 
better prediction of drug fate. 
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1.3 Nuclear Receptors and their role within ADME 
Our bodies have to respond to large numbers of xenobiotics on a daily basis both deliberately, 
through the use of therapeutics and unintentionally through environmental contaminants. When 
responding to a chemical insult the body needs to respond quickly to allow for fast uptake, 
metabolism and excretion of the chemical allowing for quick deactivation to prevent or limit 
potential damage.  Xenobiotics which are present in significant amounts can induce 
transcription of relevant transporters and enzymes to stimulate the efficient clearance of drug 
(table 1.3.2). Nuclear receptors are a key factor in this response and therefore any genetic 
variation in individuals or populations, or their interaction with different compounds such as 
drugs or food products, can change the individual’s response to different chemical insults.   
 
Nuclear receptors are an abundant class of transcriptional regulators within humans, 
responsible for the regulation of a wide range of processes essential in the maintenance of 
physiological homeostasis; these include reproduction, development and growth along with the 
processes essential to ADME.  Within the human genome there have been 48 nuclear receptors 
identified and these act as transcriptional regulators that rely upon binding of a ligand before 
they alter gene transcription through direct interaction with DNA. This interaction can occur 
as monomers, hetrodimers or homodimers. The ligands of these receptors are, generally, small 
lipophilic molecules, including steroid hormones, bile acids and fatty acids. This system 
provides a highly regulated and refined response to a wide range of stimuli, providing a network 
that is designed so no one receptor is wholly responsible for a single response pathway.  This 
ensures that any loss or reduction in a receptor doesn’t have a detrimental impact upon the 
ability for the body to responds to the different stimuli (Jacobs et al., 2003b, Plant, 2004a, 
Jacobs et al., 2003a, Janošek et al., 2006)  .  
1.3.1 Nuclear Receptor Structure 
Nuclear receptors all have the same basic structure and are made up of five regions as 
represented in figure 1.3.1. The A/B region is the most variable between receptors, providing 
the receptor with promoter and cell specific activity, allowing for the range of functions carried 
out by each of the nuclear receptors (Aranda and Pascual, 2001). The conserved DNA binding 
domain (C) allows for the recognition of the specific target sequences and upon binding 
initiates the active transcription of the gene.  This domain is formed around two zinc fingers 
that contain cysteine residues for high affinity binding to DNA. Although the DNA binding 
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sequence recognised by each nuclear receptor is different, there is enough commonality that 
this region is one of the most conserved across all members of this superfamily. The hinge 
region (D) acts as suggested, allowing rotation of the receptor for optimal binding of both 
ligand and DNA. The ligand binding domain (E) mediates the direct interaction between the 
receptor and the ligand, and as such shows considerable variability between receptors. In 
addition, this region is responsible for protein-protein interactions, including homo and hetro-
dimerization as well as receptor interactions with heat shock proteins (Aranda and Pascual, 
2001), (Bain et al., 2007).   
 
 
 
 
 
Figure 1.3.1. The basic structure of a nuclear receptor is made up of 5 regions; an NH2 
terminal region (A/B), a conserved DNA binding domain (C), a hinge region (D), the ligand 
binding domain (E) and some receptors have a COOH terminal region (F) (Aranda and Pascual, 
2001) 
Despite the name of this superfamily, the sub-cellular localisation of nuclear receptors is not 
limited to the nucleus. Nuclear receptors such as the glucocorticoid receptor are predominantly 
located in cytoplasm, bound by specific proteins such as heat shock proteins (Aranda and 
Pascual 2001). Binding of the ligand causes a conformational change and release of heat shock 
proteins, allowing the receptor to translocate into the nucleus and bind to its specific regulatory 
elements.  Sub-cellular localisation does not need to be absolute. For example, the vitamin D 
receptor is localised equally between the nucleus and cytoplasm, with this localisation changing 
to predominantly nuclear following ligand activation. Finally, receptors such as the pregnane 
X-receptor are localised predominantly in the nucleus even in the absence of ligand. In this 
case, the PXR is most likely held within the nucleus in an inactive state, bound by co-
repressors. Upon binding of the specific ligand it causes a conformational change in the 
receptor, allowing the co-repressor to be released and binding of the receptor to the specific 
promoter. Once bound co-activators are recruited to the receptor, such as histone acetylase and 
RNA polymerase II which allow active transcription of the gene (Jacobs et al. 2003).  
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Figure 1.3.2. Nuclear Receptors their function and physiological role; a dendrogram 
illustrating the clustering of nuclear receptors  and the distribution profiles among  reproduction 
and development, sCNS, circadian and basal metabolic function, lipid metabolism and energy 
homeostasis, bile acids and xenobiotic metabolism and steroidogenesis (Bookout et al., 2006). 
 
The extensive function carried out by the nuclear receptors is clustered in to five key groups, 
as demonstrated with a dendrogram in Figure 1.3.2. Nuclear receptors can act as endosensors 
controlling metabolic, development and growth processes through receptors such as vitamin D 
and estrogen receptors, responding to hormones such as Vitamin D and estrogens. Nuclear 
receptors are also referred to as xenobiotic sensors as they respond to the potentially toxic by-
products of xenobiotic metabolism and allow for the regulation of critical drug metabolising 
enzymes and transporters.  Key nuclear receptors of ADME are constitutive anndrostane 
receptor (CAR), pregnane X receptor (PXR) and farnesoid X receptor (FXR) which are briefly 
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discussed in the following sections and the different nuclear receptors and their roles are shown 
in Table 1.3.1 (Tirona and Kim, 2005), (Bookout et al., 2006), (Köhle and Bock, 2009).  
1.3.2 Pregnane X Receptor 
The pregnane X receptor (PXR), also known as steroid and xenobiotic receptor or pregnane 
activated receptor, is predominantly expressed in the liver and intestine. It can also be found at 
lower levels in the kidney, lung, skin and vasculature, replicating its role as a key xenosensor 
for the body.  Upon activation, PXR forms a hetrodimer with RXR, and the PXR:RXR 
heterodimers go on to regulate the expression of drug metabolising enzymes and transporters 
that play a key role in the cellular response to xenobiotic challenge. It has been shown that the 
pre-treatment of rodents with PXR ligands provides a protective effect against various 
toxicants, most likely through the stimulation and activity of the PXR target genes. These target 
genes include, phase I enzymes (e.g. CYP3As and CYP2Cs), phase II enzymes (e.g. UGT1A1 
and SULTS) and drug transporters (e.g. MDR1 and MRP2) (Staudinger et al., 2001), (Gao and 
Xie, 2010).  
1.3.3 Constitutive Androstane Receptor 
The constitutive androstane receptor (CAR) is a paralogue of PXR, with these nuclear receptors 
sharing 40% amino acid identity within the ligand binding domain, and a correspondingly 
similar substrate binding profile.  The expression profile of CAR is more limited than that of 
PXR, being predominantly expressed within the liver and at lower levels within the intestine, 
kidneys, heart, lungs and muscle (Jacobs et al., 2003b). CAR has one property that is unusual; 
it is constitutively active, as suggested by the name, however, the presence of the testosterone 
metabolites, adranstanol and adransteol, inhibits activity under basal conditions due to 
dissociating of the CAR:RXR:DNA complex from the co-activator SRC-1. The binding of 
androstone doesn’t impact upon the RXR dimerization and binding to the DNA promoter 
region however shifts the LBD in to an inactive conformation and prevents the recruitment of 
transcriptional activators such as SRC-1 (Forman et al., 1998).  Dissociation of androstane 
returns the LBD to an active confirmation and allows binding of ligand and recruitment of 
transcriptional activators.  Due to this unusual mode of suppressed constitutive activity, CAR 
has two distinct mechanisms of action: First, direct binding of ligand into CAR can stimulate 
its translocation into the nucleus, resulting in DNA binding and gene expression.  Second, CAR 
can be constitutively localized in the nucleus and ligand binding activates the CAR:RXR 
heterodimer, DNA binding and transcriptional activity  (Waxman, 1999), (Jacobs et al., 2003b).  
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1.3.4 Farnesoid X Receptor (FXR) 
The Farnesoid X Receptor (FXR) is predominantly expressed within the liver and intestine and 
is activated by bile acids and polyunsaturated fatty acids (PUFA), including arachidonic and 
linolenic acid (Claudel et al., 2005). After ligand binding FXR binds to the FXR response 
elements (FXREs), either as a monomer or as a heterodimer with RXR, where it can either 
activate or repress a variety of FXREs.  FXR regulates the expression of CYP7A1 and CYP8B1 
following activation by bile acids. This allows their metabolism and then further conjugation 
with compounds such as taurine or glycine for increased water solubility, which is important 
as a build-up of bile acids leads to cholestasis.  Once conjugated, these bile acids require further 
assistance to leave the cell and this is carried out with active transporters such as MRP2 which 
can excrete sulphate and glucuronide conjugates.  To ensure the coordination of these 
processes, FXR also induces expression of MRP2 and therefore aids the movement of bile acids 
through the enterohepatic circulation (Kast et al., 2002). 
Here it’s been shown that nuclear receptors are key regulators of the metabolic enzymes and 
transporters required for the ADME process and they provide a large capacity within the system 
allowing quick and efficient response to chemical insult.  The nuclear receptors, drug 
metabolizing enzymes and transporters are all susceptible to genetic polymorphisms as well as 
interactions with other food and drug compounds within the body, which can create variation 
in function potentially impacting upon drug pharmacokinetics, and this shall be discussed in 
the next section. 
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Table 1.3.1. Nuclear Receptors involved in the regulation of ADME responses; the abbreviations, tissue expression, ligands and the 
functional response of the different nuclear receptors associated with ADME regulation ((Kullak-Ublick et al., 2004), (Tirona and Kim, 2005) 
Nuclear Receptor Abbrev. Ligands ADME Genes 
Regulated 
Functional Response Expression 
Pregnane X 
receptor 
PXR 
Xenobiotics, 
Rifampin, 
Steroids, Statins, 
Phenobarbital, 
Bile salts and 
precursors 
MDR1 
Oatp2 
MRP2  
CYP2B6/CYP3A4 
UGT1A1/1A3/1A4 
Increased efflux of xenobiotics from 
hepatocytes + enterocytes.                
Increased hepatocyte uptake of organic 
anions and xenobiotics (e.g Digoxin).  
Increased efflux of anionic conjugates/ 
xenobiotics from hepatocytes + enterocytes. 
Increased CYP and UGT enzyme expression. 
Liver, Small 
Intestine,  Colon 
Constitutive 
Androstane 
Receptor 
CAR 
Xenobiotics 
Phenobarbital 
MRP2  
MRP3  
CYP2B1/CYP2B6 
UGT1A1 
Increased apical efflux of anionic conjugates/ 
xenobiotics from hepatocytes + enterocytes. 
Increased basolateral efflux of anionic 
conjugates /xenobiotics from hepatocytes, 
cholangiocytes + enterocytes. Increased 
CYP2B1, CYP2B6 and UGT1A1 expression. 
Liver 
Farnesoid X 
Receptor 
FXR Bile Acids 
OATP8 
BSEP                 
MRP2 
SULT2A1/UGT2B4 
Increased hepatocellular uptake of organic 
anions + xenobiotics.                          
Increased biliary excretion of bile salts. 
Increased efflux of anionic conjugates + 
xenobiotics from hepatocytes + enterocytes. 
Liver, Kidney, 
Small Intestine, 
Adrenals, 
Vascular Smooth 
Muscle 
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Increased SULT2A1 and UGT2B4 
expression. 
Peroxisome 
Proliferator 
Activated 
Receptor-α 
PPARα 
Fatty acids, 
fibrates, 
DHEAS 
BSEP 
ASBT (SLC10A2) 
MDR2, BSEP 
Increased phospholipid flippase at the 
canalicular membrane of the hepatocyte. 
Increased Na+ dependant bile salt uptake in 
the ileum. Increased MDR2 and reduced 
BSEP expression. 
Liver, Heart, 
Muscle, Kidney 
Liver Receptor 
Homolog (also 
known as α1-
fetoprotein 
transcription factor) 
LRH-1 Bile Acids 
MRP3 
CYP7A 
Increased MRP3 Expression resulting in 
increased efflux of anionic conjugates + 
xenobiotics from hepatocytes/enterocytes + 
cholangiocytes. Increased CYP7A 
expression. 
Liver, Small 
Intestine, 
Pancreas, Ovaries 
Glucocorticoid 
Receptor 
GR Glucocorticoids 
ASBT (SLC10A2)  
CAR/PXR         
CYP3A4/CYP2B6 
Increased transporter expression resulting in 
increased Na -dependent bile salt uptake in 
ileum. Up-regulation of CAR and PXR and 
CYP3A4 and CYP2B6 
Ubiquitous 
Liver X Receptor LXR Oyxterols 
ABCA1  
ABCG5/ABCG8 
CYP3A4/CYP2B6 
Increased cholesterol efflux from hepatocytes 
and enterocytes.             Increased cholesterol 
secretion into the bile. Reduction of  
CYP3A4 and CYP2B6 
Liver, Kidney, 
Intestine, Lung, 
Spleen, brain 
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1.4 Genetic Variation and Drug-Drug Interaction within ADME Transporters 
There are both gene sequence and protein expression differences between species and these 
differences also exist within species. This variation can cause individuals ADME response to 
drugs to be widely varied and have significant biological implications when introducing drugs 
to the system, meaning what maybe a safe dosage for one person could be toxic in another. It 
is therefore essential to understand these differences to provide optimal drug efficiency for 
individuals.  
1.4.1 Genetic variation and effects on ADME 
Genetic variations are naturally occurring differences which appear within the genome, 
between individuals of the same population or between different populations and are 
responsible for the drive of natural selection, caused due to sexual reproduction or mutation 
from environmental influences. Genetic polymorphisms can occur in both coding and non-
coding regions of DNA and both can influence the gene function, and single nucleotide 
polymorphisms (SNPs) are the most common.  Alterations to the non-coding regions may 
affect the proximal promoters of genes, effecting transcription factor binding potentially 
causing changes in gene expression. A study by (Hesselson et al., 2009) looked at the genetic 
variation in the proximal promoters of both SLC and ABC transporters, and showed that the 
majority of SNPs were found in the proximal promoter region of the transporter genes. These 
polymorphisms may affect binding of transcription complexes to their regulatory regions, 
leading to a loss or reduction of transporter expression. More polymorphisms were seen in 
SLCs than the ABC promoters, with one polymorphism occurring in every 75 base pairs and 
106 base pairs, respectively (Brown, 2002).  
Alterations in the coding region of the genome can be synonymous; where the alteration in the 
genetic code has no impact upon the amino acid sequence, or non-synonymous that does alter 
the amino acid sequence and these are classed as missense or nonsense.  Missense mutations 
are a single nucleotide change which can result in a change in the codon resulting in a change 
in the amino acid sequence of the protein. A nonsense mutation is where a codon change results 
in the introduction of a premature stop codon into the genetic sequence which results in a 
truncated protein. There are also polymorphisms referred to as INDELs, which are due to 
deletions or insertions into the genome sequence, which occur in both coding and non-coding 
regions. These polymorphisms cause a shift in the reading frame due to alteration in the codon 
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sequence of the mRNA, leading to an alteration of the protein translated (Alberts et al., 2005, 
Brown, 2002). 
Genome- wide association studies (GWAS) examine these genetic variations within different 
individuals to see if any SNPs are common among the population and if they are associated 
with specific traits of disease and health. The International HapMap Project was launched in 
October 2002 to create a genome wide database of common human sequence variation, 
available to the public providing them with information needed to guide genetic studies of 
clinical phenotypes, both within populations and between populations (International HapMap 
Consortiumm 2005). Knowledge of SNPs can help identify any differences in 
pharmacokinetics of drugs and provide insight into the pharmacogenetics, the study of the 
genetic differences in metabolic pathways which can impact upon an individual’s response to 
drugs, which could provide targets for drug therapies. Such genetic variation can be seen in all 
metabolising and transporter genes related to the ADME processes along with nuclear 
receptors. The potential for drug toxicity is known to vary between individuals for the same 
drug and a contributing factor is genetic polymorphisms in ADME genes (Urquhart et al., 2007, 
Ma and Lu, 2011, Daly, 2010).  
 
CYP2D6 is responsible for the metabolism of 25–30 per cent of prescribed medications and 
represents approximately 2-5 per cent of total CYP content of the liver.  It has the largest 
phenotypic variation with over 80 allelic variants but most are rare within the population.  Two, 
CYP2D6*3 and CYP2D6*8 have no functional activity and CYP2D*6, *9 and *10 each have 
decreased catalytic activity.  CYP2D6 is the primary enzyme which acts on tamoxifen, a breast 
cancer therapy, metabolising it to the active form endoxifen. Poor metabolizing variations of 
the enzyme reduce the circulating levels of endoxifen and increase the risk of breast cancer 
relapse (Pinto and Dolan, 2011).  UGT1A1 gene variants have been associated with the 
development of severe toxicity with the use of irinotecan, a topoisomerase I inhibitor often 
used in treatment of colon cancer. Diarrhoea and neutropenia are well known side effects of 
treatment and severity of these side effects is dependent on the efficiency of glucuronidation 
of SN-38. A tandem repeat in the TATA box region of the UGT1A1 promoter generates 
variant, referred to as UGT1A1*28, is associated with decreased expression and activity 
particularly in Caucasians (Toffoli et al., 2006).  
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A prime example of such an effect on transport is with the uptake transporter SLCO1B1 
(OATP1B1), which has many polymorphisms that have been implicated in inter-individual 
drug ADME. Statins are lipid lowering drugs used to reduce cardiovascular events and in rare 
cases myopathy occurs when statins are administered at higher doses with other medications. 
The clinical spectrum of statin-induced myopathy ranges from a mild and relatively common 
myalgia (5–10% of statin users/year) to a life-threatening and rare rhabdomyolysis. GWAS 
have been carried out into OATP1B1 variants and their role in statin induced myopathy. 
Fourteen non-synonymous SNPs were identified in OATP1B1 with the most common SNP 
associated with myopathy found to be c.521T>C. It has been found to decrease the transporters 
activity and cause significant increase in the plasma levels of statins such as simvastatin with 
doses of 80mg per day, increasing the risk of myopathy (Niemi et al., 2011),(Link et al., 2008).  
 
1.4.2 Drug and food interactions with transporters and effects on ADME 
Due to transporters and enzymes having broad substrate specificity, for both endogenous and 
xenobiotic compounds, an issue that commonly arises are drug interactions that can occur 
between them. Drug-drug interactions (DDIs) are a common problem, especially within 
western society, with individuals often taking multiple compounds from contraceptives, 
painkillers, statins down to multiple drug therapies as seen in oncology and 
immunosuppression in transplant patients (Ma and Lu, 2011). Nuclear receptors play an 
important role in DDIs as both endogenous and xenobiotic compounds act as agonists of 
nuclear receptors which results in increased gene transcription and ultimately expression of 
active enzyme and transporter proteins. Increasing these key determinants of ADME will alter 
the pharmacokinetics of a drug and potentially effect safe therapeutic dosing or drug efficacy.  
DDIs can also be caused by direct influence of the enzyme or transporter by another drug or 
endogenous compound. This can be when a competitive inhibitor has a higher affinity for the 
substrate binding site preventing the enzyme or transporter from binding other drug 
compounds, reducing their metabolism or transport in the cell. An example of this is inhibition 
of CYP2D6 mediated metabolism of dextromethorphan by quinidine (Schadel et al., 1995) 
Drugs for oncology are often administered as pro-drugs, which require metabolism to their 
active form. If these are co-administered with drugs such as rifampicin, a CYP3A4 inducer, it 
can lead to maximal concentrations of the drug being reached much quicker, leading to toxicity. 
The role of rifampicin in DDI’s is well characterized due to its importance as a co-therapy to 
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prevent opportunistic bacterial infections in treatment of a variety of diseases such as 
tuberculosis.  Rifampicin is a potent PXR agonist and is reported to affect drugs including 
anticoagulants, hypoglycaemia agents as well as contraceptives; undergoing increased plasma 
clearance due to increased metabolism and transport.  Genes affected by rifampicin are 
activated via the nuclear receptors PXR and CAR and these result in the activation of phase I 
enzymes including CYP2B6 and CYP3A4, phase II enzymes including UGTs and GSTs and 
transporters such as MDR1 (Chen and Raymond, 2006, Rae et al., 2001).  
DDIs have also been reported in in-vitro systems when looking at the treatment of metabolic 
disorders.  Metformin is a commonly prescribed drug given to type II diabetics, as it inhibits 
the gluconeogenesis pathway in hepatocytes and promotes use of blood glucose levels already 
present.   This is primarily taken up into hepatocytes by OCT1 however studies have shown 
this can be inhibited with co-administration of proton pump inhibitors, which are often 
prescribed as patients can suffer with gastroesophageal reflux disease (Nies et al., 2008). 
It is not only drug compounds that can be cause of these interactions within the body, but 
components of food such as vitamins can also potentially be a cause.  Flavonoids are a class of 
secondary plant metabolites and are found in a large part of our diet in fruits, vegetables and 
soya products.  As humans we ingest large quantities of these therefore study of their impact 
on cellular function is of interest. In vitro studies have shown that flavonoids may have many 
protective properties such as; anti-allergy, inflammatory and microbial properties as well as 
anti-cancer properties. These chemicals are of particular interest for medicinal purposes such 
as inhibition of cancer or reducing the risk cardiovascular disease (Song et al., 2007, Morris 
and Zhang, 2006). However most of these protective effects have been seen in-vitro at high 
millimolar concentrations which would not be seen in systemic circulations. Conditions in the 
body mean less than 5% of them are taken up and most of what is absorbed is quickly 
metabolized and excreted and therefore they probably have little or no direct antioxidant value 
under normal physiological conditions (Morris and Zhang, 2006). 
Flavonoids have been reported as dietary regulators of nuclear receptor activity, allowing 
altered metabolic response to food intake, with many flavonoids known to activate PPARs 
which are important in lipid regulation.  Although important in allowing regulation of food 
intake by the body they also have potential to play a key role in drug metabolism.  Nuclear 
receptors also regulate the membrane transporters and metabolic enzymes and if these are being 
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impacted upon they may cause increased or reduced clearance of a drug impacting upon the 
efficacy or safety of the drug (Avior et al., 2013).  
Grapefruit juice drug interactions have been well reported with more than 85 drugs reported to 
date whose pharmacokinetics are altered by its co-consumption. There have been two 
mechanisms identified effecting CYPs and transporters.  The first mechanism is mostly 
targeted towards the CYP3A4 enzyme in the intestinal mucosa.  Furanocoumarins are a 
component of grapefruit juice which can bind irreversibly to the enzyme.  This causes a 
reduction in the level of pre-systemic metabolism and increase the systemic exposure.  With 
reduced pre-systemic metabolism there is increased systemic exposure and risk of drug toxicity 
and this can be seen with statins and immunosuppressant drugs. The half-life of grapefruit juice 
is estimated to be around 12 hours but the effects may last anywhere between 4 and 24 hours 
and can be instigated by consuming as little as 200ml of grapefruit juice.  However, the effects 
of grapefruit on the drug pharmacokinetics are often of greater significance with regular 
consumption (Pirmohamed, 2013), (Mazi-Kotwal and Seshadri, 2012).   
The second mechanism is inhibition of transporters specifically OATPs which have been 
shown to be inhibited by flavonoids, naringin and hesperidin (also found in orange juice).  They 
reduce bioavailability reducing the amount being actively moved from the intestine into the 
systemic circulation and tissues therefore impacting upon drug efficacy.  An example of such 
an interaction is grapefruit juice with fexofenadine, showing a reduced amount of OATP1A2 
mediated uptake with increasing naringin concentration. There is also evidence of flavonoid 
modulation of ABC transporters and their movement of glutathione conjugates, with inhibition 
of P-gp and MRPs 1 and 2  (Bailey, 2010, Brand et al., 2011). However this effect is only dose 
responsive and the inhibition recovers after a few hours, therefore when taking drugs it is best 
to take a few hours before or after grapefruit consumption (Pirmohamed, 2013).  
Cranberries and blueberries also have a diverse number of phytochemicals including; 
flavonoids such as flavonol and anthocyanins, catechins and phenolic acids. These fruits have 
demonstrated anticancer properties as well as protective effects in cardiovascular disease; 
although interactions with NSAID flurbiprofen have been reported in in-vitro these have not 
been seen in clinical studies (Greenblatt et al., 2006), (Neto, 2007).  It has been published that 
dietary phenolic acids and flavonoids also have influence on nuclear receptors and hepatic 
uptake transporters, as well as effects on ABC transporters such as MDR1 and MRP2, however 
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less known about their impact on the basolateral efflux transporters, MRP3 and MRP4, and 
their influence on ADME as a whole (Huang et al., 2005), (Mandery et al., 2012), (Wang and 
Sweet, 2012). With the potential health benefits associated with flavonoid compounds, 
supplements of these compounds can be taken without prescription, with little regulation over 
the safe doses which can be consumed, with some supplements advising up to 800mg per day 
of some flavonoids.  Supplements being consumed alongside a healthy diet, which will also 
contain flavonoid compounds, and being unregulated by drug bodies opens up a potentially 
dangerous situation for drug interactions which could have serious outcomes, highlighting the 
need for these potential interactions to be studied in drug development. 
Genetic variations in nuclear receptors, enzymes and transporters have all been highlighted as 
significant influences in different drug treatments, where patients are often given large 
combinations of drugs, as seen in oncology with administration of multiple cytotoxic or 
hormonal agents along with analgesics, anti-emetics and nutritional supplements.  Taking large 
numbers of drugs together increases the risk of drug-drug interactions and this in itself reduces 
efficacy of treatment and increases negative symptoms. Understanding these differences can 
make the idea of personalized therapy a more important device for the future.  With genetic 
differences within sub-populations and ethnicities, along with the many varied diets across the 
world, patients could be screened before administration of drugs and have dietary review to 
ensure prevention of further medical problems. Utilising a combination of computational and 
wet lab experimentation, as described in the following section, can help unmask individual 
reactions influence on a system and better simulate what we would expect in something as 
complex as a human. 
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1.5 Experimental Techniques used in ADME analysis 
For the study of ADME processes there can be a variety of experimental approaches 
implemented from using animal models (in-vivo) cell culture models (in-vitro) and computer 
based bioinformatics approaches. A combination of these techniques is often used and I shall 
discuss some of these in the following. 
1.5.1 In-Vivo Modelling  
It is common practice within the drug industry to use animal models in the development process 
due to their similarities in physiology. They also have relativity short life spans, making them 
ideal to study potential long term effects of drugs within individuals and subsequent 
generations.  The most commonly used models are rats, mice, dogs and pig, with some work 
carried out in rabbits due to similarities in cardio vasculature.  However animal 
experimentation is restricted and expensive, requiring special animal husbandry facilities along 
with their general welfare costs.  There is also the issue that an animal model is not a human 
and although physiologically similar it is not the same.  There have been many papers published 
reporting the difference in the individual enzyme and transporter tissue mRNA and protein 
expression and the levels that these are present at within different tissues (Hilgendorf et al., 
2007).  
Genetic knock out animals can also be generated to see what impact individual enzyme or 
transporters knockouts have on the systems response to different chemical insults. An example 
of such a use is shown by Manautou et al (2005), where paracetamol treatment was given to 
mrp3 knockout mice and the disposition of paracetamol and its metabolites were investigated 
in-vivo. This was compared to wild type mice, which had under gone the same paracetamol 
treatment, to see how the disposition of parent and metabolite drug was altered.  Once animals 
from these types of studies are terminated the tissues can be taken and undergo histological 
analysis where the change of expression levels can be compared between the knockouts and 
wild types in the different ADME tissues. This allows us to observe the potential change in 
expression and localization of different enzymes and transporters in response to chemical 
insult. This is carried out using Immunohistochemistry (IHC), which uses the process of 
detecting antigens (proteins) in cells of a tissue section by using antibodies binding specifically 
to antigens within the tissues. The messenger ribonucleic acid (mRNA) expression levels in 
the different tissues can also be characterized utilising qualitative polymerase chain reaction 
(q-PCR) methods. The study of mRNA is of interest as they provide the precursor for protein 
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generations and expression; however changes in mRNA are not always indicative of changes 
in protein expression, i.e. a 4 fold change in mRNA will not necessarily be followed by a 4 fold 
change in protein levels. 
1.5.2 In-Vitro Modelling 
In vitro studies are those that are conducted using components of an organism that have been 
isolated from their normal biological surroundings in order to allow for a more detailed and 
convenient analysis, which cannot be done in vivo with whole organisms. These models can be 
whole cells isolated from an animal such as hepatocytes, subcellular components such as 
mitochondria or purified molecules from tissues such as deoxyribonucleic acid (DNA) and 
RNA (Li, 2001). 
Whilst carrying out these experiments every effort to use the same, single sex cell/tissue 
samples should be made so as to eradicate the potential issue of different transporter or enzyme 
expression levels between the sexes. (Lu and Klaassen, 2008) carried out a study on male and 
female large intestine, kidney, liver, jejunum to see if the level of ABC efflux and bile 
transporters differed between the two in response to chronic kidney disease.  Levels of Mrp4 
were shown to remain unchanged between the 2 sexes, but increases in Mrp3 were seen in the 
male kidneys which were not observed in the female.  It could be beneficial to compare results 
between the sexes to see if there is a significant difference between the protein levels of 
different transporters and enzymes, and whether this difference could have any implication on 
substrate metabolism or transport, i.e. will one sex be more susceptible to substrate toxicity 
than the other. 
Primary cells are derived from intact tissue and can be used for cell based assays.  At the time 
of the isolation of these cells they each express a full complement of drug transporters which 
are naturally present in that tissue and therefore are an accurate representation of the normal 
physiological conditions (International transporter consortium).  This can be useful in studying 
the drug disposition and potential clinically relevant drug interactions; however they have a 
much shorter life span in cell culture passage, usually lasting no more than 5-7 days. 
Due to the short lived nature of primary cells we also use immortalised cell lines such as human 
hepatatoma 7 cells (Huh7). An immortalized cell line is a population of cells from a 
multicellular organism which would normally not proliferate indefinitely however, due to 
mutation, has been able to evade normal cellular senescence and instead can keep undergoing 
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cell division. These cells can therefore be grown for prolonged periods in vitro. However the 
mutations required for immortality can make these cells a less than ideal model as they are now 
essentially cancerous cells. These mutations can occur naturally or be intentionally induced for 
the desired experimental purposes. 
Cell lines can also be designed to specifically over express a transporter or enzyme and measure 
its effect on the disposition of different drugs.  Cloning of different transporters or enzymes 
can be carried out using isolated cDNA and then when a complete gene is obtained it can be 
transfected into a cell to allow for its transcription and translation.  Especially when working 
with transporters the polarisation of the cells has large implications on their functionality in the 
cell. Therefore the cell culture requires strict control of the culture methods to ensure proper 
polarization of the cells, as they can adapt to the culture condition over time and if the cells 
aren’t correctly polarized, they will not act as they would do in a physiological system.  
Sandwich culture of primary hepatocytes uses suspended primary hepatocytes to reproduce the 
hepatic uptake function.  In-vitro polarity can be lost upon isolation of the cells therefore it is 
not possible to assess the ability of canalicular efflux and its effect on compound disposition.  
This polarity can be regenerated in sandwich cultures with collagen between the cell layers 
maintaining transporter localization and their functional properties. 
1.5.3 In Silico Modelling 
With the increased laboratory based assays and high throughput analysis open to us we are able 
to obtain vast amounts of both metabolic and transport data very quickly, however once this 
data is collected it is more often than not placed into large databases where little else is then 
done with it.  Most of this data is gained through experiments looking at small sets of individual 
reactions however it is well appreciated that these individual reactions won’t act the same once 
they are placed into and analysed in a larger system, only then can their true functions be 
deduced.  The novel approach of in-silico modelling offers the ability to analyse how each of 
these reactions work together and impact upon one another, allowing analysis of large amounts 
of data and investigation into the importance and amount of control placed on the cell, organ 
or whole body system, by individual reactions (Yu and Adedoyin, 2003, van de Waterbeemd 
and Gifford, 2003).  
There are considered to be two approaches to in-silico modeling; top-down and bottom-up. A 
top-down approach is the breaking down of a system to gain insight into the sub-systems that 
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make it up. In the top-down approach an overview of the system is first created without 
detailing any first-level subsystems, for example the human body can be divided into the 
different organs and each of these organs (systems) can then be studied in greater detail, and 
split into many additional system levels until the entire system is reduced to its base elements.  
A bottom-up approach is when multiple smaller systems are linked together to give rise to a 
larger overall system, for example the human body is an overall system but is often studied as 
smaller systems such as the liver, heart, brain etc. In a bottom-up approach the individual base 
elements of the system are first specified in great detail. These elements are then linked together 
to form larger subsystems, which then in turn are linked, sometimes in many levels, until a 
complete top-level system is formed.  
Initial compilation of the model takes time but once produced it can help towards the reduction 
in the amount of expensive lab work required and reduce the number of animals used for in-
vivo experiments.  Simulations of the biology can provide a very useful framework to study 
metabolism in a systematic manner, and show potential in directing rational drug design and 
development (Beste et al., 2007). For example a computer model of yeast can identify key 
reactions to increase the yield of alcohol and make the brewing process more efficient or when 
producing antibiotic from bacteria key reactions in its production can be identified to increase 
yield and overall profit of the production.  It also enables the application of different conditions 
and genetic profiles that the system can be exposed to.  For example people with genetic 
deficiencies such as that of MRP2 (Dubin Johnsons Syndrome) could be modelled and the 
implications on the system and drug ADME can be quickly analysed for different drug 
candidates. This could potentially enable better targeting of drugs in individual groups of 
patients and lead on to further development of the field of personalized medicine. 
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1.6 Hypothesis, Aims and Objectives 
The pharmaceuticals industry makes a significant contribution to the maintenance of an 
individual's health over their life course, and better understanding of the key ADME processes 
can better direct drug development. As demonstrated through this introduction, these systems 
have been shown to be a complex network of reactions, which seem to provide the body with 
the capacity to deal with both endogenous and xenobiotic compounds. This will vary with 
population, genetics and the different food and drug interactions an individual is exposed to. 
Understanding these differences could provide essential knowledge when prescribing, reducing 
undesirable side effects and improving patient wellbeing during therapy provided in diseases 
such as cancer. 
Therefore it is hypothesised that the transport and metabolism processes are balanced to allow 
for efficient handling of both endogenous and xenobiotics substrates into the excreta and 
systemic circulation.  
This has been studied with the use of both in-silico and wet lab experiments; 
1/ in the first phase of the study an ODE-based model of estradiol disposition in the liver was 
generated, capable of recapitulating the fate of estradiol in vivo.  Data from the literature was 
used to populate the model to enable the simulation of the effect of MRP3 and 4 in comparison 
to the more studied transporters. 
2/ The ODE-based model was then used to simulate the impact of FDIs and DDIs on the 
metabolism and disposition of estradiol in the hepatocyte 
3/ both human and rat ABCC3/Abcc3 and ABCC4/Abcc4 were cloned, and used to generate 
data on their efflux activity, in stable over-expressing cell lines. This data was used in 
conjunction with the in silico model to examine the relative impact of drug transport and 
metabolism on the disposition of the probe substrate estradiol.  
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2.0 Materials and Methods 
2.1 Materials  
 Material 
 Cloning 
LB Broth To a 1 L flask add 1 % (w/v) tryptone (Oxoid, Basingstoke, UK), 
0.5 % (w/v) Yeast Extract (Oxoid, Basingstoke, UK), 1% Sodium 
Chloride (w/v) (Fisher Scientific, Loughborough, UK) make up with 
Reverse Osmosis (RO) water, stir till dissolved and autoclave.  
LB Agar Make 1 litre of LB broth as shown above and place each 250 ml into 
500 ml duran bottles. To each 250 ml add 1.5 % (w/v) of bactoagar 
(Oxoid, Basingstoke, UK) and autoclave. 
SOB  For 1 litre add 2% Tryptone (Oxoid, Basingstoke, UK), 0.5 % (w/v) 
Yeast Extract (Oxoid, Basingstoke, UK), 0.05 % Sodium Chloride 
(w/v) 0.019 % Potassium Chloride (w/v) and make up with RO water, 
stir till dissolved and autoclave. 
SOC Make 1 litre of SOB as shown above and add 0.02% glucose 
1 x TE Dilute 100x Tris EDTA stock (Sigma-Aldrich, Poole, UK) to a 1X 
working solution with Milli-Q water. 
1% Agarose gel Add 1 % (w/v) of agarose to 100 ml of 1x TAE buffer and heat in 
microwave at medium setting until agarose is completely dissolved. 
Then add 50 µg/ml of ethidium bromide to allow visualisation under 
UV light.  
10 x TAE 8 M Tris, 0.1 M EDTA pH 8, 4 M Glacial Acetic Acid 
Mini-Prep Nucleotide Removal kit, QIAprep® Mini-prep kit (Qiagen) 
Midi-Prep NucleoBond Xtra Midi EF; Endotoxin-free Plasmid DNA Purification 
(Macherey-Nagel, Germany) 
Vector pTriEx™1.1 vector Invitrogen (Paisley, UK) 
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 Zero Blunt Topo PCR Cloning Kit (Invitrogen, USA) 
PCR components Dithiotreitol (DTT), Ethyleneglycol tetraacetic acid (EGTA) 
Deoxynucleotide Triphosphates (dNTPs), RNase OUT, Superscript II 
(Promega, UK) All PCR primers were ordered from Eurofins. 
Enzymes GoTaq®, Calf Intestinal Alkaline Phosphatase, Restriction 
Enzymes and reaction buffers (Promega, UK) 
 PrimerSTAR™ HS DNA polymerase, DNA ligation mighty mix 
Takara Bio Europe (St Germain en Laye, France) 
Plasticware Thin-walled PCR tubes Starlab Group (Milton Keynes, UK) 
1.5 ml Eppendorf tubes, (Axygen) 
 Cell Culture 
PBS 1 tablet of 5 x Phosphate buffered saline tablets (Oxoid, Basingstoke, 
UK) to 100 ml of RO water and autoclaved in 500 ml volumes. 
Plasticware T75 cell culture flask (Nunc, Fisher Scientific) 
T25 cell culture flask (Nunc, Fisher Scientific) 
96 Well Plates (Nunc, Fisher Scientific) 
6 well plates (Nunc, Fisher Scientific) 
12 well flat bottom plates (BD Falcon, Fisher Scientific) 
5 ml, 10 ml, 25 ml and 50 ml Starstedt Pipettes (Fisher) 
50 ml Starstedt Falcon Tubes (Fisher) 
25 ml Sterilin Tubes (Fisher) 
Cell-lines Human Hepatoma (Huh7) cells (Dr S. Hood, GlaxoSmithKline Ware-
UK)  
Madin Darby Canine Kidney II (MDCKII) cells (Dr S. Hood, 
GlaxoSmithKline Ware-UK) 
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MDCKII-human MRP2/MRP3 (The Netherlands Cancer Institute) 
Human Embryonic Kidney (HEK293) cells and HEK293-human 
MRP4 (Netherlands Cancer Institute) 
Female Primary Human Hepatocytes (donated by Pfizer) 
Cell Culture Dulbecos Modified Eagle Medium – With 4500 mg/L glucose, L-
glutamine, and sodium bicarbonate, without sodium pyruvate, liquid, 
sterile-filtered, suitable for cell culture (Sigma, St Louis MO, USA.) 
100 U/ml of Penicillin and 100µg/ml of Streptomycin and 10 X Trypsin 
EDTA Solution (Sigma, St Louis MO, USA 
Heat Inactivated Fetal Bovine Serum (FBS) and Lebovitz L-15 
Medium - + L-Glutamine and Amino Acids, (Gibco, NY, USA) 
100 X Non-Essential Amino Acids (Gibco, UK)  
0.01 % Poly-L-lysine solution (Sigma Dorset UK) 
Efflux Transport 
Assays 
Omega FluoSTAR Plate Reader ex. 504nm and em. 540nm 
5(6)-carboxy-2’,7’-dichlorofluorescein diacetate (Sigma, Dorset. UK). 
5(6)-Carboxy-2′,7′-dichlorofluorescein (Sigma, Dorset UK) 
Hyclone Hanks Buffered Saline Solution  (HBSS) (Invitrogen, UK) 
Dimethylsulfoxide (DMSO), (Sigma, St Louis MO) 
Naringin (71162; Sigma, St Louis MO) 
Hesperedin (H5254; Sigma, St Louis MO) 
Protein Assays Bicinchoninic Acid Solution (B9643-1L Sigma St Louis MO) 
Copper (II) Sulphate Solution (C2284-25ml Sigma St Louis MO) 
BSA 10,000 ug/ml solution 
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RIPA buffer: 150 mM Sodium Chloride, 1 % Nonident, 0.5 % sodium 
deoxycholate, 0.1 % SDS, 50 mM Tris pH 8 
 UPLC-MS 
UPLC Columns Acquity UPLC BEH C8 1.7 µm 2.1 x 100 mm column (Part Number 
186002878 Waters, Hertfordshire, UK) 
Acquity UPLC BEH C8 1.7 µm 2.1 x 5 mm Van Guard Pre-Column 
(Waters: Part Number 186003978) 
LC-MS Solvents Optima Grade Water 2.5 L (Fair Lawn, NJ. Fisher Scientific) 
Optima Grade Methanol 2.5 L (Fair Lawn, NJ. Fisher Scientific) 
1 L Glass Duran Bottles (Fisher Scientific, UK) 
1 L Glass Measuring Cylinder (Fisher Scientific, UK) 
LC-MS Sample 
Preparation 
2 ml Eppendorf Tubes (Fisher Scientific) 
LC-MS Grade Acetonitrile (Fisher Scientific) 
2 ml Amber Vials (Chromacol-VWR) 
0.3 ml Fixed Insert Vials (Chromacol-VWR) 
Caps - slitted PTFE/silicon (Chromacol-VWR) 
Estrone, Estradiol, Estrone-3-Sulphate Potassium Salt, 17-α-
Ethynylestradiol, Sodium Glycholate (Sigma, St Louis MO) 
LC-MS 
Equipment 
UPLC – H Class (Waters, UK) 
Xevo TQ-S (Waters, UK) 
Mass Lynx Version 4.1 
 
 
Software 
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Modeling 
Software 
Cell Designer v.4.1 (http://www.celldesigner.org/) 
COPASI v.4.6 Build 32 (http://www.copasi.org/tiki-view_articles.php) 
Gene/Sequence 
Analysis 
NCBI Blast Software  (http://blast.ncbi.nlm.nih.gov) 
Chromas Lite V. 2.01 (www.technelysium.com.au) 
Vector NTi V.10.3.0 (2006, Invitrogen Corporation) 
 Graph Pad Prism 5 (http://www.graphpad.com/scientific-
software/prism/#1) 
Data Banks BRENDA (www.brenda-enzymes.org),  
Drug Bank (http://www.drugbank.ca/),  
Gene cards (http://genecards.org/) 
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2.2 Cloning Abcc3 and Abcc4 
2.2.1 Cloning Strategy 
The Rattus Norvegicus gene sequences for Abcc3 (NM_080581.1) and Abcc4 (NM_133411.1) 
were obtained from the NCBI gene database (http://www.ncbi.nlm.nih.gov/). The cDNA 
sequence of each gene was uploaded to Vector NTI® software (Invitrogen) to identify 
restriction sites within the gene, specifically those restriction enzymes which cut the sequence 
once.  Both Abcc3 and Abcc4 are large, with a total exon length of approximately 4.5 - 5 kb. 
They are therefore difficult to amplify from cDNA as a single fragment, and hence each 
sequence was divided in to fragments for amplification that could be ligated together to form 
the whole sequence in a vector.  pTriEx 1.1 was used as an expression vector, as it has a very 
flexible multiple cloning site (MCS) giving a greater range of possibilities for the insertion of 
the fragments. Figure 2.1 shows the resultant cloning strategy, which produced three fragments 
for both ABCC3 and ABCC4 that could be reconstructed in pTriEx 1.1 to form the full exonic 
gene structure.  For each fragment, forward and reverse primers were designed around the 
restriction sites, or where necessary restriction sites were created within the reverse primer.  
 
Abcc4RATgene
4526 bp
CDS AgeI (2425) Not I (4032)PflMI (1214)
EcoRI (1250)
Abcc3RATgene
5174 bp
CDS Alo I (3076)BclI (1689)EcoRI (17) Not I (4671)
A 
B 
Figure 2.2.1. Cloning Strategy for Rattus Norvegicus Abcc3 and Abcc4: For cloning of 
the rat genes Abcc3 and Abcc4 each sequence was split into three fragments by analysis of 
the restriction sites within the gene sequence and the vector pTriEx 1.1 using vector NTI 
(A) Abcc3 rat gene cloning strategy; fragment 1 (F1) EcoRI – BclI, F2 BclI – AloI, F3 AloI 
- NotI (B) Abcc4 rat gene cloning strategy; F1 start of sequence to EcoRI, F2 PflMI – AgeI, 
F3 AgeI -NotI.  
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2.2.2 DNase I treatment  
Template RNA, previously extracted from rat liver by Dr Ciaran Fisher, was DNase I-treated 
in order to remove any contaminating genomic DNA from the sample in preparation for reverse 
transcription polymerase chain reaction (RT-PCR), according to the manufacturer’s 
instructions (Promega, Southampton, UK). Briefly, samples were incubated with DNase I at 
37 °C for 30 min followed by the addition of 1 µl 20 mM Ethyleneglycgol Tetraacetic Acid 
(EGTA) stop solution and incubated for 10 min at 60 °C, after which the samples were stored 
at -20 °C. 
2.2.3 cDNA synthesis 
cDNA was synthesised, using reagents from Promega (Southampton, UK) and RNase free tips 
and tubes.  4 μl (1 μg) DNase I treated RNA, 5 μl RNase-free water, 1.5 μl 10 mM dNTPs and 
1.5 μl 2 μM gene specific primer (see section 3.1.1) were mixed, heated to 65 oC for 5 minutes 
and then placed on ice for at least 2 minutes.  A stock reaction mix was created containing 4 μl 
of 5x RT buffer, 2 μl of 0.1 M Dithiothreitol (DTT), 1 μl RNase OUT, 0.75 μl of water and 
0.25 μl of Superscript II per reaction, which was kept on ice until added to the RNA/Primer 
mix.  The mixture was incubated at 42 oC for 50 minutes followed by 15 minutes at 70 oC.  80 
μl of water was added to give the equivalent of 10 ng/μl input RNA and store at -20 oC 
2.2.4 PCR 
Each PCR was optimised using GoTaq PCR reaction mix (Promega, Southampton, UK), 
according to the manufacturer’s instructions. The samples were run on a thermocycler with the 
following programme: Step one 94 oC for 1 minute, step two 98 oC for 10 seconds, step three 
a specific temperature gradient run for each primer set annealing temperature for 15 seconds, 
step four 72 oC for 2 minutes and repeated step 2 to 4, 34 times, step five 72 oC for 5 minutes 
and then hold at 4 oC. 
Once each primer pair was optimized using GoTaq, the high-fidelity polymerase PrimeSTAR 
HS DNA polymerase was used for final amplification of each fragment (TaKaRa, Saint-
Germain-en-Laye, France). Samples were run with 29.25 µl milli-Q water, 10 µl buffer, 4 µl 
DNTPs, 1.25 µl 10 µM primers, 5 µl template and 0.5 µl of primestar. The samples were run 
on the thermocycler using the same conditions as GoTaq polymerase above, with slight 
alterations to annealing temperature as required. 
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2.2.5 DNA Extraction 
Once the fragment of correct size was obtained from each PCR primer pair the PCR reaction 
were cleaned up with a Phenol-Chloroform extraction to remove reaction components.  A 1:1 
volume of phenol:chloroform was added to the reaction product and vortexed briefly, and then 
centrifuged at 10,000 x g for 1 minute. The top aqueous layer was removed and place in a new 
1.5 ml Eppendorf tube and precipitated with 1 tenth the volume of Sodium Acetate (NaOAc) 
and 3 volumes of ice cold 100 % ethanol. The reaction was mixed by inverting and immediately 
centrifuged at 10,000 x g for 15 minutes.  The pellet was washed with 500 μl of 70 % ethanol 
and inverted to mix, then centrifuged at 7,600 x g for 5 minutes.  Excess ethanol was removed 
and the pellet was air dried for 15 minutes. Once dry, the pellet was re-suspended in 50 µl 1 x 
TE. 
2.2.6 Phenol/Chloroform Extraction of DNA from Agarose Gel 
It is sometimes necessary to purify a PCR fragment directly from an agarose gel, to remove 
unwanted, non-specific, PCR fragments for example. First, the filter section of a 1 ml filter tip 
was inserted into a 1.5 ml Eppendorf tube. The desired fragment was cut from the gel and 
placed on top of the filter and centrifuged at 7600 x g for 1 min; 150 μl 1xTE was added to the 
top of the filter, and then centrifuged again under the same conditions to ensure that as much 
of the DNA as possible was extracted from the gel. The eluate was mixed with 250 μl 
phenol/chloroform (1:1 v/v), vortexed, and centrifuged at 7600 x g for 1 min. DNA was then 
precipitated from the supernatant using 300 mM NaOAc and 3 volumes of ice cold ethanol 
(EtOH) and inverted 3 times to mix. Samples were then spun immediately at 7600 x g for 15 
min, the pellet washed with 500 μl 70 % EtOH and spun again at 7600 x g for 5 min. Excess 
EtOH was then removed, the pelleted DNA air-dried for 5 minutes and then re-suspended in 
10-20 µl of 1X TE. 
2.2.7 Restriction Digests 
Restriction digests were required to prepare the cDNA for insertion into pTriEx, and were 
carried out as shown in figure 2.1. For each digest 1 μl of the cleaned cDNA, no more than 1 
µg/µl, was added to 1 X reaction buffer, 10 units of each restriction enzyme required and milli-
Q water was used to make the total volume up to 15 μl. The digest was carried out at the optimal 
temperature according to the manufacturer’s guidelines.   
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2.2.8 Ligation reaction  
Ligation is required to insert our gene fragments into the desired plasmid and during this work 
two different sets of ligations were used.  Takara mighty mix was used to insert cDNA 
fragments into pTriEx 1.1 but little success was had with this so a second ligation using 
Invitrogen’s TOPO blunt kit was used to help increase the number of successful 
transformations. 
2.2.8.1 Takara Mighty Mix Ligation 
Each fragment and vector was digested with their specific enzymes to create sticky ends 
allowing more efficient ligation, or where necessary fragments were digested with one sticky 
end and one blunt end to allow the correct orientation within the vector. When calculating the 
ng of insert required to react with 50 ng of vector, the following calculation from (Mulhardt, 
2007) was used; ng vector x size of insert (kb)/ size of vector x 6.  The combined volume of 
vector and insert according to manufacturer’s protocol was 5-10 μl, to which 1 volume of 
Ligation Mighty Mix (TaKaRa Saint-Germain-en-Laye, France) was added and briefly 
vortexed. This was then incubated at 16 oC for 4 hours for blunt ends, or 16 oC for 1 hour for 
sticky ends.   
2.2.8.2 Zero Blunt TOPO Ligation 
The Invitrogen Zero Blunt TOPO PCR cloning kit (Paisley, UK) was used following the 
manufacturer’s guidelines; 4 µl of PCR product was added to 1 µl of salt solution and 1 µl of 
the TOPO blunt vector and incubated at room temperate from 5 to 30 minutes. 
2.2.9 Transformation into E. coli 
2.2.9.1 Preparation of DH5-alpha Competent Cells 
LB agar plates with no antibiotic were created then using good aseptic technique, and 20 µl of 
DH5α E. coli streaked onto the plate and grown overnight at 37 oC. A single colony was used 
to inoculate 5 ml sterile SOB, and then grown at 37 oC shaking incubator (rpm) overnight. 
Next, the 5 ml culture was transferred into a 2 litre flask containing 400 ml of sterile SOB and 
grown in an orbital shaker set to 250 rpm and 37oC,  until the OD600 was approximately 0.45 
(2-3 h).  Once at the correct density, cells were placed on ice for the rest of the procedure. Cells 
were harvested by centrifugation at 7,600 x g at 4 oC for 10 minutes. The supernatant was 
decanted and the cells re-suspended in 50 ml of ice cold sterile 100 mM sodium chloride, and 
centrifuged at 7,000 rpm at 4 oC for 10 to 15 minutes.  The supernatant was decanted and cell 
64 
 
pellet re-suspended in ice cold sterile 100 mM calcium chloride and incubated on ice for 60 
minutes. The cells were centrifuged at 5,000 rpm at 4 oC for 10-15 minutes. The supernatant 
was decanted and the cell pellet gently re-suspended in 1 ml of ice cold, sterile 100 mM calcium 
chloride, without vortexing). The cell suspension was kept on ice and ice cold sterile glycerol 
was added to a final concentration of 15 % (v/v).  The cell suspension was aliquoted into 50-
100 µl portions in sterile 1.5 ml eppendorf tubes and store at -80 oC until requried. 
2.2.9.2 Transformation of Plasmids  
LB agar plates were poured with an ampicillin concentration of 50 μg/ml for pTriEx plasmids 
and 50 μg/ml kanamycin for TOPO blunt plasmids. Plates were then dried at 37 oC before use. 
Chemically-competent DH5α E. coli were defrosted on ice.  The transformation reaction for 
pTriEx comprised 45 μl of the competent cells, 4 μl of ligated vector and insert or the vector 
control, and was mixed gently with a pipette tip.  For TOPO plasmid one tube of one shot 
competent cells were defrosted and kept on ice at all times.   Two microliters of TOPO cloning 
reaction was added to the cells. The cells for both plasmid types were incubated on ice for 30 
minutes, then pTriEx was heat shocked for 45 seconds and TOPO blunt for 30 seconds, at 42 
oC to terminate the transformation reaction. The cells were incubated on ice for 2 minutes for 
recovery. For pTriEx containing cells 500 μl of LB broth was added to each tube and then 
centrifuged at 5,400 x g rpm for 1 minute. 400 μl of medium was removed and the cells were 
re-suspended in the remaining medium.  For TOPO cells 250 µl of SOC medium was added 
and then incubated for 1 hour at 37 oC in an orbital shaker (250 rpm) for optimum recovery. 
Only cells with the TOPO vector and insert will grow as the insert disrupts the kill gene in the 
plasmid. 
Each plate was labelled accordingly and 100 μl of re-suspended cells were spread across the 
plate then incubated at 37 oC overnight. 
Following overnight incubation, colonies were picked using a sterilised tooth pick and place in 
a 25 ml Sterilin tube containing 5 ml of LB broth and 50 µg/ml of ampicillin or 50 µg/ml of 
kanamycin. Colonies were grown over-night on an orbital shaker (250rpm) at 37 oC.  The result 
cultures were rapid-screened for insert presence using the phenol:cholorform approach.  60 μl 
of culture was added to 60 μl of phenol:chloroform (1:1 v/v) and 10 μl of orange loading dye 
in a 1.5 ml Eppendorf tube.  Samples were vortexed and centrifuged at 10, 000 x g for 30 
seconds. 10 μl of the top aqueous layer was separated on a 1 % agarose gel against the 
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undigested vector control.  If the cultured colonies contain vector-insert constructs they will 
run slower on the gel than the undigested vector control.   
2.2.10 Mini and Midi Prep Plasmid Extraction 
For mini preps 5 ml LB cultures containing 50 µg/ml of antibiotic were inoculated with a 
colony and grown at 37 oC overnight.  The mini prep, alkaline lysis method (Qiagen, Crawley, 
UK) was carried out using the manufacturer’s standard protocol, and re-suspended in 50 µl of 
1 x TE.   Midi-Prep Plasmid Extraction was carried out using a 100 ml of LB broth containing 
50 μg/ml of antibiotic and inoculated with 50 μl of the 5 ml LB culture containing the desired 
plasmid and shaken at 250 rpm and 37 oC overnight.  The 100 ml culture was then split between 
2 clearly labelled 50 ml falcon tubes and and centrifuged at 4,500 x g for 10 minutes at 4 oC.  
The supernatant was discarded and the pelleted cells vortexed with any remaining LB broth to 
allow for better re-suspension.  The endotoxin-free Plasmid DNA purification was then carried 
out according to the November 2010/Rev.04 Macherey-Nagel user manual.  For the 
precipitation step, the 5 ml of elute was divided between 6 x 1.5 ml Eppendorf tubes with 800 
μl of elute and 600 μl of isopropanol in each tube, and centrifuged at 15,000 x g at 4 oC for 30 
minutes.   
2.2.11 Agarose Gel Electrophoresis 
The quality and approximate quantity of DNA from PCR and plasmid preps were assessed by 
electrophoresis of samples on a 1 % (w/v) agarose gel containing 50 μg/ml Ethidium Bromide 
(EtBr). All samples had 1 μl loaded on to the gel, diluted in 7 μl of TE and mixed with Orange 
G loading dye (0.25 % Orange G, 25 % glycerol, 10 mM EDTA) in a ratio of 1:5 (a total 
loading volume of 10 μl).  These samples were loaded onto the gels alongside a DNA marker 
ladder ranging from 5 kb to 106 bp (Figure 2.2.2).  
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The electrophoresis was run at 4-5 V/cm in TAE buffer (Tris-Acetate EDTA, 0.04 M Tris 
acetate, 0.01 M EDTA) using the RunOne™ Electrophoresis Cell system (Embi Tec, San 
Diego, CA, USA) for approximately 15 min. Gels were then visualised under UV light and 
images captured using the GeneGenius Bio Imaging System (Syngene, Cambridge, UK). 
 
2.2.12 Quantification of RNA and DNA 
The NanoDrop ND-1000 spectrophotometer used 1 µl of sample loaded onto a pedestal, 
avoiding the use of containment equipment such as cuvettes. Using fibre technology and 
surface tension the sample was held between the two optical surfaces that provide the path 
Figure 2.2.2.  DNA marker ladder used for gel electropheresis analysis. The figure above 
is a representation of the DNA marker ladder when run on a 1 % agarose gel at 100 V for 15 
minutes. This ladder is achieved by the digestion of Human Globin DNA with (1) HinfI, (2) 
BamHI and SacI, (3) HindIII and EcoRI, which are then combined with orange loading dye 
ready for use. 
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length in a vertical orientation.  During each measurement the sample was measured at both a 
1 mm and 0.2 mm path allowing a wide dynamic range of measurement (e.g. 2 ng/µl to 3700 
ng/µl for dsDNA). Briefly, 1 µl 1 x TE was used as a blank, the pedestals wiped clean with 
ethanol and distilled water and 1 µl of nucleic acid sample was loaded and measured. This 
provided a value of DNA concentration in ng/µl along with absorbance path ratios for 230/260 
nm and 260/280 nm. 
2.2.13 Sequencing 
Restriction digests were used to provide intial confirmation of an insert, prior to sequencing. 
All digest were compared to a Vector NTI® virtual digest to both identify suitable digests and 
see if the plasmid digest produced the expected fragment sizes.   
Plasmids were sent for sequencing at GATC-Biotech Ltd. (London, UK). Plasmids were 
supplied for sequencing at a concentration of 100 ng/μl and primers supplied by GATC Biotech 
were used as required covering the designated sequence.  For pTriEx 1.1 plasmid primers T7 
and pTriEx down were used, for the TOPO blunt cloning vector the M13 FP and M13 RP 
primers were used. Sequencing reactions were designed to sequence only the coding region of 
the inserted gene rather than the entire length of the vector, with the forward and reverse sites 
placed either site of the multiple cloning site of the vector. Each individual sequencing reaction 
can read up to 1 kb of Phred20 quality, equivalent to 99 % accuracy. A Phred20 score is an 
assessment of the probability of an incorrect base call is 1 in 100 bases, allowing for 99% 
accuracy. 
 
2.3 Cell Culture 
2.3.1 Recovering Frozen Cells 
Cells were recovered by thawing quickly at 37 °C in a water bath, with gentle agitation of the vial. 
Cells were then removed from the vial and placed in 10 ml of warmed DMEM with 10 % FBS and 
10 U/ml of PenStrep. The cell suspensions were centrifuged at 300 x g for 3 minutes and the 
medium aspirated off to remove the entire freezing medium.  The cell pellet was re-suspended in 
10 ml fresh warm medium as before. Cell suspensions were transferred to a 25 cm2 vented tissue 
culture flask and incubated at 37 °C with 5 % CO2. The medium was replaced after 24 hours to 
remove non-adherent cells. 
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2.3.2 Freezing Down Cells 
All cells were stored in freezing medium (90 % FBS and 10 % DMSO) at a concentration of 
approximately 1x106 cells/ml before being transferred to an appropriate storage vessel. Huh7 
cells were immersed in liquid nitrogen, whilst MDCKII and MDCKII MRP2, 3 and 4 cells 
were stored in a -80 oC freezer. 
2.3.3 HuH7 Cell Line Culture 
The human hepatocellular carcinoma (Huh7) cell line is used as an in vitro hepatocyte model 
and is a differentiated, immortalised cell line derived from hepatoma tissue originally taken 
from a 57-year-old Japanese male (Nakabayashi et al., 1982).  These cells were cultured in 
DMEM supplemented with 10 % (v/v) FBS, 100 U/ml of Penicillin and 100µg/ml of 
Streptomycin.  The medium was refreshed two to three times a week and the cell count 
maintained between 1 and 3x105. These cells were obtained from the national cell culture 
center. 
2.3.4 MDCKII Cell Line Culture 
The Madin Darby Canine Kidney II (MDCK II) cell line is a sub-clone thought to be derived 
from the distal tubule or collecting duct of the nephron and is a polarised epithelial cell. As 
these cells polarise and they have often been used in vectorial transport assays, so are therefore 
suitable for this work. Wild type MDCKII cells were cultured in DMEM supplemented with 
10% (v/v) FBS, 100U/ml of Penicillin and 100µg/ml of Streptomycin.  
MDCKII cells expressing the human ABCC2 (apical), and ABCC3 (basolateral) transporters are 
used here to measure efflux of different compounds across the basolateral and apical membranes 
and the influence of other compounds in potential drug-drug interactions. Cells were first cultured 
in DMEM containing 100 U/ml of Penicillin and 100µg/ml of Streptomycin, as described above, 
to allow for recovery and then cultured in DMEM supplemented with 10 % (v/v) FBS and 500 
µg/ml of neomycin (G416) to only allow those cells overexpressing transporters to survive. All of 
these cells were obtained from the Netherlands Cancer Institute. 
2.3.5 HEK293 Cell Line Culture 
Human Embryonic Kidney (HEK) cells were originally derived from healthy human 
embryonic kidney and later experimentally transformed and cultured with adenovirus 5 DNA 
to produce the immortalized cell line now designated HEK293. Wild-type HEK293 cells are 
cultured in DMEM supplemented with 10 % (v/v) FBS, 100U/ml of Penicillin and 100µg/ml 
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of Streptomycin.  The medium should be refreshed two to three times a week and the cell count 
kept between 1 and 3x105. 
 
HEK293 cells expressing the human ABCC4 transporter are used to measure efflux of different 
compounds across the basolateral membranes and the influence of other compounds in potential 
drug-drug interactions. Cells were first cultured in DMEM containing 100 U/ml of Penicillin and 
100µg/ml of Streptomycin to allow for recovery and then cultured in DMEM supplemented with 
10 % (v/v) FBS and 500 µg/ml of neomycin (G416) to only allow those cells overexpressing 
transporter to survive. Both of these cells were obtained from the Netherlands Cancer Institute 
2.3.6 Primary Human Hepatocyte Cell Culture 
Primary human hepatocytes of female origin were donated by Pfizer (Sandwich, UK) and were 
used for in-vitro validation of the in silico model simulations. These cells were cultured in 
Leibovitz’s L-15 medium supplemented with 10% (v/v) FBS, directly into six well plates ready 
for assay, this was carried out due to their short culture life (5-7 days).  Antibiotics were not 
used in culture to reduce risk of drug interactions within time course assays. 
2.3.7 Cell Line Maintenance 
Cells were passaged when they reached approximately 80 % confluence. Medium was removed 
and cells washed with sterile phosphate buffered saline (PBS). The cells were incubated at 37 
°C with 2 ml 1 x trypsin-EDTA for 5-10 minutes. 10 ml of medium was added to inactivate the 
Trypsin-EDTA and the cell suspension was split between new 75 cm2 vented cell culture flasks. 
The exact ratio of cell splitting was dependent on both the cell type and the experimental 
requirement, and varied between 1: 2 and 1: 10. To ensure phenotypic consistency throughout 
experiments, each cell line was only used for a fixed number of passages after recovery storage: 
Huh7 cells were used up to 30 passages after receipt and MDCKII cells were used up to passage 
60 from a new stock. 
2.3.8 MTT Cell Viability Assay 
The MTT assay is a colorimetric test that measures the activity of mitochondrial enzymes that 
reduce MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow 
tetrazole) to form insoluble purple formazan crystals. As such, it can be used to measure both 
cell viability and compound cytotoxicity to be assessed.  
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For each experiment, a 96 well plate was seeded at 40x103 cells per well, and left to grow 
overnight in DMEM containing 10 % FBS (v/v), 100 U/ml Penicillin and 100 µg/ml 
Streptomycin, with a total volume no bigger than 100 µl per well. Cells were checked the next 
day to confirm cell growth, and if more than 70 % confluent the cells were considered ready 
for treatment. Medium was removed by aspirator and varying concentrations of drug added to 
the plate in 100 µl of serum-free medium and each drug concentration was carried out in 
triplicate. The plate was incubated for 24 hours at 37 oC.  After 24 hours the media was removed 
from the cells and 100 µl of serum free medium containing 50 µg/ml of MTT added to each 
well. The plate was incubated at 37 oC for 1-2 hours, the medium carefully removed and 100 
µl of DMSO added to each well. Following a 10 minute incubation at room temperature, with 
shaking, to dissolve crystals, the absorbance measured at 540 nm and results expressed as 
percent viability relative to the control. 
2.3.9 Carboxydifluorescein Diacetate Efflux Assays 
Carboxydifluorescein Diacetate (CDFDA) is taken up into cells by passive diffusion, once in 
the cells the substrate is converted by esterases to its fluorescent metabolite CDF which is 
transported actively out of the cells.  This can be used to measure the transport kinetics of 
different cellular efflux transporters and inhibitory constants of different compounds. 
Cells were plated in sterile 12 well plates at 2x105 cells per well and left for 48 hours at 37 oC 
in serum containing medium to allow cell attachment. Next, cells were washed and incubated 
in warmed sterile HBSS for 10 minutes, and then exposed to 10 µM CDFA in HBSS at 37 oC 
for 10 minutes to load cells with CDFDA.  Cells were washed three times with ice cold PBS 
to remove any excess extracellular CDFDA, with the culture plates being held on ice to 
minimise energy-dependent metabolite efflux. Efflux was initiated once again through the 
addition of 3 ml pre-warmed HBSS and incubated for 15 minutes at 37 oC H. CDF 
accumulation in the HBSS was determined using the OmegaFluoStar to measure fluorescence 
intensity at 504 nm excitation, 540 nm emission and concentrations of CDF were extrapolated 
from a standard curve. Flavonoids, naringin and hesperedin, for inhibition were prepared at 
100 mg/ml in 100 % DMSO and diluted down in HBSS to maintain a DMSO concentration no 
more than 1.5 % (v/v). Each experiment was carried out with three independent repeats, 
achieved by repeating the experiment each time with a different passage of cells, e.g passages 
5, 7 and 9. 
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2.4 Ultra Performance Liquid Chromatography and Triple Quadropole Mass 
Spectrometry (UPLC-MS) 
2.4.1 Sample preparation 
2.4.1.1 Estradiol for cell culture treatment 
Estradiol was prepared at 1 mg/ml with 0.1 % DMSO (v/v) in Fisher optima grade methanol.  
This was then diluted down to a final concentration of 1 µg/ml Estradiol along with 2 mM of 
the bile salt sodium glycocholate in Fisher optima grade methanol. The sample was gas dried 
with nitrogen and re-suspended in HBSS buffer supplemented with 10 mM 2-(N-morpholino) 
ethanesulfonic acid (MES) to mimic a biorelevant medium and prevent drug precipitation 
during cell culture treatment. 
Cells were seeded at 3×105 cells per well (HuH7) or 1 x 106 cells per well (primary 
hepatocytes).  Plates were incubated for 24 hours to allow cell adherence, in serum containing 
DMEM medium or Leibovitz-L15 medium at 37 oC.  After 24 hours medium was aspirated 
and each well washed twice with sterile PBS. Eight hour time course experiments were run 
with the cells exposed to 1 mM estradiol in serum-free medium.  Samples of medium and cell 
lysate were taken at 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 minutes and then once an 
hour till 8 hours. These were placed at -20 oC until extraction, as described below. 
2.4.1.2 Extraction of Cell Medium Samples 
From each well 0.75 ml of the cell medium were collected and placed into 2 ml Eppendorfs 
and stored on ice for immediate extraction or at -20 oC for extraction later. 
Media Samples were vortexed for 30 seconds and then left to rest for 30 minutes at room 
temperature.  They were then vortexed again for 30 seconds; acetonitrile or methanol was 
added to the media in a 1:1 ratio (v/v) and samples were vortexed again for 30 seconds and left 
to rest for 30 minutes at room temperature. The samples were vortexed once more for 30 
seconds and then spun at 10,000 x g for 15 minutes. An aliquot of 300 µl of supernatant was 
taken and placed in to an amber chromacol vial with insert, for analysis on the LC-MS. The 
pellet formed by centrifugation was also re-suspended in 300 µl of methanol or acetonitrile, 
spun at 10,000 x g for 1 minute, and the supernatant remaining was placed in an amber 
chromacol vial. 
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2.4.1.3 Extraction of Cell Lysate Samples 
Once the medium was removed from the cells, 0.75 ml of ice cold (4 oC) water was added to 
each well and the cells were detached from the plate using a cell scraper.  Next, cell suspension 
was pippetted up and down vigorously to ensure greatest possible recovery of cells for analysis, 
and the sample transferred to a 2 ml Eppendorf tube.  Samples were stored in labelled 1.5 ml 
Eppendorf tubes and kept on ice to stop any metabolism, or at -20 oC for extraction later.   
An equal volume of ice cold acetonitrile (0.75 ml) was then added to the cells and vortexed for 
30 seconds to lyse the cells, and samples left on ice for 30 minutes. Samples were then vortexed 
for a further 30 seconds and centrifuged (10,000 x g) at 4 oC for 15 minutes. For analysis, 300 
µl of supernatant was taken and placed in an amber chromacol vial. 
2.4.2 LC-MS analysis of cell and culture medium extracts 
2.4.2.1 Instrumentation 
An Acquity UPLC system (Waters Ltd., Hertfordshire, U.K) coupled to Xevo triple quadropole 
mass spectrometer (Xevo TQ-S) was used for LC-MS analysis. An Acquity UPLC BEH C8 1.7 
µm, 2.1 x 100 mm column (Part Number 186002878 Waters, Ireland) was used for 
chromatographic separation along with an Acquity UPLC vanguard column of the same 
chemistry. 
2.4.2.2 Chromatographic separation setup (Acquity UPLC system) 
The method used with the Acquity UPLC BEH C8 column was based on Guo et al. (2008) 
methodology with modifications.  The separation of metabolites were carried out under reverse 
phase conditions using Fisher optima grade water as mobile phase A and optima grade 
methanol as mobile phase B.  Table 2.1 shows the gradient and flow rates used for the method 
of separation. 
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Before the Acquity system can be used, it was primed to ensure there was no air in the system 
and check all the pumps were working correctly.  The seal wash was primed for 2 minutes. 
During this time the tubing was checked to ensure that liquid was being pumped through; if 
not, a syringe was connected to the tubing and the seal wash pulled through the tubing 
manually. Once completed, control was selected in the Acquity control panel and the system 
was started up.  This lasts approximately 21 minutes and primes both the sample manager and 
the quaternary solvent manager.  Once the system prime was completed, the column was 
conditioned to carry out the chromatographic separation described in table 2.1. This step is 
important to prevent column damage due to quick increases in flow rates and large changes in 
solvent mixtures. The flow rate was increased at 0.1 ml/min increments until the required flow 
rate for the separation method was achieved.  The mobile phase was equilibrated to the column 
by starting the mobile phase at 100 % organic solvent, methanol (Phase B) and increasing the 
amount of aqueous solvent in 10 % increments until the starting solvent combination was 
reached.  The column temperature was set to 40 oC and regulated by the column manager.  The 
sample manager was set to keep samples at 4 oC and sample injection volume was set to 10 µl 
for all samples. 
A B 
Table 2.5.1. LC inlet gradients used for the optimisation of estrogens separation: These 
two tables show the gradient of Fisher optima grade water (mobile phase A) and Fisher optima 
grade methanol (mobile phase B) over 2 different gradients used in the optimisation of 
oestrogen separation. Table A shows a 15 minute gradient run at a flow rate of 0.5ml/min and 
Table B shows a 17 minute gradient run at 0.4 ml/min.  
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2.4.3 Mass Spectrometer Setup 
Once the column and UPLC system were primed, the MS tune page was opened and the mass 
spectrophotometer switched on. The mass spectrophotometer must be switched to operating 
mode before starting the method; this was done by switching both the API and collision gases 
on and checking the voltages of the instrument were stabilised. The system then was purged to 
ensure any potential contamination from previous runs was removed from the electrospray 
needle.  In the MS tune page the fluidics tab was opened and the fluidics purged.  This was 
carried out a minimum of 6 times before any samples were run to ensure robust data capture. 
The sampling cone requires regular cleaning between sample batches, so as to remove any 
chemical residue that may build up and effect performance.  Any build up on the cone can 
reduce the detection intensity and sensitivity compound analysis.   
Settings of the Xevo TQ-S were based on the recommended settings listed in the manufacturers 
operating guide: negative ESi mode with capillary and cone voltages of 1.6 kV and 30 V 
respectively.  The desolvation temperatures were set at 400 oC and each compound was 
individually tuned to the MS instrument using direct infusion of the compound at 1 µg/ml and 
a flow rate of 20 µl/min with no LC flow, with the tune page set in MS mode.  A broad range 
scan and a more specific range scan were opened in 2 windows, with the molecular mass of 
compound being studied set as the mass to be scanned for; e.g estrone has a molecular weight 
of 270.2 and 269.2 is set as the mass to scan for as we are using negative ion mode and lose an 
ion.   
The compound to be tuned (1 µg/ml) was placed in an amber glass vial with pierced cap and 
attached to the Xevo TQ-S for direct infusion, and the infusion was started at a rate of 20 µl 
per minute with no LC flow.  Looking at the scan windows, when a peak of approximately the 
correct size was seen data was acquired for 30 seconds in MS mode.  Once the acquisition was 
complete, the spectrum was analysed and the molecular weight of the parent ion being detected 
by the Xevo T-QS identified. Once the parent ion was confirmed, the instrument was switch to 
MS-MS mode to select daughter ions for the MS method.  The parent ion mass, confirmed in 
the first step of optimisation, was used as the set parent mass to detect suitable daughter ion 
candidates for the compound. The infusion of compound was started at 20 µl/min with a 
collision voltage of 4 V and gradually the collision voltage was increased till a large number 
of fragments were visible and the detection of the parent ion was reduced to approximately 
20%. Data acquisition was then started for 30 seconds in daughter scan mode.  The daughter 
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ions with the highest detection were selected for the MS method and their collision voltage was 
used in the MS method.  An additional daughter ion was picked to act as a qualifier ion, 
allowing confirmation of compound detection. Table 2.2 shows the parent and daughter ions 
used for the scans of compounds in this method. 
 
 
 
 
 
 
 
 
2.5 In-Silico Modelling 
2.5.1 CellDesigner™ v.4.0 
Cell designer is a diagram editing package for drawing biochemical networks and uses a set of 
symbols to represent these networks as process diagrams (Kitano et al., 2005).  This provides 
a graphical representation of a biological network, where the species and reactions are linked 
with kinetic laws described as ordinary differential equations (ODEs). The programme 
supports the systems biology mark-up language (SBML), a universal XML language allowing 
models to be transferred and analyzed by several hundred different programmes (Funahashi et 
al., 2003).   
 Cell designer was used to reconstruct a network diagram of estradiol metabolism in the 
hepatocytes, plus transport in and out of the hepatocyte via basolateral and sinusoidal 
membranes. Information on the estradiol biochemical network was obtained from data banks 
including BRENDA (www.brenda-enzymes.org), a collection of functional data for some 
40,000 enzymes, and Drug Bank (http://www.drugbank.ca/), a database that holds detailed 
drug data.  Gene cards (http://genecards.org/) were also used to gather genomic data on proteins 
Table 2.5.2. Multiple Reaction Monitoring Pairs for estrogen compound detection. 
Shows the multiple reactions monitoring (MRM) set for each compound; Estrone (E1), 
Estradiol (E2) and Ethinylestradiol (EE2) and the collision voltage used for each.  The 
capillary and cone voltage were set to 1.6 Kv and 30 V respectively, for all compound MRMs.  
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involved within the pathway. Where information was not available from a database it was 
gained from literature searches.  
2.5.2 COPASI™ v.4.6 (Build 32) 
The SBML scripts generated in CellDesigner, were imported into the Complex Pathway Simulator 
v.4.6 (COPASI; http://www.copasi.com), which can be used to run simulations and analysis of 
biochemical networks and their dynamics, and simulate the network behaviour using the ODEs 
for all species, compartments and global quantities within the model.  It enables multiple types 
of analysis of the network dynamics including time course analysis, sensitivity analysis and 
enables parameter estimation. This software gives us a means of visualizing the data in multiple 
formats; tables, plots and histograms.  For modelling purposes the concentration units used in 
our model were set to be in pmol/pl. 
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3.0 Liquid Chromatography and Mass Spectrometry (UPLC-MS) method 
development; for the detection of Estradiol and its metabolites in cell culture 
samples. 
3.1 Introduction 
To allow the examination of the individual roles of ABCC family transporters on drug 
disposition, in silico models are a valid approach as they allow the computational separation of 
respective inputs of each protein species into the overall network, and it’s emergent phenotype. 
Estradiol represents an ideal probe substrate for such studies as it is a compound which has 
metabolites transported by all of the ABCC transporters of interest (Hirouchi et al., 2009, 
Russel et al., 2008). Estradiol is one of a group of endogenously made steroids called estrogens, 
of which estradiol is the most abundant. It is often used in the oral contraceptive pill and 
hormone replacement therapy.  In order for any in silico model to be of true predictive value, 
it must both be populated with realistic kinetic data, and needs to be tested and validated to 
ensure biological relevance to human metabolism. To enable this validation phase, we 
developed a method using an ultra-pressure liquid chromatography (UPLC) coupled to a triple 
quadropole mass spectrophotometer (MS), which could detect estradiol and its metabolites in 
cell culture samples.  
 
 
 
 
 
 
 
 
Estrogens are present in nanomolar levels in cells, are all very similar in structure, as shown 
with estrone and estradiol in Figure 3.1.1 and it can be very difficult to accurately detect and 
quantify the individual compounds in a sample. RadioImmuno Assays (RIA) have been shown 
Estrone Estradiol 
Figure 3.1.1. This shows the chemical structures of both Estrone and Estradiol which have 
molecular weights of 270.36 g/mol and 272.38 g/mol respectively. Both compounds are very 
similar in structure and molecular weight, with the difference being an additional OH group 
within the estradiol. 
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to be sensitive and have specific detection, however it requires special precautions and 
licencing to carry out this work due to the use of radiation.  These RIAs are considered the gold 
standard, but there is a desire to move towards the safer, non-radioactive, Enzyme Linked 
Immuno-Sorbent Assays (ELISA) that uses a colorimetric- or florescence-based endpoint. 
These assays are sensitive; however, they often have little specificity for the metabolites of 
estradiol and often separate kits are required to detect estrone and estradiol from a sample. This 
is not ideal as more aliquots of samples are used and it increases the risk of experimental error 
and variation in the results. Alternatively, analytical methods that are coupled with mass 
spectrometry use gas chromatography for estrogen compound separation, and only require one 
aliquot of sample for detection of all the desired compounds, which is ideal for the limited 
sample volume seen from cell culture samples (Guo et al., 2008, Giton et al., 2010, Faupel-
Badger et al., 2010).  
Due to the hydrophobic nature of estrogens, samples often require derivitisation before analysis 
to improve detection via MS.  This process requires a specific functional group of the 
compound to participate in the derivatisation reaction, and transforms the chemical into a 
product of similar chemical structure called a derivative; improving its reactivity, solubility, 
boiling point and/or melting point. This process produces derivative compounds with new 
chemical properties, which can be used for the separation and quantification of the compound 
of interest. This process is especially useful when analysing compounds of similar chemical 
structures as different derivative processes can produce distinct chemical patterns for clearer 
distinction between compounds However; derivitisation is often a long process that uses 
compounds that are both toxic and carcinogenic. Derivatisation also adds an additional step to 
sample preparation, meaning the quality and quantity of sample remaining for separation and 
detection can be greatly reduced, pH and temperature changes can lead to falsely high estrogen 
measurements in samples, requiring larger initial sample sizes for analysis (Franke et al., 2011, 
Faupel-Badger et al., 2010, Fiers et al., 2012).  
Many research groups have developed MS methods coupled to liquid chromatography to detect 
estrogens in different biological matrices. For example, (Guo et al., 2008) and (Huang et al., 
2011) both using reverse phase liquid chromatography coupled to negative electrospray 
ionisation (ESi-) and triple quadropole MS, without sample derivitisation.  Comparisons of 
RIA, ELISA and LC-MS have been carried out on urine samples, and the LC-MS results 
correlated strongly with the RIA and ELISA measurements. However, there were lower 
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coefficients of variation with LC-MS compared to RIA and ELISA, and LC-MS showed better 
sensitivity at lower concentrations of estrogens and their metabolites (Faupel-Badger et al., 
2010), (Giton et al., 2010). 
For the work carried out in this chapter, the methods used in plasma and cell culture samples 
in Guo et al. (2008) and Huang et al. (2011) respectively, and were used as the basis for 
development of a UPLC-MS detection method for estradiol and its metabolites in both cell 
medium and lysate samples. 
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3.2 Results 
3.2.1 LC-MS Optimisation 
Method development was started by selecting compounds that would be of use in the next 
phase of the project, validating the in silico model.  As mentioned previously, estradiol was 
selected as the parent compound for in silico modelling, and thereore meaning that the LC-MS 
method is required to detect estradiol, as well as estrone and estrone-3-sulphate, which are both 
metabolites of estradiol metabolism in the hepatocyte.  In addition, ethinyl estradiol, a synthetic 
analogue of estradiol, was selected to act as an internal standard. Stock solutions of each of the 
compounds were prepared in methanol at a concentration of 1 µg/ml and directly infused into 
the mass spectrometer at a rate of 20 µl per minute.  An acquisition scan was then run for 30 
seconds in ESI- MS mode with a cone voltage of 30 V to find the mass of the parent ion.  The 
spectrometer was then placed in MS-MS mode and a range of collision voltages were used to 
find the optimal settings for detection of each compound.  Table 3.2.1 shows the parent ions 
and daughter ion pairs chosen for the MS method along with the collision voltage required for 
their detection. These parent ions and subsequent daughter ions are called multiple reaction 
monitoring (MRM) pairs. Two MRMs were generated for each compound, one as the 
quantitative MRM and the other as confirmation of compound detection.  
Table 3.2.1. Ion pairs chosen for the detection of estradiol and its metabolites for the LC-
MS methodology; this table shows the multiple reaction monitoring (MRM) pairs set for each 
compound. Estrone (E1), Estradiol (E2), Ethinylestradiol (EE2) and Estrone-3-Sulphate (E3S) 
and the collision voltage used for each. The mode of ionisation was negative electrospray and 
the capillary and cone voltages were set to 1.6 kV and 30 V respectively, for all compound 
MRMs. 
 
Each of the MRM pairs shown in table 3.2.1, the parent and daughter ions of each compound, 
along with the cone and collision voltages were entered into the acquity and saved as an MS 
method within Mass Lynx.  This method controls the quadropole and cone voltages within the 
mass spec and allows for specific detection of the estrogen compounds of interest during the 
LC inlet gradient. The inlet gradient used is described in section 2.2.6, with the flow rate at 
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0.5ml/min, and a run time of 15 minutes with a gradual shift from 98% water to 100% 
methanol. Pure estrogen compounds were prepared to a concentration of 1mg/ml (3.6mM) in 
methanol and 10µl of a 1µg/ml (0.36mM) solution of each compound was then run through the 
UPLC column for separation and detection.  These were run against an acquity MS method for 
all compound MRMs, to ensure only the detection of the compound in its own MRM channel 
as well as individual retention times.  This is shown in figure 3.2.1 with (A) estrone-3-sulphate 
MRMs having retention times of 10.74 and 10.80 mins, (B) Ethinyl estradiol with a retention 
times of 10.22 and 10.25 mins, (C) Estradiol with a retention time of 10.08 mins in both MRMs 
and (D) Estrone with a retention time of 9.99 mins in its 269.2>145.8 MRM only.  The second 
MRM showed no detection with a total ion count (TIC) seen only in the hundreds, whereas the 
other MRMs all show TIC values in the thousands.   
 
  
 
 
 
 
 
 
 
 
 
Figure 3.2.1. Chromatographic separation and mass spectrometry detection of estrogens.  
Shows the separation of a mixed sample of 1µg/ml of (D) Estrone (E1), (C) Estradiol (E2), 
(B)17-α Ethinyl estradiol  (EE2) and (A) Estrone 3 Sulphate (E3S).  Each compound was 
prepared at 1mg/ml and diluted with 100% Optima grade methanol to obtain 1ug/ml (3.6mM) 
for each compound. 10µl (0.36mM) of sample was run at 0.5 ml/min inlet (section 2.6.2).  
 
A 
C 
D 
B 
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The peaks EE2 and E2 all showed reasonably smooth and sharp peaks in comparison to that of 
E1 and E3S where there is a shoulder at the front of the E1 peak registering at 9.91 minutes 
and a large broad peak spanning one minute retention time compared to the thirty seconds seen 
in others. This peak appearance could be improved with further optimisation of the inlet 
method. 
For optimisation of the inlet method pure estrogen compounds were prepared in methanol, as 
before.  These samples were run with two variations of the inlet gradient (section 2.2.6), one 
with a lower flow rate of 0.4ml/min and extended gradient time of 17 minutes (Figure 3.2.2.A) 
and a second with a flow rate of 0.5ml/min and run time of 15 minutes. (Figure 3.2.2.B) The 
lower flow rate produced short, broad peaks that are sub-optimal for quantitation, whereas the 
0.5 ml/min flow rate with a shorter gradient time (Figure 3.2.2.B) produced larger, sharper 
peaks much better suited for a quantitative method.  Blank samples of 10µl of 0.1% DMSO 
(v/v) in methanol were injected, and these were run to ensure no background detection in the 
MRMs from the solvent being used for dilution, which are absent as shown in Figure 3.2.2.A 
and B. 
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Figure 3.2.2. Comparison of two different chromatographic gradients for the 
separation of 1µg/ml estrogen samples. This figures shows 1µg/ml of Estrone (E1), 
Estradiol (E2), 17-α Ethinylestradiol (EE2) and Estrone 3 Sulphate (E3S) prepared at 
1mg/ml in 0.1% DMSO and diluted with 100% optima grade methanol.  These samples 
were all run on both the (A) 0.4ml/min inlet gradient and B) 0.5ml/min inlet as described 
in methods section 2.2.6. 
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In order to assess the impact of the inlet method on sample separation and detection, the peak 
heights and peak areas of each compound, from both gradients, were plotted and are shown in 
figure 3.2.2.  The higher flow rate method of 0.5ml/min pushes sample through the LC faster 
and this provided considerably larger peak heights and areas for all estrogen compounds; with 
marked improvements seen in the estrone 3 sulphate detection producing a 75% increase in 
peak height and 62% in peak area. Considerable differences were also seen in the other 
compounds with estrone detection by peak height improved by 42% and 29% for peak area, 
estradiol detection improved 38% and 48% and ethinylestradiol improved 32% and 37%, 
respectively. 
 
 
 
 
 
 
 
 
 
 
As well as comparing the impact of inlet flow rates, the means of preparation of the pure 
compound in methanol was also examined.  Estradiol is a very hydrophobic compound, with a 
logP of 4.2, potentially limiting its solubility in methanol.  Dimethyl sulfoxide (DMSO) was 
examined for its potential to mitigate this limiting factor in compound preparation.  Pure 
compound was prepared at 1 mg/ml in 100 %, 0.1 % and 0 % (v/v) DMSO:methanol and then 
diluted to 1 µg/ml with Fisher Optima grade methanol, resulting in final DMSO concentrations 
of 0.1%, 0.001% and 0% (v/v), respectively, 10µl of each pure compound sample were injected 
and run on the 0.5ml/min flow rate gradient. 
Figure 3.2.3. Comparison of the Peak Area and Peak height of 1ug/ml estrogen samples run 
at two different flow rates. In this figure A and B show a representative of 3 independent repeats 
where the comparison of the Peak Height and Peak Area, respectively, of Estrone (E1), Estradiol 
(E2), 17-α Ethynyletradiol (EE2) and Estrone 3 Sulphate (E3S) prepared in 0.1 (v/v) DMSO and 
Fisher Optima Grade Methanol; using the 0.5ml/min LC gradient and the extended 0.4ml/min 
gradient as described in section 2.6.2. 
 
B A 
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The impact of using DMSO during sample preparation on peak heights and peak areas are 
shown in Figure 3.2.4. It can be seen that the increasing percentage of DMSO (Figure: 3.2.4) 
improved estrone (E1) detection.  Although improvement was seen in estrone detection, with 
increase in detection, it was shown to cause a reduction in the detection of estradiol (E2), 
ethinyl estradiol (EE2) and estrone 3 sulphate (E3S), when 10µl of a 1µg/ml (36 nanomoles) 
was loaded on to the column.  Estrone (E1) detection with 0.1% DMSO (v/v) increased peak 
area by 44% and peak height by 29% and with 100% DMSO it showed an increase of 102% 
peak area and 71% peak height. The presence of DMSO at 0.1% (v/v) showed detection of 
ethinyl estradiol to decrease 2% and 7% in peak area and height respectively, and the presence 
of 100% (v/v) generated increases of 33% and 35% respectively. DMSO negatively impacted 
upon the detection of both estradiol and estrone with decreases seen in both peak area and 
height with increasing DMSO percentage. As such, a compromise between improved E1 
detection and reduced E2, EE2 and E3S needs to be struck; and was decided that 0.1 % DMSO 
produced the best detection results for all compounds and was used in all further sample 
preparations. 
 
 
 
 
 
 
 
Figure: 3.2.4. Comparison of the Peak Area and Peak height of chromatograms run at a 
0.5ml/min flow rates with 0, 0.1 or 100% DMSO (v/v) used in sample preparation. In this 
figure A and B  show the comparison of the Peak Area and Peak Height, respectively, of 36nM 
column loaded Estrone (E1), Estradiol (E2), 17-α Ethinyl estradiol (EE2) and Estrone 3 Sulphate 
(E3S) prepared in 0, 0.1 and 100% (v/v) DMSO and Fisher Optima Grade Methanol; using the 
0.5ml/min LC gradient as described in section 2.5.2.2.  
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Using pure compound samples prepared at 1 mg/ml in 0.1 % (v/v) DMSO and methanol, a 
concentration range of 36 nano moles to 0.36 pico moles was loaded onto the column and 
analysed using the 0.5 ml/min inlet gradient (section 2.2.6).  Figure 3.2.5 show the plots of 
both peak area and height against increasing nano moles.  For estrone, estradiol and estrone-3-
sulphate the plots of their peak heights and areas showed a strong linear relationship.  This is 
indicated by large r2 values for the peak area and height of estrone 0.91 and 0.99, estradiol 0.96 
and 0.95, and estrone-3-sulphate 0.98 and 0.96, respectively.  In contrast the generated 
concentration-peak plot for ethinyl estradiol showed a poorer fit to linear regression with peak 
area and height r2 values of 0.90 and 0.87 respectively.  A closer linear fit is observed for all 
compounds at the lower end of the concentration range, from 0-10nM, with the most deviation 
observed from the linear fit, at concentrations above 20 nM.  Accuracy is most important within 
the lower nano moles range as estrogen levels would not be expected to be found above these 
levels, even with contraception or hormone therapy. 
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Figure 3.2.5. Analysis of the detection limits of the UPLC-MS for the different estrogen compounds prepared in methanol. This figure shows 
the increasing nanomole amounts of each compound individually loaded onto the column and their peak heights and areas plotted against the nanomoles 
of compound loaded onto the column.  Each compound was prepared in fisher optima grade methanol and the injection volume was altered from 10 
down to 2 microlitres to alter the amount of nanomoles loaded and run on the column with the 0.5ml/min LC gradient as described in section 2.2.6. 
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There is split opinion in the scientific community as to whether the peak area or peak height is 
better for analysis and quantification.  One approach is to undertake a regression analysis 
between peak area and height. If all points follow a linear regression it is suitable to use either 
the height or area for future analysis. As can be seen in Figure 3.2.6, the data plots for all four 
compounds exhibit a good fit to linear regression between peak area and peak height, with r2 
values of 0.99 for estrone, 0.98 for estradiol, 0.99 for ethinyl estradiol and 0.97 for estrone 3 
sulphate.  
As discussed with the previous plots, shown in Figure 3.2.5, with increasing nanomolar 
concentration the points begin to deviate from the line of fit and this is seen most dramatically 
in estradiol and estrone 3 sulphate, which is shown with the r2 values that are lower than 0.99.  
The peak heights for all compounds are plotted on the y axis with a range of 0 – 3000000 
arbitrary units, however estrone 3 sulphate was plotted again with a y axis ten times smaller set 
from 0 to 300000 arbitrary units, and the deviation from linear regression can be seen more 
clearly.  A closer linear fit is again observed for all compounds at the lower end of the 
concentration range providing the method with the accuracy required. As there is good linear 
fit observed for each of these pure compounds, for both peak area and height, either are 
applicable for further analysis; within this thesis peak height will be used throughout.   
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Figure 3.2.6. Checking the suitability of peak area against peak height for use in sample analysis. Peak area and height data for Estrone, 
Estradiol, Ethynylestradiol and Estrone 3 Sulphate, from the detection assay shown in figure 3.2., were taken and plotted against each other 
and their R2 value calculated and shown on the graphs above.  If plotted and linear both peak area and height are suitable measurements to 
take for analysis and quantification.  All R2 values obtained were above 0.97 showing good linear relationships between peak area and height 
for LC—MS analysis for all our estrogen compounds. 
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3.2.2 Optimisation of extraction method 
Having optimised the method for detection of estradiol, its metabolites and the internal standard 
by LC-MS, it was necessary to optimise metabolite extraction from cell culture samples. A 
liquid phase extraction method using the organic solvents methanol and acetonitrile were 
tested.  In Figure 3.2.7, A and B represent methanol and estradiol spiked samples, respectively, 
extracted with methanol and the final pellet re-suspended in 300 µl methanol. Panels C and D 
are also methanol and estradiol spiked samples extracted with methanol, but the pellets are re-
suspended in 300 µl of acetonitrile. The extraction shown in Figure 3.2.7 A and B produces a 
poor quality peak and substantial background noise with a ghost estradiol peak appearing in 
the methanol blank, while acetonitrile re-suspension shown in Figure 3.2.7 C and D, produces 
a similar estradiol peak quality, but with fewer background peaks and no ghost peak appearing 
in the methanol blank.  
In Figure 3.2.8 A and B are methanol and estradiol spiked samples, respectively, extracted with 
acetonitrile and the final pellet re-suspended in 300 µl methanol. Panels C and D are also 
methanol and estradiol spiked samples, extracted with acetonitrile but the pellets are re-
suspended in 300 µl of acetonitrile.  As can be seen the acetonitrile-based extraction (Figure 
3.2.8) produced visually much sharper peak quality, with reduced background noise compared 
to the methanol-based extractions (Figure 3.2.7). The re-suspension of samples in methanol (A 
and B) still produces a significant number of background peaks compared to samples that have 
been re-suspended in acetonitrile (C and D).  The peak for estradiol is visually less intense in 
B than in D and when comparing the peak heights they were 3422 and 58520 respectively, a 
seventy one per cent increase when using acetonitrile for both extraction and re-suspension.  
For this reason an acetonitrile-based extraction was used for all further experiments.
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Figure 3.2.7. Comparison of methanol phase separation of spiked media samples with re-suspension in methanol or acetonitrile. This 
figure shows the methanol extraction carried out as described in section 2.6.1 of media spiked with methanol (A) and media spiked with 1ug/ml 
Estradiol (B) with the pellets formed during centrifugation re-suspended in methanol. Media spiked with methanol (C) and media spike with 
1ug/ml Estradiol (D) with the pellets formed during centrifugation re-suspended in acetonitrile. Ten microlitres of each sample were run on the 
column along with the 0.5ml/min inlet gradient as described in section 2.2.6. The estradiol peak is highlighted with a box in each chromatogram. 
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Figure 3.2.8. Comparison of acetonitrile phase separation of spiked media samples with re-suspension in methanol or acetonitrile.  This 
shows the acetonitrile extraction carried out as described in section 2.6.1 of media spiked with methanol (A) and media spiked with 1ug/ml 
Estradiol (B) with the pellets formed during centrifugation re-suspended in methanol. Media spiked with methanol (C) and media spike with 
1ug/ml Estradiol (D) with the pellets formed during centrifugation re-suspended in acetonitrile. Ten microlitres of each sample were run on the 
column along with the 0.5ml/min inlet gradient described in section 2.6.2.  Acetonitirile re-suspension showed a 71% increase in peak height of 
estradiol. 
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Due to the poor quality of peaks from analysis of the re-suspended pellet, the supernatant from 
the extraction was tested to investigate if the estradiol had remained in the liquid phase. 
Samples were run under the same conditions and are shown in Figure 3.2.9B, and shows that 
visually peaks are of sharper quality and upon comparison of peak height between the two 
samples, pellet re-suspension produced a peak height of 2560 and supernatant 139029.  This is 
over a fivefold improvement and therefore indicates the supernatant is more suitable for 
analysis as the estrogens are remaining in the solvent phase and are not coming out of solution 
and forming a pellet during centrifugation.  As a result for future experiments only the 
supernatant was used for sample analysis. 
To confirm that the optimised sample extraction and LC-MS analysis conditions allowed 
sufficient detection in samples derived from cell cultures, medium samples were spiked with a 
range of estradiol concentrations, samples extracted (section 2.6.1) and analysed on the column 
using the 0.5 ml/min inlet gradient (section in 2.6.2).  An example of the re-suspended pellet 
of a medium extraction is given in Figure 3.2.9, which shows media spiked with 75ng/ml 
(27.2nM) of estradiol and run through the LC-MS producing a small, poor quality peak.  
After identifying the supernatant to be optimal for sample analysis, media samples spiked with 
estradiol from 2.5ng/ml (9nM) to 750ng/ml (2.7µM) underwent acetonitrile extraction and the 
supernatant was analysed.  The peak height for each sample was plotted against the ng/ml of 
estradiol and is shown in Figure 3.2.10.  No estradiol peak was detectable in samples spiked 
with 2.5ng/ml or 5ng/ml and are not included on this plot.  Blank, methanol-DMSO only, 
spiked samples were also extracted and run with no estradiol peaks detected in these samples.  
The work shown in Figure 3.2.10 shows the analysis of three individual repeats.  Using the 
standard deviation values from the data it was possible to calculate the limit of detection (LOD) 
of estradiol using this LC-MS analysis, which was found to be 8.6ng/ml (32nM) using 
calculation (Armbruster and Pry, 2008). 
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Figure 3.2.9. Comparison of acetonitrile extraction supernatant and acetonitrile re-
suspennded pellet. This shows the acetonitrile extraction carried out, as described in section 
2.6.1, of media spiked with 75ng/ml of estradiol with 10µl of the re-suspended pellet produced 
after centrifugation (A) and 10µl of the supernatant produced during the centrifugation (B). 
Both samples were run on the Acquity column with the 0.5ml/min inlet gradient as described 
in section 2.2.6.  
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Figure 3.2.10. Analysis of a concentration range of estradiol spiked media samples which 
underwent acetonitrile based extraction and supernatant analysis. One millilitre DMEM 
media samples were generated and spiked with pure estradiol prepared in methanol to create 
samples with the equivalent of 2.5, 5, 7.5, 10, 25, 50, 75, 100, 250, 500 and 750ng/ml.  Samples 
were then extracted with acetonitrile and 10µl of each samples supernatant was individually 
injected and analysed on the xevo TQ-S.  The peak heights of these samples were plotted 
against the ng/ml estradiol concentration and the fit to linear regression was analysed giving 
an r2 value of 0.9153.  This data represents three individual repeats and was used to calculate 
the limit of detection (LOD) of estradiol within the assay giving a limit of 8.564ng/ml (31.5nM) 
n=3. 
 
There was concern that due to the hydrophobic nature of estradiol, that it was precipitating out 
of solution when added to medium for dosing the cells. To prevent this 10 µg/ml of estradiol 
was prepared in methanol, along with 2 mM of sodium glycocholate and sonicated for 20 
minutes to ensure complete re-suspension into the solvent. The sample was then gas dried with 
nitrogen and re-suspended in Hanks Buffered Saline Solution (HBSS) with 10 mM 2-(N-
morpholino) ethanesulfonic acid (MES) to recreate a bio-relevant media (Ilardia-Arana et al., 
2006). Figure 3.2.11.B shows an injection of 10 µl of a 1 µg/ml estradiol sample in HBSS to 
ensure it would still be detected by the inlet gradient (section 2.6.2), and that its suspension in 
bio-relevant medium does not cause an increase in background signal. 
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Figure 3.2.11. The preparation of estradiol in bio-relevant medium for its use in media and its effect on sample detection. This figure shows 
a blank HBSS and 10mM MES solution (A) and a 1ug/ml Estradiol prepared in HBSS and 10mM MES (B) run on the inlet gradient as described 
in section 2.6.2. This is compared to a 0.1% DMSO (v/v) methanol blank (C) and estradiol prepared in a 0.1% (v/v) DMSO and methanol solution. 
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When comparing the estradiol in biorelevant medium (B) to the DMSO-methanol prepared 
samples (D) peak heights of 156,2125 and 665,593 respectively were seen which sees almost 
one hundred and fifty per cent increase on peak height with estradiol preparation in a bio 
relevant medium.  This indicates that bio-relevant medium may be reducing the loss of estradiol 
though precipitation, increasing estradiol availability and ensuring that when dosing cells for 
future experiments the correct dose is readily available and not out of solution.  
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3.2.3 Method Validation in Cell Culture Samples 
To determine if the optimised LC-MS and extraction methods could detect changing levels of 
estradiol and its metabolites in cell culture samples, both cell medium and cell lysate samples 
were collected over an eight hour time course. Before the time course samples were run, blank 
culture medium and lysate samples were extracted and run against all MRM channels, to check 
for any ghost peaks in the different MRM channels.  The blank samples (Figure 3.2.12) showed 
no peaks in any channels except for the MRM of Ethinylestradiol (EE2) (295.3 <145.1), where 
peaks were detected in both medium and lysate samples. For this reason it was therefore 
decided, EE2 could no longer be used as an internal standard.  Human Hepatoma (Huh7) cells 
were used for these time course experiments as they are readily available compared to primary 
human hepatocytes, are easy to grow and maintain, and therefore make an ideal model to 
investigate before experiments with primary human hepatocytes. The Huh7 cells were plated 
at a density of 3 x 105 per well in a 6 well plate and then dosed with 1 µM of estradiol and over 
8 hours. Samples of medium and lysate were taken and extracted for seventeen time points 
(section 2.6.1) and run on the 0.5 ml/min inlet gradient (section 2.6.2).  
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Figure 3.2.12. LC-MS analysis of extracted, non-spiked media control samples. In A and B 
show the LC-MS analysis for estrone (E1), estradiol (E2), ethinylestradiol (EE2) and estrone-3-
sulphate (E3S) in media and lysate samples, respectively, extracted using the method described 
in section 2.6.1 and run on a 0.5ml/min inlet gradient as described in 2.6.2. The chromatograms 
are time (x) plotted against percentage of total ion count set to 2 x104(y). Both sets of extractions 
show a peak detected with the 295.3<145.1 MRM for EE2 indicating EE2 maybe present within 
the samples or another compound is being detected with this MRM. 
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Figure 3.2.13. LC-MS analysis of media samples taken from cultured Huh7 cells, dosed with 1uM of estradiol, over an 8 hour period. In 
this figure, A shows both the peak heights and area for estrone and estradiol detected in seventeen 0.75ml media samples taken over an 8 hour 
period and extracted using the method described in section 2.6.1 and run on a 0.5ml/min inlet gradient as described in 2.6.2. B and C are plots 
of the peak area vs peak height of estradiol and estrone respectively, to determine if both can be used for analysis in media extracts. 
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Seventeen time point samples of both Huh7 cell medium and lysate were taken over eight hours 
to measure the changes of estradiol and estrone and assess the capability of the method in cell 
culture samples. In Figure 3.2.13A the peak areas and peak heights are plotted for both estrone 
and estradiol detected in the cell medium. The levels of estradiol decrease over time and begin 
to plateau after four hours whilst estrone steadily increases. This is to be expected as estradiol 
will be taken up into the cells and then metabolised to estrone, which in turn will move back 
out into the cell medium by passive transport processes. As seen with the analysis of pure 
compound samples, peak area and peak height show a strong fit to linear regression with r2 
values of 0.98 for estrone (C) and 0.94 for estradiol (B), indicating either is suitable to use for 
analysis, therefore for further analysis only peak height will be used for culture medium 
analysis. 
As with the cell medium samples, the peak area and peak height values for estrone and estradiol 
from cell lysate samples were plotted against time and are shown in Figure 3.2.14A.  Estradiol 
is not initially detected and after thirty minutes there has been sufficient uptake for there to be 
detection in the lysate. The level of estradiol remains reasonably constant for the first three 
hours and as estradiol levels fall estrone is shown to steadily increase over time. The plots of 
peak area against peak height for estradiol (B) and estrone (C) again showed exceptable fit to 
linear regression with r2 values of 0.81 and 0.98 respectively, so peak height will be used for 
all further cell lysate analysis.  
Both cell medium and lysate samples were tested for estrone-3-sulphate, along with estradiol 
and estrone, but there weren’t sufficient levels present for detection by this LC-MS method. 
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Figure 3.2.14.  LC-MS analysis of cell lysate samples taken from cultured Huh7 cells, dosed with 1µM of estradiol, over an 8 hour period. 
In this figure, A shows both the peak heights and area for estrone and estradiol detected in seventeen cell lysate samples taken over an 8 hour period 
and extracted using the method described in section 2.6.1 and run on a 0.5ml/min inlet gradient as described in 2.6.2. B and C are plots of the peak 
area vs peak height of estradiol and estrone respectively, to determine if both can be used for analysis in cell lysate extracts. 
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3.3 Discussion 
Due to the hydrophobic nature of estrogens, it has previously been easier to separate and detect 
their presence in samples using derivitisation and gas chromatography coupled with mass 
spectrometry. However, this requires extra sample preparation and use of noxious chemicals 
during preparation (Franke et al., 2011).  The method constructed here uses UPLC coupled to 
negative electrospray ionisation (ESI-) and triple quadropole mass spectrometry. This method, 
in comparison to others, requires minimal sample preparation without use of derivitisation 
reagents. It has the ability to separate and detect the primary estrogens, estradiol (E2) and estrone 
(E1), as well as the estrone-3-sulphate (E3S) metabolite and ethinyl estradiol (EE2) internal 
control in both pure and mixed samples. Each were detected within appropriate nanomolar ranges 
for the application of model validation ( 
Figure 3.2.1 and Figure 3.2.5) and when testing the extraction of estradiol spiked media samples 
the limit of detection was found to be 31.5nM.  
There has been much work published in the detection and analysis of these compounds from a 
range of biological substances including serum and urine using varying chromatographic 
techniques (Giton et al., 2010, Franke et al., 2011, Azzouz and Ballesteros, 2012); however, there 
have been fewer publications on their extraction, separation and detection from cell samples 
using GC or LC-MS techniques. The extraction method used (section 2.6.1), was primarily based 
on that of (Guo et al., 2008); a simple solvent phase extraction method using acetonitrile, with 
minimal steps to reduce the risk of sample contamination or loss.  As previously mentioned, 
estradiol is a hydrophobic compound and when preparing it in medium it precipitates out of 
aqueous solutions.  Therefore, it was necessary to create optimum conditions for its re-
suspension into cell culture medium.  A bio-relevant medium in which to prepare the drug better 
simulates the conditions created by the fluids present within the body and is achieved by adding 
bile salts and phospholipids, natural surfactants that increase the solubility of hydrophobic 
compounds (Ilardia-Arana et al, 2006). Estradiol samples were prepared with the bile salt sodium 
glycocholate, then gas dried and re-suspended in MES for the best dissolution. Improvement of 
compound solubilisation and availability of the compounds was demonstrated by the preparation 
of samples with sodium glycocholate and MES that were then used to spike medium to a 1 µM 
concentration and run through the LC-MS. This preparation produced no visible precipitation in 
medium, and did not have a detrimental effect on the detection of estradiol.  
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During the development of this method, attempts to tune a third metabolite, estradiol-17-β-
glucuronide, were also made, however there was little success with a methanol standard, and so 
due to time constraints this was abandoned. These compounds maybe better suited to detection 
with ESCi® mass spectroscopy. The ESCi® Multi-Mode Ionization Source provided with the 
Xevo-TQ-S allow for the combined use of ESI and Atmospheric Pressure Chemical Ionization 
(APCI) within the ion source, which enables the use of multiple MS methods with differing 
combinations and durations of both ESI and APCI within the same analysis. ESI is a successful 
analysis technique for many compound classes; however less polar analytes, such as estrogens, 
may require APCI and therefore this combined approach may give better results.  
The investigation of the sensitivity of the method used to detect estrone-3-sulphate in its 
methanol standards appeared to cover a good range of concentrations. However, once the method 
was applied to extracts from the medium and lysate, a drop in sensitivity was seen so as to prevent 
metabolite detection in cell culture samples.  Ethinyl estradiol was also measured in the Huh7 
medium samples, but a peak was detected with the range of the MRM (295.3<145.1) in media 
and cell lysate controls (Figure 3.2.12).  By investigating the medium content it was determined 
that ethinyl estradiol or other estrogens may be contaminants present during sample preparation; 
therefore, it could be assumed that at this MRM, contaminating ethinyl estradiol is being 
detected, although no definitive proof exists for this hypothesis.  Another potential cause of this 
background within the cell lysate could be from the primary hepatocytes themselves.  These cells 
were taken from human female samples and therefore there is the possibility that the donor in 
question was on oral contraceptive medication containing ethinylestradiol.  Due to the 
hydrophobic nature of estrogens this compound maybe retained within the lipid of the cells, such 
that it would be present in primary hepatocytes in cultures, and detected upon extraction.  For 
this reason, ethinyl estradiol could no longer be used as an internal control for this method.  Given 
this problem, it might be more suitable to use a deuterated standard as the internal control. These 
standards are usually an isotopically labelled version of the molecule being measured which will 
co-elute with the compound being quantified. They act as a measure of control for extraction, 
UPLC and ionisation variability between samples and are essential for a robust high-throughput 
assay.  These standards are, however, very expensive and as this methodology is not intended to 
be used as a high throughput assay such an approach was unfeasible.  
Ratios of the change in estrone and estradiol levels will be calculated from the peak height and 
used to assess the biological relevance of the model of estradiol metabolism and transport 
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generated in chapter 4.  The final experiments for model validation are shown with primary 
human hepatocytes in chapter 5.  
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4.0 Development of an in-silico model of the metabolism and transport of 
17β Estradiol within human hepatocytes. 
4.1 Introduction 
As discussed in the thesis introduction, the processes of ADME play key roles in determining 
the fate of a compound in the body. Therefore, a lack of understanding of these processes often 
leads to the failure of novel compounds during drug development. As this often occurs during 
the latter stages (pre-clinical or clinical trials) it is costly both in financial terms, and in time 
spent developing failed drugs rather than successful ones.  The reason for late stage failure is 
often due to unforeseen side effects, which occur in humans but not in animal models, or within 
a specific human sub-population. Improved understanding of drug ADME, and in particular the 
use of computational models to explore the robustness of the ADME system, will increase our 
ability to extrapolate between different model systems and/or pose ‘what if’ questions to examine 
sensitive population responses (Yu and Adedoyin, 2003, van de Waterbeemd and Gifford, 2003).  
The use of animal models during pre-clinical studies is both costly and time consuming, not to 
mention the ethical considerations that accompany such experiments.  Beyond these two 
important considerations, in the last decade it has become acknowledged that the physiology of 
humans and non-clinical model species such as rodents, although similar in many aspects, has 
significant differences. For example, the expression of metabolic enzymes and membrane 
transporters can vary significantly between species (Chu et al., 2013a). These differences are 
further compounded by the often significant inter-individual expression of these proteins both in 
non-clinical species and humans. Due to these inter- and intra- species variations, there is large 
scope for error in clinical trials, supporting the high loss of novel compounds seen after large 
and costly development (Hilgendorf et al., 2007, Ma and Lu, 2011). The pharmaceutical industry 
now supports the movement towards the reduction, refinement and replacement (three R’s) of 
animal models of which includes making use of computer simulations along with better in-vitro 
models to better direct the development of new compounds and potentially reduce the fail rate. 
Over the past 50 years a broad understanding of the role of metabolising enzymes in drug 
clearance has been gained; however, it is only in the last 20 years that the importance of drug 
transporters and their impact on the disposition and ultimate efficacy of drug compounds has 
been fully appreciated. Transporters were first highlighted due to their central role in drug 
resistance, with the identification and characterisation of transporters such as p-glycoprotein 
(MDR1), an efflux protein and negative prognostic marker in cancer treatment. Since then, many 
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groups have furthered our knowledge of the role of transporters in both the uptake and efflux of 
chemicals, and their roles in drug-drug interactions (Dobson et al., 2009, Szakacs et al., 2008, 
Petzinger and Geyer, 2006, Deeley et al., 2006).    
Due to the complex nature of transporters, which often possess multiple membrane spanning 
domains, they are much harder to isolate and study compared to their metabolic counterparts, 
which are often cytosolic or tethered to membranes through peptide tails. As such, a lot less is 
known both about how transporters function individually and as part of the integrated 
metabolism-transport system.  We have a broad knowledge of the uptake transporters and for 
efflux transporters we know considerably more about the function of the apical transporters such 
as MRP2 and MDR1; however our understanding of their basolateral counterparts MRP3 and 
MRP4 are more poorly understood (Deeley et al., 2006, Hediger et al., 2004, Kullak-Ublick et 
al., 2004). 
To address the relative lack of understanding of the role of basolateral efflux in determining 
compound fate, a computer model of the metabolism and transport processes of estradiol within 
the hepatocytes has been developed. Estradiol is the most abundant member of a group of 
endogenous steroids called estrogens, and is clinically-used in the oral contraceptive pill and 
hormone replacement therapy. Estradiol was chosen as the compound for the model as it, or its 
metabolites, are transported by the ABC transporters of interest across both the apical and 
basolateral membrane go (Hirouchi et al., 2009, Russel et al., 2008) Genego 
(http://lsresearch.thomsonreuters.com/maps/850/).  Using Celldesigner 4.1, to draw and populate 
the model, and COPASI, to run simulations and analyse the model, we have been able to 
investigate the impact of the different processes on the overall system and determine the 
importance of individual reactions on ultimate estradiol fate. This model has also been 
biologically validated with the use of in-vitro cell experiments and the LC-MS methodology 
developed in chapter three. 
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4.2.0 Results 
A model of estradiol metabolism and transport was initially generated in the software package 
celldesigner, simulations run in CopASi and the model validated using the LC-MS method 
developed in the previous chapter.  Each of these stages of development are discussed in the 
following sections. 
4.2.1 Development of model in Cell Designer 
The model of estradiol metabolism and transport was initially developed using Celldesigner 
version 4.2.  This software allows us to generate a process diagram to represent the metabolism 
and transport of estradiol within a hepatocyte. Each node represents the state of a single molecule 
or complex, while arrows represent state transitions between these nodes.  A simplified example 
of the resulting diagram produced is shown in Figure 4.2.1.  
 
Figure 4.2.1. The metabolism and transport of estradiol and the major resulting 
metabolites; passive diffusion is represented by a solid black, double headed arrow moving 
parent and metabolite in both directions across the membrane (↔). Active transport is 
represented with a single headed, dashed line arrow (←) and metabolism (state transition) of 
estradiol is represented by a dotted line, single headed arrow (↑↓). Each compartment is labelled 
with its corresponding ID shown in Table 4.2.1.    
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The process diagram includes five compartments to represent biologically separate components 
within the model; namely, the blood and bile (extracellular), the cytosol (intracellular) and two 
lipid membrane fractions to represent the basolateral and apical membranes. The volumes were 
set in litres for the compartments and are shown in Table 4.2.1 below, and represent biologically 
realistic values.  
Table 4.2.1. The compartments assigned to the cell designer model of estradiol disposition; 
this table shows the different compartments and their assigned identification numbers along with 
their volumes in litres. 
Compartment Name Volume  
  (L) 
C1 Blood 5 
C2 Liver 2.00E-12 
C3 Bile 6.00E-03 
C4 
Basolateral 
Membrane 5.00E-13 
C5 Apical Membrane 5.00E-13 
 
 
An overview of the pathways of estradiol metabolism was generated from Genego 
(http://lsresearch.thomsonreuters.com/maps/850/), and a list of species generated for inclusion 
in the model. All species in the model are shown in Table 4.2.3 and their concentrations and 
compartment allocations are indicated, along with references for the values obtained.  
Concentrations were calculated from protein values per µg of cytosolic or membrane protein 
with the breakdown shown in Table 4.2.2.  The molecular weight of each species was obtained 
and used to calculate the number of moles of protein and then converted to moles per cell using 
the known ng/cell of different cell protein fractions, as shown in Table 4.2.2. Finally the 
nanomolar concentrations for each protein transporter and enzyme were calculated and then 
applied to the model. 
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Table 4.2.2. The total mass of a cell in its different cellular fractions; this table shows the 
number of nanograms (ng) per cell of different cellular fractions which include DNA, membrane 
and cytosolic protein and cytosolic liquid to a total of 10 ng per cell (Wilson et al., 2003). 
Compartment ng/cell 
Cytosolic liquid 2 
Membrane Protein 0.2429907 
DNA 0.006 
Cytosolic Protein 7.7510093 
Total Cell Protein 10 
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Species ID Name Class Compartment Concentration Reference 
    (D/SM/P)   nM   
S1 Estradiol D C1 0.01 (Reichman et al., 1993) 
S2 Estradiol D C4 0   
S3 Estradiol D C2 0.01 (Reichman et al., 1993, Schaefer et al., 2012)  
S4 E217BG SM C2 0   
S6 UGT2B7 P C2 15840 (Schaefer et al., 2012) 
S9 E217BG SM C1 0.5 (Zumoff et al., 1982) 
S10 MDR1 P C5 1677 (Schaefer et al., 2012) 
S11 MRP2 P C5 1875 (Schaefer et al., 2012) 
S12 ABCG2 P C5 547 (Schaefer et al., 2012) 
S13 E217BG SM C3 0   
S14 Estrone SM C2 0.17 (Reichman et al., 1993) 
S15 HSD17B1 P C2 50 (Hayes, 1996) 
S16 Estrone 3G SM C2 1.4 (Zumoff et al ., 1982) 
S17 UGT1A1 P C2 3696 (Schaefer et al., 2012) 
S18 Estrone 3G SM C4 0   
S19 Estrone 3G SM C1 1.4 (Zumoff et al., 1982) 
S23 Estrone SM C4 0   
S24 Estrone SM C1 0.17 (Reichman et al., 1993) 
S25 Estradiol 3S SM C2 2.25 (Reed et al., 1983) 
S26 Estradiol 3S SM C4 0   
S27 Estradiol 3S SM C1 2.25 (Reed et al., 1983) 
S28 SULT 2A1 P C2 11821 (Riches et al., 2009) 
Table 4.2.3. Species and their IDs as present in the cell designer model of estradiol disposition; this table shows the species and their 
identification numbers and concentrations at a steady state and their position, by compartment, within the model. All bile concentrations were 
set to 0nM to allow the model to reach steady state conditions. 
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Species ID Name Class Compartment Concentration Reference 
    (D/SM/P)   nM   
S29 Estrone 3S SM C2 1.2 (Reichman et al., 1993) 
S30 Estrone 3S SM C4 0   
S31 Estrone 3S SM C1 1.2 (Reichman et al., 1993) 
S36 2OHE2 SM C2 1.6 (Reichman et al., 1993) 
S37 2MOHE2 SM C2 1.15 (De Crée et al., 1997) 
S38 4OHE2 SM C2 0   
S40 CYP1B1 P C2 0   
S41 COMT P C2 10320 (Zhang et al., 2009) 
S43 UGT1A3 P C2 0 (Izukawa et al., 2009) 
S44 4OHE2 SM C4 0   
S45 4OHE2 SM C1 0   
S46 2OHE2 SM C4 0   
S47 2OHE2 SM C1 1.6 (Reichman et al., 1993) 
S48 2MOHE2 SM C4 0   
S49 2MOHE2 SM C1 1.15 (De Crée et al., 1997) 
S50 Estrone 3S SM C3 1.2 (Reichman et al., 1993) 
S61 Albumin P C1 599999.74 (Sodergard et al., 1982) 
S65 TeBG P C1 59.77 (Sodergard et al., 1982) 
S123 MRP4 P C4 24 (Schaefer et al., 2012) 
S124 MRP3 P C4 219 (Schaefer et al., 2012) 
S133 SULT1E1 P C2 38 (Riches et al., 2009)  
S134 Albumin Bound Complex C1 0.26 (Sodergard et al., 1982) 
S135 TeBG Bound Complex C1 0.23 (Sodergard et al., 1982) 
S136 Total Estradiol D C1 0.5 (Sodergard et al., 1982) 
S137 HSD17B2 P C2 3500 (Hayes et al., 1996) 
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Species ID Name Class Compartment Concentration Reference 
    (D/SM/P)   nM   
S138 Estrone 3S SM C5 0   
S139 E217BG SM C4 0   
S140 E217BG SM C5 0   
S141 Estrone 3S SM C4 0   
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4.2.2 The individual reactions of metabolism and transport 
Reaction for passive diffusion, which was addressed for both the parent and the metabolite species, 
and constants for movement both in and out of the lipid membrane were calculated and applied to 
the model (Figure 4.2.2). The k1 constant represents the movement of compound into the lipid 
membrane and is calculated using equation 1, while the k2 constant represents the movement of 
compound out of the lipid membrane and is calculated using equation 2 (Figure 4.2.3) and the 
calculated constants are shown in Table 4.2.4.  
LogP-Log(0.412xP+1)-3.985    Eqn 1 
-Log(0.411xP+1)-3.985    Eqn 2 
Figure 4.2.2. Calculation of passive diffusion constants in and out of the lipid membrane; 
shows the LogP values used for each compound and its metabolites, and the derived k1 and k2 
constants, along with the references used for the data.  All values given were taken from their 
databases in December 2010 (Personal communication van de Waterbeemd, 2010). 
 
 
Figure 4.2.3. Calculation of constants for the action of passive diffusion into and out of a lipid 
membrane. Using the LogP value of a compound and a calculation by van de Waterbeemd a 
constant for the movement of a compound by passive diffusion into a lipid membrane (K1) 
represented by Eqn 1 and movement out of the lipid membrane by passive diffusion (K2) 
represented by Eqn 2.  
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Table 4.2.4. Passive diffusion constants calculated for the application to the cell designer 
model of estradiol disposition; the constants for movement into the lipid membrane (K1) and out 
of the lipid membrane (K2) calculated using the equations LogP-Log(0.412x(+1)-3.985 and 
Log(0.411xP+1)-3.985 respectively (Van de waterbeemd). 
Compounds LogP P K1 K2 Reference 2010) 
Estriol 2.94 870.964 -3.60 -6.54 5553 ChemSpider ID 
Estrone 3 Glucuronide 1.92 83.1764 -3.61 -5.53 HMDB04483 
2 Hydroxyestradiol 4.3 19952.6 -3.60 -7.90 HMDB00338 
4 Hydroxyestradiol 3.34 2187.76 -3.60 -6.94 HMDB05896 
2 Methoxyestradiol 3.7 5011.87 -3.60 -7.30 HMDB00405 
Estradiol 3 Glucuronide 1.46 28.8403 -3.63 -5.09 HMDB06224 
Estradiol 3 Sulphate 0.25 1.77828 -3.97 -4.22 HMDB10358 
Estradiol 4.2 15848.9 -3.60 -7.80 Drugbank.ca 
Estrone   3.6 3981.07 -3.60 -7.20 Drugbank.ca 
Estrone 3 sulphate 1.4 25.1189 -3.64 -5.04 Nozawa (2004) 
Estradiol 17 B Glucuronide 1.46 28.8403 -3.63 -5.09 HMDB06224 
 
Mass action kinetics, are applied to the passive diffusion of compound across the lipid membranes. 
This uses the law of mass action to describe the behavior of solutions in a dynamic equilibrium. 
In contrast, all protein-catalyzed reactions (metabolic conversions, active transport) are described 
by Michaelis-menten kinetics , and are dependent on the maximal rate (Vmax) and Michealis 
constant (Km) (Eqn 3);  
Vo=Vmax.[S]/[S]+Km    Eqn 3 
V0 represents the initial velocity of the reaction, Vmax represents the maximal velocity of the 
reaction, [S] represents the substrate concentration and Km represents the Michaelis-menten 
constant, which is the substrate concentration at half the maximal velocity, and is shown in Figure 
4.2.4. The kinetics values are applied to the enzymatic and transport process within the model. 
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Figure 4.2.4. An example plot of michaelis menten kinetics; this is a plot of michaelis menten 
kinetics, substrate concentration plotted against enzyme activity. The maximal velocity (Vmax) 
and the michaelis menten constant (Km) are shown on the graph and labelled.  
 
A key concept in Michaelis-menten kinetics is that the Vmax for a reaction is a function of the 
protein concentration. As shown in Eqn 4, the Vmax value for a reaction represents the product of 
the catalysis constant for enzyme (Kcat) and the enzyme concentration ([E]). Including these terms 
in the model (eqn 5) allows changes in protein level (both increases and decreases) to be simulated, 
as these will impact upon the Vmax for all reactions catalysed by that protein. This makes the model 
more dynamic and, therefore, more able to reproduce the altered network dynamics that are 
observed upon changes in an enzyme or transporter expression level;  
Vmax = [E]*Kcat     Eqn 4 
Vo= [Enzyme/Transporter].Kcat.[S]/[S]+Km            Eqn 5 
 
The reactions present in our model are shown in Table 4.2.5 along with the mathematical equation 
used to describe the reaction.  For each reaction the reactant, product and modifiers are each 
identified by their species ID within the model as shown in Table 4.2.3.  For passive diffusion, the 
K1 values in Table 4.2.4 represent the mass action constant of diffusion as calculated and shown 
in Figure 4.2.3.  For active transport and enzyme induced state transitions, the K1 and V1 values 
represent the michaelis menten constant (Km) and the maximal velocity (Vmax) of the reaction.  
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Table 4.2.5. Reactions and their IDs as present in the cell designer model of estradiol disposition; this table shows the reactions and their 
identification numbers as described in the cell designer model. This also shows the reactants, products and any modifiers associated with each 
reaction and the mathematical formula applied to the model. The K1 values for passive transport are those passive diffusion constants as calculated 
in Table 4.2.1 and the K1 and V1 values for state transitions and active transport represent the michaelis menten constant (Km) and maximal 
velocity (Vmax) values. 
Reaction 
ID 
Type Reactants Products Modifiers Maths k1 v1 References 
1 Passive Transport s1 s2   s1*k1 3.6   Table 4.2.4 
2 Passive Transport s2 s3   s2*k1 7.8   Table 4.2.4 
3 Passive Transport s3 s2   s3*k1 3.6   Table 4.2.4 
4 Passive Transport s2 s1   s2*k1 7.8   Table 4.2.4 
5 State Transition s3 s4 s6 v1*s3*s6/(k1+s3) 11000 0.06  (Pfeiffer et al., 2005) 
6 Active Transport s4 s9 s124 v1*s4*s124/(k1+s4) 26000 1.74  (Akita et al., 2002) 
7 Active Transport s4 s9 s123 v1*s4*s123/(k1+s4) 30000 21.25 (Chen and Klaassen, 2004) 
8 Active Transport s4 s13 s11 v1*s4*s11/(k1+s4) 98000 31.87 Pedersen, Matsson et al. 2008 
9 Active Transport s4 s13 s12 v1*s4*s12/(k1+s4) 44200 1 (Pfeiffer et al., 2005) 
10 Active Transport s4 s13 s10 v1*s4*s10/(k1+s4) 62000 0.14  (Huang et al., 2011) 
11 State Transition s3 s14 s137 v1*s4*s10/(k1+s3) 350 234  (Lu et al., 2002) 
13 State Transition s14 s16 s17 s14*v1*s17/(k1+s14) 38000 0.00406  (Lepine et al., 2005) 
15 Passive Transport s18 s19   s18*k1 5.53   Table 4.2.4 
16 Passive Transport s19 s18   s19*k1 3.61   Table 4.2.4 
17 Passive Transport s18 s19   s18*k1 5.53   Table 4.2.4 
18 Passive Transport s16 s18   s16*k1 3.61   Table 4.2.4 
24 Passive Transport s14 s23   s14*k1 3.6   Table 4.2.4 
25 Passive Transport s23 s24   s23*k1 7.2   Table 4.2.4 
26 Passive Transport s24 s23   s24*k1 3.6   Table 4.2.4 
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Reaction 
ID 
Type Reactants Products Modifiers Maths k1 v1 References 
28 State Transition s3 s25 s28 v1*s3*s28/(k1+s3) 1520 0.021 (Riches et al., 2009) 
29 Passive Transport s25 s26   s25*k1 3.97   Table 4.2.4 
30 Passive Transport s26 s27   s26*k1 4.22   Table 4.2.4 
31 Passive Transport s27 s26   s27*k1 3.97   Table 4.2.4 
37 Passive Transport s30 s29   s30*k1 5.09   Table 4.2.4 
40 State Transition s3 s36 s40 v1*s3*s40/(k1+s3) 780 0.0065 
 (Hayes et al., 1996, 
Badawi et al., 2001) 
41 State Transition s3 s38 s40 v1*s3*s40/(k1+s3) 710 0.0286 
 (Hayes et al., 1996, 
Badawi et al., 2001) 
43 State Transition s36 s37 s41 v1*s36*s41/(k1+s36) 108000 6.8 
(Dawling et al., 
2004, Dawling et al., 
2001) 
44 Passive Transport s38 s44   s38*k1 3.6   Table 4.2.4 
45 Passive Transport s44 s38   s44*k1 6.94   Table 4.2.4 
46 Passive Transport s45 s44   s45*k1 3.6   Table 4.2.4 
47 Passive Transport s44 s38   s44*k1 6.94   Table 4.2.4 
48 Passive Transport s36 s46   s36*k1 3.6   Table 4.2.4 
49 Passive Transport s46 s47   s46*k1 7.9   Table 4.2.4 
50 Passive Transport s47 s46   s47*k1 3.6   Table 4.2.4 
51 Passive Transport s46 s36   s46*k1 7.9   Table 4.2.4 
52 Passive Transport s37 s48   s37*k1 3.6   Table 4.2.4 
53 Passive Transport s48 s49   s48*k1 7.3   Table 4.2.4 
54 Passive Transport s49 s48   s49*k1 3.6   Table 4.2.4 
55 Passive Transport s48 s37   s48*k1 7.3   Table 4.2.4 
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Reaction 
ID 
Type Reactants Products Modifiers Maths k1 v1 References 
56 Active Transport s29 s50 s12 v1*s29*s12/(k1+s29) 17000 21.39 
 (Suzuki and 
Sugiyama, 2002) 
148 State Transition s61, s1 s134   s61*s1*k1 60   
 (Sodergard et al., 
1982) 
149 State Transition s134 s61, s1   s134*k1 1380000   Table 4.2.4 
150 State Transition s1, s65 s135   s135*k1 60   Table 4.2.4 
151 State Transition s135 s65, s1   s135*k1 155   Table 4.2.4 
152 State Transition s136 s1   s136*k1 10   Table 4.2.4 
153 State Transition s1 s136   s1*k1 500   Table 4.2.4 
154 State Transition s14 s3 s15 v1*s14*s15/(k1+s14) 70 90 (Zhang, 2012) 
155 Passive Transport s138 s50   s138*k1 5.09   Table 4.2.4 
156 Passive Transport s50 s138   s50*k1 3.64   Table 4.2.4 
157 Passive Transport s138 s29   s138*k1 5.09   Table 4.2.4 
158 Passive Transport s29 s138   s29*k1 3.64   Table 4.2.4 
159 Passive Transport s4 s139   s4*k1 3.63   Table 4.2.4 
160 Passive Transport s139 s4   s139*k1 5.09   Table 4.2.4 
161 Passive Transport s139 s9   s139*k1 5.09   Table 4.2.4 
162 Passive Transport s9 s139   s9*k1 3.63   Table 4.2.4 
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4.2.3 The Completed Model 
Figure 4.2.5 shows the Cell Designer representation of the complete model of estradiol 
disposition.  There are five compartments as previously discussed in Table 4.2.1 and these are 
shown in this figure with the yellow edged squares; with one for blood, bile, intracellular and 
two compartments for lipid membranes. Within these compartments are the different species as 
described in Table 4.2.3, with enzyme and transporter species identified with green square tokens 
and drug and metabolite species represented with green circular tokens.  All lines in the model 
represent transport and metabolic reactions within the model and these are each described in 
Table 4.2.5.  In Figure 4.2.5 an example of basolateral membrane sequestration of estradiol, 17-
β-glucuronide is highlighted with a red box, its passive diffusion is indicated with a green arrow 
and its active transport is highlighted with a blue box.  
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Figure 4.2.5. SBGN representation of estradiol metabolism and disposition in hepatocytes; A qualitative model was generated encompassing 
estradiol metabolism, passive diffusion and transport within a human hepatocyte.  Free estradiol in the blood may enter hepatocytes, where it is 
metabolised into both estrone (E1) and estradiol (E2) metabolites. These metabolites, plus parent E2 may exit back into the blood or bile by passive 
or active transport. 
  
 
Active Transport  
(Michaelis Menten 
Kinetics) 
Passive 
Transport  
(Mass Action 
Kinetics) 
Lipid Membrane 
Sequestration 
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4.2.4 Testing and Validation of the Model 
As described in chapter 3, estradiol and estrone levels were measured over 8 hours in primary human 
hepatocytes. Cells were exposed to 1µM of estradiol and cell medium and lysate concentrations of 
estradiol and estrone measured at 17 time points, over 8 hours by LC-MS.  The data is plotted as peak 
height against time in hours and the analysis in both medium and cell lysate is shown in Figure 4.2.6 
A and B, respectively.   
 
 
 
 
 
 
 
 
As shown in Figure 4.2.6 A, the levels of estradiol steadily decrease from 15 minutes onwards, this 
drop is matched by a simultaneous and steady increase in the level of estrone present in the medium, 
which becomes a larger, steeper level of increase from 1.75 hours onwards.  This is expected as a 
major metabolite of estradiol is estrone, through metabolism by HSD17B1. As the primary means of 
transport of estrone is passive diffusion, the level of estrone needs to increase within the cell before 
it shall undergo any diffusion out into the medium, and this therefore explains the initial time delay 
before the sharp, increasing estrone levels.  When looking at the lysate samples Figure 4.2.6 B, similar 
changes in estrone and estradiol levels can be seen.  Initially there is a peak in the estradiol level, 
which can be placed down to the cells taking up the estradiol. After 30 minutes these estradiol levels 
are seen to come back down and the level of estrone steadily increases, this follows with what is seen 
in the medium samples.  In the lysate samples estradiol wasn’t detected by LC-MS after 5 hours. By 
taking the raw data from the LC-MS analysis and creating ratios of estradiol to estrone as shown in 
Table 4.2.6, we are able to compare the computer predictions from the model with experimentally 
derived ratios.   
A B 
Figure 4.2.6. An eight hour time course analysis of estradiol (E2) and estrone (E1) in the medium (A) 
and lysate (B) samples of primary human hepatocytes, in response to a 1µM dose of estradiol. The 
estradiol (●) and estrone (■) levels are seen to change simultaneously, where the reduction in the estradiol 
level is tallied with an increase in estrone. 
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Table 4.2.6. Ratios of estradiol to estrone from LC-MS data; The estradiol (E2) and estrone (E1) 
values within medium and lysate are given as their raw arbitrary peak height values as given by the 
LC-MS analysis software Mass Lynx.  The ratios describe the amount of estradiol present in relation 
to the estrone present. 
Time 
(Hr) 
E2 
(Lysate) 
E1 
(Lysate) 
E2:E1 
(Lysate) 
Time 
(Hr) 
E2 
(Medium) 
E1 
(Medium) 
E2:E1 
(Medium) 
0 9841 2010 4.8960199 0 82781 0   
0.25 11559 1831 6.312943747 0.25 92268 3736 24.69700214 
0.5 12141 3330 3.645945946 0.5 79612 7236 11.00221117 
0.75 8160 1723 4.735925711 0.75 64161 10067 6.373398232 
1 7033 2667 2.637045369 1 65035 16421 3.960477437 
1.25 8834 3391 2.60513123 1.25 55474 19037 2.91400956 
1.5 11133 5167 2.154635185 1.5 54723 18257 2.997370871 
1.75 5014 4084 1.227717924 1.75 49707 20846 2.384486232 
2 6532 4448 1.46852518 2 50939 29628 1.719285811 
2.5 6907 5760 1.199131944 2.5 48841 42043 1.161691601 
3 2395 8016 0.298777445 3 35445 53088 0.667665009 
3.5 6509 8069 0.806667493 3.5 35651 60709 0.587244066 
4 3944 7376 0.534707158 4 29220 82790 0.352941176 
5 2257 8487 0.265936138 5 28729 92301 0.311253399 
6 ˉ 11292 ˉ 6 19773 107842 0.18335157 
7 ˉ 10208 ˉ 7 9618 108690 0.088490201 
8 ˉ 13706 ˉ 8 16796 122767 0.13681201 
 
The base model, which is run at steady state, is shown in Figure 4.2.7 and the initial estradiol to 
estrone ratio is set within the model at a five to one ratio which is an experimentally derived value 
taken from the literature (Zhang, 2012). These plots clearly show that the trend in estradiol and 
estrone change is unlike that of the in-vitro LC-MS analysis, with the levels of estrone not increasing 
with time, or exceeding the levels of estradiol present.  The initial ratio of estradiol to estrone is 
correct within the model and the ratio calculated from the LC-MS data shown in Table 4.2.6 matches 
the previously experimentally derived data, this supports that the steady state of the model itself is 
correct however the time course is incorrect on comparison  This suggests that either; 
 The metabolic flux from estradiol to estrone is too low  
 Estrone itself is being converted to its metabolites too quickly  
 Too much estradiol is being forced through metabolism into its other metabolites by UGTs 
present within the cell.   
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As this initial analysis allowed identification of potential causes, a range of simulations were carried 
out with biologically realistic changes to the enzyme levels of; SULT1E1, regulator for the flux of 
estrone to estrone 3 sulphate, HSD17B1, regulator for flux of estradiol to estrone and HSD17B2 the 
regulator of the flux back from estrone to estradiol. Simulations were also carried out with changes 
to the levels of UGT enzymes 1A1 and 2B7 (data not shown), however this had little impact on the 
model and did not shift levels of estrone and estradiol towards the expected biological trend shown 
in Figure 4.2.6. 
Figure 4.2.8 B-H show 7 different simulations with different combinations of changes to the levels 
of HSD17B1, SULT1E1 and HSD17B2 within the model.  The changes in the enzyme levels were 
each done within biologically reasonable levels. In this figure (B) with 10nM HSD17B1 and 10nM 
SULT1E1 and (D) 5nM HSD17B1, 10nM SULT1E1 and 1500nM HSD17B2, are both highlighted 
with a red box as they are two enzyme combinations which created a biological trend most similar to 
that shown in Figure 4.2.8.  The levels of estradiol and estrone were taken from the model for the 
lysate and medium equivalents, calculated using the cell and lipid fractions and blood and bile 
fractions respectively, and then these values were plotted against time, in minutes. Ratios were then 
calculated for the estradiol to estrone levels for each time point in both medium and lysate, as with 
the LC-MS data in Table 4.2.6, and these were placed in Table 4.2.7 for comparison. 
. 
Figure 4.2.7. Model simulation of 1000nM estradiol exposure in an eight hour time course with 
analysis of the changes in estradiol (E2) and estrone (E1) in the medium (A) and lysate (B) 
equivalents. The estradiol (●) and estrone (■) levels are seen to change simultaneously with time 
in both medium (blood and bile compartments) and lysate (intracellular and lipid compartments) 
equivalents to the in-vitro system.  
A B 
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Figure 4.2.8. Model simulations carried out with a 1000nM of estradiol applied to a variety of changes in key enzyme levels. A baseline 
simulation (A) unchanged enzyme levels and a total estradiol concentration of 1000nM, were run alongside six simulations with changes to 
HSD17B1, SULT1E1 and HSD17B2 (B) 10nM HSD17B1 and 10nM SULT1E1, (C) 10nM HSD17B1 and 20nM SULT1E1, (D) 5nM HSD17B1, 
10nM SULT1E1 and HSD17B2 1500nM, (E) 50nM HSD17B1, 10nM SULT1E1 and 1500nM HSD17B2, (F) 50nM HSD17B1, 20nM SULT1E1 
and 1500nM HSD17B2, (G) 200nM HSD17B1, 10nM SULT1E1 and1 500nM HSD17B2, (H) 50nM HSD17B1, 20nM SULT1E1 and 500nM 
HSD17B2. Both medium (i) (blood and bile compartments) and lysate (ii) (intracellular and lipid compartments) equivalents to the in-vitro system 
are shown. 
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Table 4.2 7. The comparison of ratios of estradiol to estrone between the LC-MS analysis, and 
the 2 models with altered enzyme levels highlighted from Figure 4.2.7. 
 
 
Table 4.2.7 shows a very small difference between the ratios obtained from the parameter sets 
shown in B, 10nM HSD17B1 and 10nM SULT1E1, and D, 5nM HSD17B1, 10nM SULT1E1 
and 1500nM HSD17B2.  Comparing these values to the LC-MS analysis, it can be seen that 
the trend for ratios to decrease in the medium are similar between the model and the LC-MS 
data; however, the ratio decreases much faster in the model, dropping from 5 to approximately 
0.002 in 240 minutes, compared to a decrease from 4.8 to 0.5 in the experimental data over the 
same period.  The lack of congruency in the absolute values is not unexpected as the model has 
an estrone level set in the blood (0.17 nM), while estrone was undetectable within the primary 
hepatocyte medium samples in the time zero sample. If the blood concentration (medium 
equivalent) is set to zero there are no changes observed in the lysate equivalent ratios, however 
the medium ratios start at levels fifty fold lower than when estrone blood levels are set at 
 
  
LC-MS analysis 
 
10nM HSD17B1 10nM 
SULT1E1 (B) 
5nM HSD17B1 10nM 
SULT1E1 1500nM 
HSD17B2 (D) 
Time E2:E1 
(Medium) 
E2:E1 
(Lysate) 
 
E2:E1 
(Medium) 
 
E2:E1 
(Lysate) 
 
E2:E1  
(Medium) 
 
E2:E1  
(Lysate) 
 
0 ˉ 4.89 5882.35 5 5882.352 5 
15 24.69 6.31 9.47 0.027 9.508 0.028 
30 11.00 3.64 4.66 0.015 4.686 0.015 
45 6.37 4.73 3.06 0.010 3.080 0.010 
60 3.96 2.63 2.26 0.007 2.275 0.008 
75 2.91 2.60 1.78 0.006 1.791 0.006 
90 2.99 2.15 1.45 0.005 1.467 0.005 
105 2.38 1.22 1.22 0.004 1.236 0.004 
120 1.71 1.46 1.05 0.003 1.062 0.004 
150 1.16 1.19 0.81 0.003 0.819 0.003 
180 0.66 0.29 0.65 0.002 0.657 0.002 
210 0.58 0.80 0.53 0.002 0.543 0.002 
240 0.35 0.53 0.45 0.001 0.458 0.002 
300 0.31 0.26 0.33 0.001 0.342 0.001 
360 0.18 ˉ 0.26 0.001 0.268 0.001 
420 0.08 ˉ 0.21 0.001 0.219 0.001 
480 0.13 ˉ 0.17 0.001 0.184 0.001 
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0.17nM. Although the estrone levels were undetectable within the scope of the LC-MS 
analysis, it does not show that there is no estrone present within the samples and therefore it is 
not biologically sensible to set this value to zero within the model.  When comparing the lysate 
ratios between the model simulations and the LC-MS analysis they follow the same trend 
however those from the model simulations are 100 times lower than the primary hepatocyte 
LC-MS analysis. 
As the predicted change in the estradiol:estrone ratio within the in silico model changes quicker 
than observed in primary human hepatocytes, a potential explanation is that the reactions within 
the model occur at too high a rate. This increased rate could be due to an artificially high Vmax 
(Kcat or protein concentration) increasing the catalytic capacity, or low Km, increasing affinity.  
For example, the data plots in Figure 4.2.8 (B) and (D) compared to the LC-MS data in Figure 
4.2.6 clearly demonstrate that plateauing levels of estrone are reached much quicker in the 
model simulations.  Estradiol levels within the simulations decrease over time until they reach 
a minimal plateau, consistent with the experimental data. In contrast, the estrone levels are 
predicted to increase over time until they reach a maximal plateau after 300 minutes (five 
hours) within the simulation data, whereas the LC-MS data shows estrone levels continuing to 
increase over the full time course of the experiment (8 hours) within both the medium and 
lysate.  Although there are differences they are negligible between the trends and ratios of these 
2 simulations; this is evident with a change in the level of HSD17B2 not having a significant 
impact upon the biological trend showing that there is robustness within the system. This shows 
the model system of estradiol metabolism and transport is able to cope with changes in 
component protein levels, showing capacity within the system.  For this reason all further work 
carried out in this chapter is done with the enzyme conditions shown in Figure 4.2.8 (B), 
keeping any change to a minimum and within the biological parameters obtained from their 
individual sources, referenced in Table 4.2.3.   
Protein measurements are often the least robust with the measured levels dependant on the 
conditions the cell environment is exposed to and the Vmax being dependent upon the system it 
is measured in.  As the values in the model are taken from a multitude of systems it can be 
anticipated this will be where the largest error lies and will have the most effect on the rate at 
which the model runs. For this reason the simulation was then run again with HSD17B1 and 
SULT1E1 set at 10nM, and the Vmax of each reaction within the model reduced to 50, 60, 70, 
80 and 90% of its original value. The data was plotted, as previously, with the levels of estradiol 
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and estrone against time, in both medium (i) and lysate (ii), and are all shown in  Figure 4.2.7. 
Alterations of fifty and seventy percent were made to the Vmax values, as shown in Figure 4.2.8 
(A) and (B) respectively, and each showed similar effects to the levels of estrone over the 8 
hour period (460 minutes). Both of these changes in Vmax reduced the maximal level of the 
plateau, but did not prevent the simulation reaching this plateau. However, altering the Vmax 
did prevent the appearance of a decrease in the estrone level from 400 minutes onwards, which 
is seen in the unaltered Vmax plot shown  Figure 4.2.7 (E).  As these predicted estrone/estradiol 
levels are more consistent with the experimental data, all further analysis carried out the Vmax 
was set to 70%.  
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 Figure 4.2.7. Alterations in Vmax (A) 50%, (B) 70%, (C) 80%, (D) 90%, (E) 100% were 
made and changes in estrone (■) and estradiol (●) were measured in both the (i) medium and 
(ii) lysate equivalents within the model and compared to the same equivalents in the LC-MS 
analysis of single donor, primary hepatocytes treated with 1000nM of estradiol (F).
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 4.2.3 Analysis of the model in COPASI 
Once the model was completed in Cell Designer, and parameters optimised to best reproduce 
the observed experimental data, the XML format could be exported in to COPASI, a software 
program designed for the simulation and analysis of biochemical networks and their dynamics.  
Using COPASI, the model can be run to identify the steady-state fluxes of each reaction. Under 
steady-state conditions, levels of all species are constant, essentially meaning that the sum of 
all fluxes producing a species must equal the sum of all fluxes removing a species. In linear 
networks such as the one described here, where unidirectional reactions drive metabolites in a 
specific direction (in this case estradiol metabolism), it is necessary to create steady-state 
kinetics which can be approximated by setting all terminal species as constant. The 
understanding of steady-state kinetics is central to understanding the impact of network 
perturbation, as it ensures that any changes observed in the model are due to the perturbations 
to the model and not due to the kinetics of the linear network.  Figure 4.2.8 shows the predicted 
fluxes of metabolic, active and passive processes that occur within the base network at steady-
state.  The figure shows passive processes have the largest flux input in the system, followed 
by metabolic and then active processes. This is perhaps not surprising as passive transport is 
often considered a high capacity system due to the relatively large surface area over which 
transport can occur, coupled with the physiochemical properties of estrogens that make them 
lipophilic. By contrast, protein-dependent reactions (metabolic and transport) are limited by 
the level of the protein and the affinity between the protein and target chemical. As such, these 
systems, while more specific will be used to a lower degree under physiological conditions.    
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Figure 4.2.8. Prediction of steady state fluxes of passive transport, active transport and 
metabolic conversions of estradiol in a hepatocyte; following full parameterisation of the 
model, the simulation was run to reach a steady state, predicting fluxes through each reaction 
under these conditions. In general, passive processes have the highest flux rates at steady state 
conditions; active transport reactions were predicted to be at least an order of magnitude less, 
while metabolic conversions were predicted to be minimal under these conditions. 
 
An alternate way of viewing this flux data is presented in Figure 4.2.10, where a heat map helps 
to visualise the amount of flux through different reactions under comparable conditions. Such 
a visualisation is particularly useful to identify how changes in network topology alter the flux 
dynamics. In this case, virtual knock-down or over-expression experiments were undertaken in 
COPASI.  In the case of knock-down, key metabolic enzymes and transporters had their protein 
concentrations set to 0nM within the model, and these are indicated in the heat map with an ‘x’ 
next to the species name. For over-expression, baseline concentrations of different enzymes 
and transporters were increased tenfold. The reaction fluxes predicted at steady-state for the 
original network are indicated with a black box in Figure 4.2.10. As shown from these 
simulations, changes to the metabolic enzyme levels generally had little effect on reaction 
fluxes, demonstrating the robustness of the network. The exception to this was up regulation 
and knockout of HSD17B1, which resulted in a significant change in reaction fluxes through 
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reaction 11 and 154 which are the conversion of estradiol to estrone and back again. The 
changes in these reaction fluxes are understandable as the conversion of estradiol to estrone is 
the primary route towards elimination (Figure 4.2.9) and therefore any changes to their enzyme 
levels present will have the greatest impact upon the ultimate fate of estradiol. 
 
Figure 4.2.9. The main reactions associated with changes in fluxes within the model of 
estradiol metabolism and transport. Reaction 11 represents the conversion of estradiol to 
estrone by the hydroxysteroid (17-beta) dehydrogenase 1 and reaction 154 represents estrone’s 
conversion back to estradiol by hydroxysteroid (17-beta) dehydrogenase 2. Reaction 56 
represents the active transport of estrone 3 sulphate by ABCG2 across the apical membrane. 
 
With respect to transporter levels, the up-regulation of the apical transporter ABCG2 was 
observed to cause the largest changes in reaction fluxes. These changes seem to mostly 
converge around the passive and active transport of estrone-3-sulphate, shown through 
reactions 34 to 36 (Figure 4.2.10) on the heat map, which is produced by the conversion of 
estrone (E1) by SULT1E1 (reaction 33) and the flux between estradiol and estrone regulated 
by enzymes HSD17B1 and HSD17B2 shown in reactions 11 and 154.  
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Figure 4.2.10. A heat map of flux data taken from virtual knock-out and up regulation 
experiments of different species within the model; this figure shows the effect of virtual 
enzyme and transporter knockouts (x), where the concentrations were set to 0nM and virtual 
overexpression experiments where the baseline concentration for each enzyme and transporter 
were increased 10 fold. This data plot is expressed using the ember colour scheme in the 
heatmap, heirichal clustering tool of the HIV sequence database. The baseline is highlighted in 
this figure with a black box, there is also a blue box to highlight the flux changes and cluster 
analysis for the up regulation and knockout of the apical transporters ABCG2 and MRP2, 
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where there are changes seen around the estrone-3-sulphate flux pathways and the conversion 
between estradiol and estrone by HSD17B1 and HSD17B2.  
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Hierarchical cluster analysis is also carried out as part of the heat map generation, grouping 
together virtual experiments that result in similar steady-state flux predictions.  Hierarchal 
clustering calculates the Euclidean distance between points to assess their dissimilarity, 
determining if these points should be split or grouped together.  This analysis is shown to the left 
of the heat map, in Figure 4.2.11. The clustering of the transporters shows the most significant 
similarity within the apical membrane transporters in both up regulation and knockout of ABCG2 
and MRP2, and the ABCC transporters MRP2, MRP3 and MRP4 show varying levels of 
similarity.  All of the metabolic enzymes in the system are grouped together showing similarity 
when both up regulated and knocked out during simulation. This means that if levels of any 
grouped enzyme or transporter are changed, it can be expected to have an influence on associated 
reactions and their fluxes. 
The cluster analysis was also carried out on the similarity between reactions showing reactions 
responsible for active transport and metabolic activities are clustered together toward the bottom 
of the heat map. These include all active transport reactions within the model, six to ten and fifty 
six, along with state transition of estradiol to estradiol 3 sulphate and estrone to estrone 3 
glucuronide (reactions thirteen and twenty eight respectively), and the passive diffusion of 
estradiol 17 beta glucuronide (reaction 165) into the cell. The remaining passive transport 
processes are all clustered together. 
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4.3 Discussion 
 In-silico modelling approaches provide a tool for ADME prediction and screening of new drug 
compounds.  Traditionally, these models have been limited to the prediction and/or 
extrapolation of drug ADME properties, and are collectively called physiologically based 
pharmacokinetic (PBPK) models. PBPK approaches have been successfully used to predict 
pharmacokinetic parameters, along with plasma and tissue concentration-time profiles. As 
these models become more sophisticated the pharmaceutical industry has used them 
increasingly in conjunction with in vivo and in vitro screening methods, allowing streamlining 
of a company’s time and resources in the development process (Bouzom et al., 2012, Bois, 
2010). As we increase our depth of knowledge to the molecular basis of ADME it can 
potentially produce more sophisticated whole body scale models with the potential to replace 
in vivo models and meet the requirements of the industry three R’s; reduction, refinement and 
replacement of animal models (van de Waterbeemd and Gifford, 2003). 
The advent of systems biology raises the possibility to use the legacy data from the sum of 
experimental knowledge is integrated into predictive models (Kitano, 2002, Westerhoff and 
Palsson, 2004). As such, is should be able to progress beyond PBPK models, which must be 
reductionist in nature due to the lack of precision in biological knowledge, to more robust 
models that make mechanistic predictions, and ultimately to digital organisms (Kolodkin et al., 
2012). While this science is far from mature, significant steps have been made toward 
producing mechanistically robust predictions of small scale network behaviours (Krauss et al., 
2012, Fisher et al., 2013, Geenen et al., 2013)  
As part of this drive to produce mechanistically robust, predictive in-silico models, this chapter 
shows the reconstruction of a model of the metabolism and transport of estradiol in hepatocytes, 
which has progressed from a simple process diagram into a fully parameterised model that can 
reproduce the known biology. The LC-MS method for estradiol detection, developed in chapter 
3, was utilised on primary human hepatocytes cultured and exposed in vitro, simulating the 
situation within a human and being represented by this model. The detection data of estradiol 
and estrone was plotted against time to visualise change over an eight hour time course and 
altered into ratios of estradiol to estrone for comparison to the model simulation as shown in 
Figure 4.2.6.   This allowed identification of areas in the model that have parameters which 
required altering; SULT1E1 and HSD17B1 both control conversion of estradiol to estrone, and 
by altering these values within their experimental parameters, it is possible to correct the flux 
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and ratios observed from the model to be a better biological fit.  With the enzyme concentration 
values corrected to generate the best possible fit within the model, it was clear that the 
simulations were running faster than seen in the in vitro model, so the Vmax values of all 
reactions were altered to 90, 80, 70 and 50% to reduce the time in which plateauing of estrone 
was observed.  By carrying out this variation in the levels of Vmax it can be seen that the fluxes 
observed within the system change very little, other than slowing down.  This is consistent with 
a highly robust system, as large changes in Vmax do not cause large shifts in flux, providing us 
with a robust start point for ADME analysis. Biological robustness is a key property of many 
biological networks, allowing them to maintain core functionality in the face of external 
perturbation, and is often referred to as homeostasis (Kitano, 2004).   
The levels of estradiol observed in the model simulation followed the correct trend when 
plotted, but predicted levels were much lower than observed in the in vitro system. There are 
two major reasons why this disparity could occur: First, the enzyme and transporter parameters 
for the model were taken from a number of species and experimental model types due to the 
incomplete nature of the biological data available. In addition, parameters derived using 
techniques of different precision were used, leading to potential errors. As such, it can be 
expected that there will be a degree of variance between the model and the in vitro test system.  
Second, the in vitro experiment undertaken herein, used a much higher concentration of 
estradiol (1µM) than the nanomolar levels normally seen in a cell, due to the detection limit of 
measurement with LC-MS. This could influence the system, for example causing altered 
enzymatic or transport processes through nuclear receptor activation, which are not currently 
considered within this model.  Although this validation has been done with a primary 
hepatocyte model, the hepatocytes used in these experiments come from a single donor, rather 
than being a pooled sample from multiple donors.  The advantage to using a multiple donor 
hepatocyte sample would be the ability to incorporate the intra-species variability previously 
discussed in the introduction. As we have corrected some of the model parameters with this 
data it has been assumed that this single donor model is correct.  To better improve this analysis, 
the data generated so far could be compared to replicate experiments in hepatocytes of both 
different ethnicities and sexes and the model parameters corrected to the average across the 
donors.  
With validation of the model, this allowed simulation of the data, analysis of the directions of 
flux and identification of the key pathways in estradiol metabolism and transport.  Multiple 
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experiments were carried out to visualise the influence of different metabolic and transport 
species on the fluxes through the different types of reactions in the model. The completed 
model script was imported into COPASI, allowing more complex analysis (Hoops et al., 2006). 
The behaviour of the system was then predicted under basal conditions, and when the protein 
levels of each transporter and metabolic enzyme were knocked-out, (i.e. protein level set at 
zero), and over-expressed (i.e. protein level set at tenfold base value).  (Luo et al., 2002) shows 
an approximate thirty fold induction in PXR activity in reporter gene assays carried out with a 
range of drugs including rifampin, clotrimazole and phenobarbital, with a two to tenfold 
induction in CYP3A4 activity seen in the presence of rifampin.  From this observation the 
tenfold up regulation of metabolic and transport components for over expression analysis is 
biologically feasible.  Complete knockout of genes is less frequent, however we do see loss of 
transporter or metabolic function through genetic polymorphisms, influencing the functionality 
of the protein produced.  Dubin Johnson’s syndrome is a relatively well studied example of 
this where there is loss of functional MRP2, reducing bile acid efflux across the apical 
membrane, increasing hyperbilirubinemia and cholestasis.  Mutations can also cause a reduced 
expression of enzymes such as UGT1A1*28, causing reduced glucuroidation of irinotecan to 
SN-38, increasing the negative side effects to the chemotherapy treatment (Jada et al., 2007). 
As such, the data from these in silico manipulations will provide insight into the system 
behaviour under biologically realistic boundary conditions. 
In Figure 4.2.11 a heat map was generated to analyse the fluxes generated from these different 
virtual knock-out and up regulation experiments.  The up regulation and knock out of the apical 
transporters is highlighted in the figure with a red box and the heat map shows the most change 
occurred here, within the different reaction fluxes following the knockout and up regulation of 
ABCG2 and MRP2.  From the cluster analysis carried out on the data shown in Figure 4.2.11, 
the active processes within the system, and passive diffusion of estradiol into and out of the 
cell, are all clustered together.  This is to be expected as the active processes of metabolism 
and transport cannot occur if the estradiol is not moved into the cell by passive transport.  The 
remaining passive processes are clustered together as they have similar influences on fluxes 
through in the system.  This analysis also shows that the changes observed in the fluxes mostly 
converge around the metabolism of estrone to estrone-3-sulphate and its subsequent transport,  
as highlighted in Figure 4.2.10, which is a well-known substrate of the uptake transporter 
OATP1B1. However, this model only takes into consideration the passive diffusion and active 
139 
 
efflux of estradiol and its metabolites, but with many well-known and characterised drug 
interactions with OATP1B1, such as statins (Niemi et al., 2011), in-corporation of the role of 
uptake transporters in to the model could provide a better insight into the balance of metabolism 
and transporter processes during drug ADME.  
This work has shown that at the low nanomolar levels of estradiol normally present, the 
processes of metabolism and transport work together to eliminate estradiol without exceeding 
the capacity of any of the reactions involved in the system.  With individual loss of  metabolic 
and transport reactions the system is able to re-direct fluxes to eliminate estradiol without 
exceeding the capacity of any one reaction, this shows that both transport and metabolism 
together provide a robust system in estradiol ADME.  If higher levels of estradiol were present, 
due to such drugs as contraceptives or hormone replacement therapy, the system would cope.  
However, this model looks at an individual chemical, and with more chemicals present we 
would potentially see these fluxes altered; indeed, this is the tenet of systems biology, where 
increasingly complex behaviours can be observed through the construction of increasingly 
complex, and realistic, models (Kitano, 2002).  With DDIs responsible for increased expression 
of enzymes such as CYP3A4 the clearance rates of estradiol could be altered. For example, 
rifampin is responsible for a well-documented DDI seen with users of contraceptives (Chen 
and Raymond, 2006). When modelling DDIs, it is important to consider not only true DDIs 
(i.e. between two pharmaceutical compounds), but also CDIs, where a non-drug chemical 
impacts upon drug action. Good examples of such CDIs exist in the many food constituents 
that interact with ‘drug’ transporters and ‘drug’ metabolising enzymes (Holbrook et al., 2005, 
Bailey et al., 1998). As such, the flavonoid class of chemicals is of interest in the present study 
(Bailey et al., 1998, Moon et al., 2006). To address the issue of food-ADME interactions, the 
influence of flavonoid compounds found in fruit juices such as grapefruit and orange juice were 
studied and applied to the model to assess their potential influence of ADME fluxes.  
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5.0 Comparison of ABCC3 and ABCC4 transporters, from Rattus 
norvegicus and Homo sapiens, on drug disposition. 
5.1 Introduction 
As discussed in the introduction, with the identification of new chemical entities their needs to 
be thorough testing with the use of whole organism trials to ensure both safety and efficacy, 
before clinical trial and market authorisation is provided.  The drug development pipeline 
outlines two phases to drug development; preclinical and clinical.  In the preclinical trials 
experiments are carried out both in-vitro and in-vivo using ranging doses of the study drug to 
obtain preliminary figures for efficacy, toxicity and pharmacokinetic information, allowing a 
company to decide if a drug candidate has scientific merit for any further development (Kola 
and Landis, 2004).  
Development work is initially carried out in vitro, in different human cell lines, to identify any 
toxicity or safety issues before taking the drugs use into a whole organism. The rat is a 
commonly used animal model in the drug development process, along with canines and pigs, 
and is used for the identification of any further problems with a drug candidate that could stop 
it going into human clinical trials. An animal model simulates the whole body effect seen on a 
drug, which single cell lines cannot, and as discussed previously in the introduction the true 
impact of ADME on a compound.  Models such as the rat are used and are considered ideal for 
this purpose as they have physiology similar to that of humans and can allow us to extrapolate 
the safety and efficacy data generated into a human model, providing minimised risk when 
taking a compound to clinical trials; however it is now well documented that the protein 
expression levels and their function can differ between the two species which is of significant 
importance when considering ADME and ultimate drug safety and efficacy.  Differences can 
also be observed in transporter and enzyme levels within individuals and across populations 
and this genetic variation can contribute to  differential drug response (Chu et al., 2013a, 
Hilgendorf et al., 2007, Niemi et al., 2011, Nishimura and Naito, 2006, Lu and Klaassen, 2008).  
As discussed previously, the ABC transporters are responsible for the efflux of drug 
compounds and their metabolites from a cell, and may thus impact upon the efficacy/toxicity 
of a drug.  With particular regard to liver metabolism, ABC transporters exist on both the apical 
and basolateral membranes of hepatocytes, moving compounds into the bile and blood, 
respectively (Deeley et al., 2006, Szakacs et al., 2008). Compounds transported into the blood 
through the hepatocyte basolateral membrane will, generally, be excreted via the renal route, 
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but are able to interact with the body before elimination. In contrast apical membrane transport 
into the bile leads directly to faecal excretion. There is thus a need to understand the relative 
importance of these two routes, and the potential biological implications of using one route or 
the other. To date, the majority of research has focussed on the apical membrane-localised 
transporters of the hepatocyte, in particular MDR1 (ABCB1), MRP2 (ABCC2) and BCRP 
(ABCG2), in rat models.  However, there are also closely-related ABC transporters localised 
to the hepatocyte basolateral membrane, namely MRP3 (ABCC3) and MRP4 (ABCC4), which 
transport substrates out into the blood stream.  MRP3 and MRP4 are known to play an 
important role in a number of physiological functions, such as the transport of the signalling 
molecules cAMP and the inflammatory marker LTC4, but little is understood about their role 
in drug clearance, or how the basolateral and apical transporters work together (Deeley et al., 
2006).  
The promiscuous nature of ABC transporters with respect to their substrate profile means that 
an area of particular interest is the potential for drug-drug and food-drug interactions. It is 
accepted that drug-drug and food-drug interactions are important with respect to determining 
the metabolic fate of a compound through interaction with the metabolic enzymes. However, 
equally important is the potential for altered drug transport; this could impact both upon the 
fate of a drug/it’s metabolites by altering the balance between apical and basolateral transport, 
and alter the extent of metabolism by altering the rate of cellular clearance through transport 
(Planchamp et al., 2007).   
To address this question, the main objective of this chapter was to collect data on the relative 
inhibition of MRP2, MRP3 and MRP4 by members of the flavonoid group of food chemicals. 
Assays using the flavonoids Hesperidin and Naringin were carried out, with both compounds 
found to be present in citrus fruits such as grapefruit and orange (Morris and Zhang, 2006). 
Flavonoids are well documented as anti-oxidants and have been implicated in ROS-
scavenging. Due to these factors, and the reported benefit of ROS-scavengers in cancer 
prevention, flavonoids are promoted as food supplements, however, it is unclear how these 
compounds might impact upon the efficacy/safety of concomitantly used therapeutic drugs 
with reported drug interactions being seen with foods such as grapefruit. There are publications 
suggesting uptake transporters and ABC transporters may have their activity modulated by 
flavonoids present within our diets (Mazi-Kotwal and Seshadri, 2012, Bailey et al., 1998, 
Gupta et al., 2014, Wenzel, 2013, Marchetti et al., 2007).  
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Taking this into consideration and with food supplements currently unregulated by drug 
authorities, investigating flavonoid-transporter interactions and their influence on overall 
ADME could be important in understanding drug toxicities.  
This chapter shows the cloning of Abcc3 and Abcc4 from R. norvegicus with the intention of 
creating plasmids which could be transfected and expressed in the MDCK II cell line for 
investigation of transport capabilities. Over-expressing cell lines of human MRP2, MRP3 and 
MRP4 from the Netherlands Cancer Institute were used for transporter inhibition assays. 
Finally, this experimental data was used to examine their influence on the metabolism and 
transport processes in the estradiol model developed in chapter 4.  
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5.2  Results - Cloning 
5.2.1 Cloning of Rattus Norvegicus transporters Abcc3 and Abcc4 
The apical membrane transporters MDR1 and MRP2 for both rats and humans have been 
previously cloned and functionally characterised using heterologous expression systems. 
Human MRP3 and MRP4 have been cloned and studied in overexpressing models, however 
less is known about the rat MRP3 and MRP4 basolateral transporters and their influence in 
ADME processes of drug disposition (Deeley et al., 2006, Hirouchi et al., 2009).  Through the 
cloning of the Rattus norvegicus Abcc3 and Abcc4 genes, and their subsequent functional 
characterisation under heterologous expression conditions, it will be possible to determine the 
influence of these basolateral transporters on the ADME processes of rat hepatocytes. In 
addition, it will be possible to compare their characteristics to those of the human MRP3 and 
MRP4 transporters. This isolation and characterization of the transport proteins will allow a 
species characterization and analysis of the suitability of rats as ADME models. 
5.2.2 PCR Optimisation 
A major complicating factor in the cloning of ABC transporters is their length: the coding 
sequences for Abcc3 and Abcc4 are 5174 and 4526 base pairs, respectively. Due to this, PCR 
amplification of the sequence as a whole is extremely difficult, and hence it was decided to 
clone each transporter in three fragments, subsequently ligating these together to reform the 
complete sequence.  The cDNA ref sequence for each gene was obtained from NCBI, and was 
split into three fragments utilising the restriction enzyme sites present in both the gene sequence 
and the plasmid multiple cloning site of pTriEx 1.1. Primers were designed around the cloning 
strategy described in section 2.2.1 and are shown in Appendix Figure 9.1, with six primer pairs 
in total being optimised.  
Amplification of the desired fragment was optimised for each primer pair using first GoTaq 
polymerase and then PrimeStar polymerase, as discussed above in section 2.2.4.  Amplification 
of the Abcc3 fragments 1 and 3 was found to be optimal under annealing conditions  of 56oC  
for 15 seconds, while  fragment 2 of Abcc3 amplified best under annealing conditions of 60oC 
for 15 seconds per cycle (Figure 5.2.1 A).  The optimised PCR primers for the Abcc4 fragment 
1 required an increasing annealing temperature programme, going from 56oC to 60oC.  This 
was carried out with one degree temperature increases each run for 5 cycles, with a final 
annealing temperature of 61oC run for 10 cycles:  all annealing steps had duration of 15 
seconds. Primers for Abcc4 Fragment 2 worked efficiently under annealing conditions of 63oC 
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for 15 seconds. Amplification of abcc4 Fragment 3 was achieved by using a nested PCR 
approach using two sets of primers, used in two successive runs of polymerase chain reaction. 
The second pair of primers is used to amplify a secondary target within the first run product, 
reducing the non-specific binding and amplification of other sequences. With the first set of 
Abcc4F3 primers an annealing temperature of 66oC was used for fifteen seconds a cycle for a 
total of thirty cycles. Once the initial PCR amplification was complete five microlitres of PCR 
product was taken and used with the secondary Abcc4F3 primers at annealing temperature of 
64oC for fifteen seconds, with a total of thirty cycles (Figure 5.2.1 B).  Amplification using all 
six primer pairs was successful, as shown in Figure 5.2.1.  
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Figure 5.2.1. Primer Opitimisation: 
(A) Shows the optimised primers for 
each of the fragments that make up the 
gene sequence for Abcc3; F1 and F3 
both work at an annealing temperature 
of 56oC for 15 seconds and F2 at 60oC 
for 15 seconds when using PrimeStar 
taq polymerase. (B) Shows optimised 
primers for the fragments of the Abcc4 
gene; F1 working at an increasing 
annealing temperature from 56oC to 
60oC each at 5 cycles with a final 
annealing temperature of 61oC for 10 
cycles at 15 seconds each, F2 working 
at an annealing temperature of 63oC for 
15 seconds, F3 working through nested 
PCR with primers being used first at 
66oC and secondly at 64oC of annealing 
temperature for 15 seconds, all using 
PrimeStar taq polymerase. These were 
all run on a 1% agarose gel with 
10µg/ml ethidium bromide at 4.5V/cm 
and visualised under UV light. 
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5.2.3 pTriEx 1.1 Transformation 
Once amplification for all fragments was the optimized, 50µl of PCR product was produced 
for each fragment and cleaned up using the phenol-chloroform extraction, as described in 
section 2.2.5. These amplification products were then used for cloning. There were several 
attempts with the TaKaRa Ligation mighty mix following the protocol laid out in sections 
2.2.6.1 and 2.2.7.1.  Any successful fragment insertions into the vector were found to be of 
incorrect fragments when restriction digests were carried out.  After several attempts with 
different samples of PCR product for each fragment and blunt cloning fragments into an 
EcoRV digested pTriEx1.1, this approach was deemed unsuccessful.  After this had failed the 
alternative TOPO-Zero blunt cloning, as described in section 2.2.7.2 was used. 
5.2.4 TOPO – Zero Blunt Cloning Transformation 
Each amplified fragment was ligated into the TOPO blunt vector following the protocol 
described in section 2.2.7.2.  Due to the nature of the TOPO blunt vector, only plasmids with 
successfully inserted fragment should produce colonies on agar. Colonies were then picked and 
grown in LB broth, and plasmids purified using the mini prep extraction kit as described in 
section 2.2.9.1.  For each fragment inserted into the TOPO blunt vector, the resulting plasmid 
was subject to an initial diagnostic digest, using the restriction enzyme combinations shown in 
Table 5.2.1.  
Table 5.2.1. The enzyme digestions required for Abcc3 and Abcc4 fragment removal 
from plasmid. 
Abcc3 5’ Enzyme 3’ Enzyme Size 
(bp) 
Abcc4 5’ Enzyme 3’ Enzyme Size 
(bp) 
F1 Eco RI Bcl I 1672 F1 Eco RV Acc65I 1214 
F2 Bcl I Alo I 1387 F2 Eco RI Age I 1211 
F3 Alo I Not I 1595 F3 Age I Not I 1607 
 
The digested plasmids were run on a 1% agarose gel alongside DNA markers. Those plasmids 
with fragments that matched the expected size, Figure 5.2.2, were then prepared for sequencing 
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as explained in section 2.2.13.  Figure 5.2.2 shows the plasmids and their digests for the 
ABCC3 gene fragments and B shows the plasmids and their digests for the ABCC4 fragments. 
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UD D 
 1.58Kb 
3.3Kb 
1.1Kb 
 
3.3Kb 
1.58Kb 
1.1Kb 
UD D 
 
 
3.3Kb 
1.58Kb 
1.1Kb 
F1 F3 F2 
F1 F2 F3 
3.3Kb 
1.58Kb 
1.1Kb 
B 
A 
Figure 5.2.2. (A) Rattus norvegicus Abcc3 gene fragents and their individual digestions for removal from the TOPO blunt Vector; F1 was 
digested with Eco RI and Bcl I producing a 1672 base pair fragment, F2 was digested with Bcl I and Alo I producing a 1387 base pair fragment and 
F3 was digested with Alo I and Not I producing a 1595 base pair fragment. (B) Rattus norvegicus Abcc4 gene fragments and their individual 
digestions for removal from the TOPO blunt vector; F1 was digested with Acc65I and Eco RV producing a 1214 base pair fragment, F2 was 
digested with Age I and Eco RI producing a 1211 base pair fragment and F3 was digested with Age I and Not I producing a 1607 base pair. 
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Once sequencing was completed, it was analysed using the NCBI Blast programme to confirm 
identity against the Rattus norvegicus sequence.  This information on the base identity and its 
percentage match against the template sequence are detailed in Table 5.2.2. As shown there is 
high sequence identity for each fragment to its gene sequence, showing efficient PCR and 
cloning reactions.  Where discrepancies existed between the amplified fragment and the 
template RefSeq, the sequence trace was examined to determine if this was an introduced 
mutation, or sequencing artefact. This ensures that the PCR fragments being chosen are suitable 
for re-ligation and completion of the entire gene cDNA sequence into pTriEx.  The sequences 
each contain the additional primer sites either side of the desired fragment and this is included 
in the total base identity. 
Table 5.2.2. Abcc3 and Abcc4 sequencing NCBI Blast data; this shows us that all fragments 
have at least 99% base identity to that sequence in the NCBI gene database when run through 
the NCBI BLAST tool. 
Abcc3 Base Identity % Identity Abcc4 Base Identity % Identity 
F1 1746/1756 99% F1 1244/1255 99% 
F2 1539/1551 99% F2 1239/1239 100% 
F3 1646/1659 99% F3 1630/1630 100% 
 
Once the sequence identities were confirmed, the fragment-containing plasmid was grown up 
in large volume usually 100ml and underwent midi prep, as described in section 2.2.10, to 
produce a high quantity and concentration of the correct plasmid to allow for attempts at the 
re-ligation of the gene sequence into the plasmid pTriEx 1.1. Each fragment was digested 
overnight with its specific enzyme pair, shown in Table 5.2.1 and then each fragment ligated 
into the target plasmid at a ratio of 6:1. After several attempts of inserting the fragments into 
the vector there was no success and due to time constraints this part of the project was placed 
on hold. 
As the aim of this work was also to study the human ABCC3 and ABCC4 counterparts, stable, 
overexpressing cell lines for these transporters were purchased from The Netherlands Cancer 
Institute.   
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5.3.0 Results – Transporter Inhibition 
5.3.1 Influence of Flavonoids on Human ABCC transporters 
There have been several drugs that once on the market have shown drug interactions with 
components found in both foods and drinks, with perhaps the most infamous example being 
the inhibition of MDR1 and CYP3A4 by bergamottin, a component of grapefruit juice (Honda 
et al., 2004). Drugs where clinically relevant interactions were reported include antihistamines, 
statins and the anti-diabetic drug metformin (Mandery et al., 2012). Another significant class 
of food constituent are the flavonoids, which are found in a range of foods from fruit juice to 
chocolate. These compounds have been previously examined for their ability to inhibit some 
drug transporters, most notably MRP2, but their impact on other members of this transporter 
family are unclear. Understanding the potential influence of these compounds within fruit juice, 
on the ADME processes will allow better guidance when prescribing and reduce the risk of 
adverse reactions. 
5.3.2 Carboxydichlorofluroescein Diacetate (CDFDA) Transport Assay Time Course  
Carboxy dichlorofluroescein Diacetate (CDFDA) is the diacetate promoiety of 5 (and 6)-
carboxy-2',7'-dichlorofluorescein (CDF). CDFDA is metabolised by esterases within the cell 
to the fluorescent compound CDF, which is actively transported out of the cell by members of 
the ABCC family. CDF is a fluorescent metabolite; however its excitation and emission 
wavelengths alter depending on the solution it is prepared in. As CDF was being measured in 
HBSS for this work, the excitation and emission wavelengths were determined using a 1µM 
solution of CDF prepared in 1 x HBSS. The sample was then run on a broad range absorbance 
and emission scan to identify the optimum wavelengths for both, as shown in Figure 5.3.1. 
From this it was determined that an excitation wavelength of 504 nm and an emission 
wavelength of 540 nm would be suitable for this analysis. 
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Previous work has been carried out in the Plant lab utilising CDFDA in sandwich culture and 
confocal microscopy (Howe et al., 2007). However, for the current work a monolayer culture 
was used, with excretion of CDF into the medium measured directly. Hence, it was necessary 
to determine optimum times for measurement of efflux of CDF. Overexpressing cell lines of 
MRP2, MRP3 in MDCKII cells and MRP4 in HEK 293 cells were obtained from The 
Netherlands Cancer Institute and used for transport assays. To check optimum sampling time 
for CDF efflux a time course experiment was carried out in both wild type MDCK II cells and 
HEK 293 cells as shown in figure 3.3.1 and carried out as described in section 2.3. 
 
 
 
 
 
 
Figure 5.3.1. Absorbance and Emission spectra of 5 (and 6)-carboxy-2',7'-
dichlorofluorescein. The absorbance (A) and emission (B) values of 5 (and 6)-carboxy-2',7'-
dichlorofluorescein (CDF) were established when prepared as a 10mM stock in DMSO and 
dissolved to 10µM in HBSS maintaining a DMSO concentration of 0.1% (v/v).  These spectra 
show us that the optimum absorbance wavelength for CDF is between 504nm and the emission 
wavelength is 540nm.   
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Graphs in Figure 5.3.2 show that the relative fluorescence units measured, indicating CDF 
present in cell medium, increased linearly with time in both cell types.  From this data it was 
decided that 15 minutes would be a sufficient amount of efflux time for measurement of any 
transporter inhibition in the following experiments, as it produced a large amount of 
fluorescence and was in the middle of the determined linear range, and therefore any inhibition 
would be accurately measured in later assays. 
 
 
 
 
 
  
A B 
 
Figure 5.3.2. Optimisation of the CDF Efflux Assay in MDCKII and HEK 293 Cell 
Culture. MDCKII wild type (A) and HEK 293 wild type (B) were both plated at 2x105 cells 
per well and left for 48 hours at 37oC in 5% CO2. These cells were then treated with 10uM of 
CDFA for 15 minutes and then left in pre-warmed HBSS for efflux. Three 100µl samples were 
taken of the HBSS to measure the CDF efflux at 5, 10, 15, 20, 25 and 30 minutes. Efflux was 
measured by the relative fluorescence when read at an excitation of 504nm and emission of 
540nm.This data represents three technical repeats with the standard error above and below the 
mean.  
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5.3.3 The Impact of dietary flavonoids on CDF efflux by human MRP2, MRP3 and MRP4 
overexpressing cell lines. 
Before beginning the transporter inhibition assays, each compound was prepared at the relevant 
test concentrations (flavonoids 0-1400ug/ml and MK571 at 0-30µM) in HBSS and measured 
at an excitation wavelength of 504nm and emission wavelength of 540nm.  This was carried 
out to control for any compound-specific interference at the CDF measurement wavelengths, 
which wouldn’t influence the measurement of fluorescence intensity and extrapolated transport 
efficiency. As shown in Figure 5.3.3, none of the compounds examined produced significant 
background florescence at these wavelengths, nor did this alter with increasing concentration; 
however it is shown in the plot of MK571 that at the lowest concentration of 0.1µM it has an 
unusually high level of absorbance, compared to the other plotted concentrations.  This point 
also has a considerably large error which is not seen with the other data points for MK571 so 
it can be assumed this is an anomalous result, and no impact will be seen on the data collected. 
 
Figure 5.3.3. Relative background florescence produced by inhibitor compounds. 
Naringin (A), Hesperidin (B) and MK571 (C) were both prepared in DMSO and diluted in 1 x 
HBSS to produce the concentration range 0 – 1400µg/ml, used in transport experiments. For 
each concentration 100ul was run in triplicate in a black 96 well plate, and read using the CDF 
efflux method on the omega plate reader to check for any influence on IC50 
interpretation.(n=3)  
 
Five cell lines were tested using the CDF efflux assay; MDCKII wild type, MDCKII 
overexpressing MRP2 and MRP3, HEK 293 wild type and HEK 293 over expressing MRP4. 
Each cell line was put through the CDF assay, as described in section 2.2, with the presence of 
varying concentrations of two flavonoids, hesperidin and naringin and the chemical MK 571, 
a known ABCC multidrug resistance protein 1 (MRP1) inhibitor.  
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MK571 is a known MRP1 (ABCC1) transport inhibitor and was used to ensure that the efflux 
assay was working efficiently.  MK571 was initially prepared in DMSO and diluted to the 
desired dosing range of 0-30µM in warmed HBSS. Figure 5.3.4 shows the MK571 treatment 
of each cell line; A MDCKII wild type, B MRP2 and C MRP3 over expressing type all show 
reduced CDF fluorescence with increasing MK571 concentration and IC50 values were 
calculated from their log concentration graphs with variable slope analysis and these can be 
seen in Table 5.3.1. The over expressing MRP2 and MRP3 both showed a marked increase in 
their IC50 constant compared to the wild type going from 4.96µM to 7.34µM and 6.93µM 
respectively. In the HEK 293 overexpressing MRP4 (E) and HEK 293 wild type (D) cells, 
MK571 was shown to have no influence on the efflux of CDF and therefore provided no 
determinable IC50. 
 
Figure 5.3.4. The influence of MK571 treatment, from 0 - 30µM, on CDF efflux in 
MDCKII Wild Type (A), MDCKII overexpressing MRP2 (B) and MRP3 (C), HEK293 
Wild Type (D) and overexpressing MRP4 (E). Each were plated in 12 well plates at a seeding 
density of 2x105 and left for 48 hours before commencement of the transport assay. This data 
represents three independent repeats with variable slope analysis and standard error above and 
below the mean. 
Figure 5.3.5 shows the naringin treatment of each cell line, A MDCKII wild type, B MRP2 
over expressing type and D HEK 293 wild type, all showed reduced CDF fluorescence with 
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increasing naringin concentration, and IC50 values were calculated from their log 
concentration graphs with variable slope analysis and these can be seen in Table 5.3.1. The 
IC50 values of naringin on wild type MDCKII cells were placed at 1.33mM and the 
overexpressing MRP2 cells showed a decreased IC50 of 1.19mM (±0.01mM). In the MDCKII 
overexpressing MRP3 (C) the graph does not follow a slope suitable for the calculation of an 
IC50 and follows a mostly linear path, unchanging with increasing naringin concentration.  
Similar was seen with the HEK 293 overexpressing MRP4 (D) cells, where naringin was shown 
to have no influence on the efflux of CDF and therefore had no determinable IC50. 
 
Figure 5.3.5. The influence of naringin treatment, from 0-1400µg/ml, on CDF efflux in 
MDCKII Wild Type (A), MDCKII overexpressing MRP2 (B) MRP3 (C) HEK 293 Wild 
Type (D) and HEK293 overexpressing MRP4 (E). Each were plated in 12 well plates at a 
seeding density of 2x105/well and left for 48 hours before commencement of the transport 
assay. This data shows three independent repeats and shows the standard error above and below 
the mean. 
 
Figure 5.3.6 shows the hesperidin treatment of each cell line and all 5 cell lines show reduced 
CDF fluorescence with increasing hesperidin concentration and IC50 values were calculated 
from their log concentration graphs with variable slope analysis and these can be seen in Table 
5.3.1Error! Reference source not found.. The MDCKII wild type produced an IC50 of 1.28mM 
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(±0.01mM) and the IC50s observed in the overexpressing cell lines of MRP2 and MRP3 were 
0.98mM (±0.01mM) and 1.3mM (±0.01mM) respectively.  The IC50 for MRP2 showed a more 
significant difference, with only a marginal difference observed between the MRP3 and 
MDCKII wild type. The HEK 293 wild type cells showed an IC50 of 0.366mM (±0.01mM) 
and the overexpressing MRP4 cell line had a significant increase to 0.68mM (±0.04mM), 
showing that increasing hesperidin concentration does impact upon MRP4 transport of CDF. 
This indicates that hesperidin can place an influence upon the transporter activity of MRP2, 
MRP3 and MRP4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.4 Hesperidin treatment 0-1400µg/ml in MDCKII Wild Type (A), MDCKII 
overexpressing MRP2 (B) and MRP3 (C). HEK293 overexpressing MRP4 (E) Each were 
plated in 12 well plates at a seeding density of 2e5 and left for 48 hours before commencement 
of the transport assay. (n=3) 
  
For each of these inhibition experiments the transporter assay was carried out as three 
independent repeats, with each repeat being carried out on a different passage of cells. 
Following completion of these transport inhibition assays, the IC50 constants for the over 
Figure 5.3.6. The influence of hesperidin treatment, from 0-1400µg/ml, on CDF efflux in 
MDCKII Wild Type (A), MDCKII overexpressing MRP2 (B) and MRP3 (C) HEK293 
wildtype (D) and  overexpressing MRP4 (E) Each were plated in 12 well plates at a seeding 
density of 2x105/well and left for 48 hours before commencement of the transport assay. This 
data shows three independent repeats and the significant error above and below the mean. 
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expressing cell lines, as shown in Table 5.3.1 were applied to the estradiol model described in 
chapter 4.  This was carried out to assess the potential, overall impact on the metabolism and 
distribution of estradiol, and the analysis is shown in the next section. 
Table 5.3.1.  IC50’s of flavonoids, naringin and hesperidin, and chemical inhibitor 
MK571 on the CDF efflux from five different cell types; Mardin Darby Canine Kidney II 
(MDCKII) wild type, MDCKII overexpressing MRP2 and MRP3, Human Embryonic Kidney 
293 (HEK 293) wild type and HEK 293 over expressing MRP4, with the standard error above 
and below the mean. These were all calculated from the graphs as shown in Figure 5.3.4, Figure 
5.3.5 and Figure 5.3.6, with variable slope analysis. 
  MDCKII 
WT 
MDCKII 
MRP2 
MDCKII 
MRP3 
HEK 293 
WT 
HEK 293 
MRP4 
Naringin 
(µg/ml) 
777.1 
±4.81 
695.5    
±6.11 
ND 
- 
811.4  
±3.09 
ND 
- 
mM 1.33  
±0.01 
1.19      
±0.01 
ND 
- 
1.36    
±0.01 
ND 
- 
Hesperidin 
(µg/ml) 
786.0 
±6.49 
602.6   
±3.19 
797.2    
±4.57 
223.7 
±15.09 
418       
±24.49 
mM 1.28 
 ±0.01 
0.98    
 ±0.01 
1.30      
±0.01 
0.34   
±0.01 
0.68      
 ±0.04 
MK571 
(µM) 
4.96 
  ±3.86 
7.34   
±9.73 
6.93 
±2.70 
ND 
- 
ND 
- 
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5.3.4 The effect of the dietary flavonoids IC50 constants of MRP3 and MRP4 transport 
on the metabolism and transport of estradiol. 
The IC50 constants calculated from the transporter inhibition assays, as shown in Table 5.3.1, 
were used to further parameterise the in-silico model, allowing the impact of flavonoids on 
chemical fate to be examined. In this analysis, the maximal concentrations of hesperidin and 
naringin were set to 200,000 nM in the blood compartment, consistent with experimental data 
demonstrating that large doses of flavonoids given intravenously could achieve this 
concentration in the plasma (Morris and Zhang, 2006). It has also been shown that after 
ingestion of citrus fruit juices, such as grapefruit and orange juice, plasma concentrations of 
these flavonoids can be measured as high as 60,000nM, with large inter-individual variation 
observed (Erluand et al., 2001).  Table 5.3.2 provides the additional compound names, species 
IDs and associated compartments that were added to the model; all other species within the in 
silico model remained as described in section 4.2.1. 
Table 5.3.2. The new flavonoid model species ID in addition to the species described in 
the estradiol model in section 4.2.1. 
Compound 
Species 
ID  Compartment 
Species 
ID Compartment 
Hesperidin S143 C1 S144 C2 
Naringin S142 C1 S145 C2 
 
Next, the kinetic laws for the MRP2, MRP3 and MRP4 transport reactions were re-written as 
irreversible inhibition reactions and the mathematic formula and the constants utilised in the 
reaction are shown in Table 5.3.3.  All other reactions within the model have remained 
unchanged from those described in section 4.2, and therefore assumes no impact from the 
flavonoids on other species present. 
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Table 5.3.3. The flavonoid inhibitory constants and the kinetic laws for their irreversible 
inhibition of active transport by MRP2, MRP3 and MRP4. 
R
ea
ctio
n
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ct. 
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ro
d
. 
M
o
d
ifie
rs 
Maths K1 V1 Ki (KiN) 
nM 
Ki (KiH) 
nM 
Re6 s4 s9 
s124 
s142 
s143 
(v1*s4*s124/K1) 
1+(s4/K1 + s142/KiH + s143/ KiN) 
2.60E+04 1.74E+00 8.00E+05 1.36E+06 
Re7 s4 s9 
s123  
s142 
s143 
(v1*s4*s123/K1) 
1+(s4/K1 + s142/KiH + s143/ KiN) 
3.00E+04 2.13E+01 0.00E+00 6.80E+05 
Re8 s4 s13 
s11 
s144  
s145 
(v1*s4*s11/K1) 
1+(s4/K1 + s144/KiH + s145/ KiN) 
9.80E+04 3.19E+01 1.19E+06 9.80E+05 
 
Once these reactions had been applied to the model, simulations were run with the 
concentrations of naringin and hesperidin both set at; 200,000nM, 100,000nM, 50,000nM, 
10,000nM, 1000nM, 100nM, 10nM and 1nM. With plasma concentrations seen as high as 
60,000nM and with variation observed as large as ±54,000nM (Erluand et al., 2001) 
concentrations modelled up to 200,000nM, although large, could be significant to an everyday 
scenario. As naringin and hesperidin are both present within citrus fruits, such as grapefruit 
and orange, they are simulated in the model as acting upon the transport reactions 
simultaneously.  The raw flux data from these simulations is displayed in Table 5.3.4, with 
yellow highlight denoting reactions where a change in flux was predicted (nmol/min) compared 
to baseline (no flavonoid).  This information is also displayed as a heat map (Figure 5.3.7), 
using a Euclidean distance hierarchical clustering method, as provided by the Hierarchical 
clustering tool, in the HIV sequence database (www.hiv.lanl.gov).   
The heat map (Figure 5.3.7) provides a visual representation of predicted changes in estrogen 
(and its metabolites) fluxes caused by the presence of hesperidin and naringin.  The most 
significant areas of change are highlighted with a black box. Across all concentrations of 
flavonoid applied, reduced passive diffusion of estradiol 17 beta glucuronide was predicted, 
and a 10 fold increase in the MRP2 transport of estradiol 17 beta glucuronide was predicted in 
the presence of flavonoid. When examining the raw flux data shown in Table 5.3.4, it can be 
seen that there are changes across all the active transport processes of estradiol glucuronide, 
with flux by MRP4 being eliminated and flux through MDR1, MRP3 and BCRP being reduced 
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by a factor of 104.  All other reactions and their fluxes are shown, in both Table 5.3.4 and Figure 
5.3.7, to remain unchanged by the presence of these flavonoids. 
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Table 5.3.4. Flux data from model simulations in the presence of Flavonoid; simulations of the estradiol model described in chapter 4, were 
run with 5 different concentrations of both naringin and hesperidin. The levels of hesperidin and naringin were set to the same levels, both in the 
blood and the cell, at 200000, 100000, 50000, 10000, 1000nM, 100nM, 10nM and 1nM compared to the baseline run with no flavonoid. 
  BASELINE 1nM 10nM 100nM 1000nM 10000nM 50000nM 100000nM 200000nM 
re1 3.60E-02 3.60E-02 3.60E-02 3.60E-02 3.60E-02 3.60E-02 3.60E-02 3.60E-02 3.60E-02 
re2 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 
re3 3.54E-03 3.54E-03 3.54E-03 3.54E-03 3.54E-03 3.54E-03 3.54E-03 3.54E-03 3.54E-03 
re4 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 1.98E-02 
re5 5.95E-05 5.95E-05 5.95E-05 5.95E-05 5.95E-05 5.95E-05 5.95E-05 5.95E-05 5.95E-05 
re6 2.28E-03 2.23E-07 2.23E-07 2.23E-07 2.22E-07 2.14E-07 1.82E-07 1.48E-07 9.37E-08 
re7 2.65E-03 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 
re8 9.47E-02 9.07E-01 9.07E-01 9.07E-01 9.07E-01 9.07E-01 9.07E-01 9.07E-01 9.08E-01 
re9 1.92E-03 1.88E-07 1.88E-07 1.88E-07 1.88E-07 1.84E-07 1.69E-07 1.49E-07 1.11E-07 
re10 5.40E-04 5.28E-08 5.28E-08 5.28E-08 5.27E-08 5.18E-08 4.74E-08 4.20E-08 3.12E-08 
re11 1.61E+00 1.61E+00 1.61E+00 1.61E+00 1.61E+00 1.61E+00 1.61E+00 1.61E+00 1.61E+00 
re13 4.92E-05 4.92E-05 4.92E-05 4.92E-05 4.92E-05 4.92E-05 4.92E-05 4.92E-05 4.92E-05 
re15 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 
re16 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 
re17 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 
re18 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 5.05E+00 
re24 6.40E-01 6.40E-01 6.40E-01 6.40E-01 6.40E-01 6.40E-01 6.40E-01 6.40E-01 6.40E-01 
re25 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 
re26 6.12E-01 6.12E-01 6.12E-01 6.12E-01 6.12E-01 6.12E-01 6.12E-01 6.12E-01 6.12E-01 
re27 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 6.26E-01 
re28 1.65E-06 1.65E-06 1.65E-06 1.65E-06 1.65E-06 1.65E-06 1.65E-06 1.65E-06 1.65E-06 
re29 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 
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  BASELINE 1nM 10nM 100nM 1000nM 10000nM 50000nM 100000nM 200000nM 
re30 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 
re31 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 
re32 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 8.93E+00 
re33 2.06E-03 2.06E-03 2.06E-03 2.06E-03 2.06E-03 2.06E-03 2.06E-03 2.06E-03 2.06E-03 
re34 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 
re35 4.10E+00 4.10E+00 4.10E+00 4.10E+00 4.10E+00 4.10E+00 4.10E+00 4.10E+00 4.10E+00 
re36 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 
re37 4.14E+00 4.14E+00 4.14E+00 4.14E+00 4.14E+00 4.14E+00 4.14E+00 4.14E+00 4.14E+00 
re56 5.13E-01 5.13E-01 5.13E-01 5.13E-01 5.13E-01 5.13E-01 5.13E-01 5.13E-01 5.13E-01 
re154 1.60E+00 1.60E+00 1.60E+00 1.60E+00 1.60E+00 1.60E+00 1.60E+00 1.60E+00 1.60E+00 
re155 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 
re156 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 4.37E+00 
re157 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 4.12E+00 
re158 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 3.88E+00 
re159 8.05E-01 7.88E-05 7.88E-05 7.88E-05 7.86E-05 7.72E-05 7.07E-05 6.26E-05 4.65E-05 
re160 1.31E+00 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 
re161 1.31E+00 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 9.08E-01 
re162 1.82E+00 1.82E+00 1.82E+00 1.82E+00 1.82E+00 1.82E+00 1.82E+00 1.82E+00 1.82E+00 
re163 8.05E-01 7.88E-05 7.88E-05 7.88E-05 7.86E-05 7.72E-05 7.07E-05 6.26E-05 4.65E-05 
re164 4.03E-01 3.94E-05 3.94E-05 3.94E-05 3.93E-05 3.86E-05 3.54E-05 3.13E-05 2.32E-05 
re166 4.03E-01 3.94E-05 3.94E-05 3.94E-05 3.93E-05 3.86E-05 3.54E-05 3.13E-05 2.32E-05 
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Discussion 
Figure 5.3.7. A heat map of flux data, taken from the simulation of the dietary flavonoids 
Hesperedin and Naringin, to analyse their possible influence on the metabolism and 
disposition of estradiol. Shows computer simulations of the irreversible inhibition of both naringin 
and hesperidin, which are dietary flavonoids found in citrus fruits such as grapefruit and orange.  
Nine concentrations of both flavonoids were measured in a range from 0nM (Baseline) to 
200,000nM, and the model was run at steady state and the fluxes for each reaction were entered in 
to the hierarchal clustering tool, set to a 15 colour ember colour palette.   
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5.4 Discussion 
A major aim of drug studies carried out in vitro is to characterize with a reasonable level of 
accuracy what the fate of a chemical entity will be in vivo. As previously discussed there are a 
multitude of factors that contribute to the fate of a chemical, meaning that a range of in vitro 
screens must be used to study each of these ADME processes in isolation. While such an 
approach allows us to analyse the significance of each of these individual factors in the ultimate 
elimination of a chemical it has one major disadvantage; biological systems do not act in 
isolation. A central tenet of systems biology is that to fully understand a system you must study 
the whole system and not just the individual parts in isolation (Kitano, 2002). The in vitro 
screening of individual behaviours for each drug transporter or metabolic enzyme, for example, 
is a sensible, pragmatic approach to gain information on the key players in determining drug 
fate. However, to truly leverage the information from these studies and increase the robustness 
of extrapolations, these isolated behaviours must be combined into larger networks where more 
complex behaviours may emerge (Kolodkin et al., 2012).  One area where such a systems 
approach has been applied in the pharmaceutical industry for many years is the combination of 
in vitro enzyme activity assays and pharmacokinetic measurements to generate PBPK models 
that can then inform decisions about what chemical entities could make suitable drugs (Smith, 
2013, Li, 2001).  
 
While the study of metabolic enzymes, and the generation of suitable screening tools, is an 
established science (Plant, 2004b), drug transport proteins are currently under-represented 
(Giacomini et al., 2010). As such there is a drive towards the isolation and heterologous 
expression of ABC and SLC transporters, allowing a more in depth understanding of 
transporter kinetics as well as the influence of other compounds on their activity. This can be 
done by cloning, transfecting and over expressing specific transporters in a cell system to 
analyse their substrate specificities and kinetics.  However, there are several issues with such 
an approach: First, the genes, and coding regions, encoding ABC transport proteins tend to be 
large (>4Kbp) and difficult to work with; second, correct processing of a nascent protein is 
required to ensure integration into the cell membrane; third, for full functionality, cell 
polarisation is often required; fourth, in an analogous manner to the CYP enzymes, the 
promiscuity in substrate binding means that identifying specific probe substrates is difficult, 
and that transporter functionality is not faithfully reproduced across species; fifth, there are 
also significant species differences in protein expression levels, which may influence the role 
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of DDIs in drug metabolism (Keogh, 2012). Together this can lead to unpredicted drug 
toxicities through drug interactions, or poor drug efficacy, which are both factors also 
influenced by intra-species differences (Chu et al., 2013a). Taken together, the general need 
for an increasingly system-level approach to examine biological behaviours, and the specific 
need to better understand drug transporters, suggests that any systems level approach for 
ADME must encompass drug transport processes at its heart.  
 
This chapter has shown a strategy for the cloning of ATP binding cassette (ABC) transporter 
proteins Abcc3 and Abcc4 from Rattus norvegicus, an animal model frequently used in pre-
clinical trials of drugs. As such information on these drug transporters would be important for 
robust extrapolation of ADME properties from rodent studies to humans. These genes both 
have large cDNA sequences, each being almost five kilo bases in size, which are large portions 
of DNA to successfully clone.  For this reason, each gene was split into three segments with 
PCR primers designed around the presence of restriction enzyme sites in the sequence. Each 
primer pair was successfully optimized and each gene fragment grown in the topo blunt vector 
however attempts at re-construction of the two sequences into the pTriEx 1.1 plasmid were 
unsuccessful.  Many factors can impact upon this failed re-construction, including enzyme 
efficiency and the quality of the DNA fragments being used.  All enzymes were used with the 
manufacturers recommended optimum conditions however the quality of the DNA varied as 
the digested fragments from each plasmid were extracted via agarose gel extraction using 
phenol chloroform, which could potentially impact upon the digestion efficiency.  Each 
generated topo plasmid was sent for sequencing showing that the plasmid-fragment sequences 
had a minimum of ninety nine per cent base identities to the gene ref sequence in the NCBI 
database.  
 
Upon completion of this cloning work it was planned for their use in creating stable transfects 
of the transporters into the MDCK II cell line to study the transporter characteristics.  Due to 
the time constraints of the project it was decided that stocks of each fragment containing 
plasmid should be grown up and stored at -20oC and placed on hold to attempt completion 
later.  As the cloning of the rat transporters was unsuccessful the remainder of the transporter 
characterization work was carried out in the overexpressing human cell lines purchased from 
the Netherlands Cancer Institute and analysis was carried out on the impact of the flavonoids 
on the transport activity of MRP2, MRP3 and MRP4.  
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Hesperidin and naringin are two flavonoids found in grapefruit and orange, and hence are 
commonly consumed on a regular basis by individuals in the form of fruit juice drinks and 
whole fruits. Their common molecular structure of a two phenyl rings and a heterocyclic ring 
makes them potential substrates for a range of drug metabolising enzymes and drug transporters 
(Middleton et al., 2000) (Morris and Zhang, 2006). As such, it is not surprising that they have 
been linked with a number of DDIs, perhaps most famously grapefruit juice and the 
antihistamine terfenadine (Kane and Lipsky, 2000). While the inhibition studies was originally 
focused on drug metabolising enzymes, and most notably CYP3A4 (Dresser et al., 2000), it 
has become increasingly clear that inhibition of ABC transporter can have a significant impact 
(Morris and Zhang, 2006). To examine this, hesperidin and naringin were prepared at 0 to 
1400µg/ml and transport assays were carried out using carboxy dichlorofluorescein diacetate 
as a probe substrate. CDFDA passively diffuses into the cell, whereupon it is metabolised by 
esterase’s to CDF, which is actively effluxed out of the cell by ABC transporters, and in 
particular ABCC sub-family members (Howe et al., 2007).  Increasing amounts of hesperidin 
and naringin were introduced to the over expressing cell lines to measure the amount of 
compound required to inhibit fifty per cent of the transport providing an IC50 constant for each 
compound on each transporter. These IC50 constants generated and shown in table 5.3.1, were 
applied to the estradiol model from chapter 4 and the model was simulated to measure any 
changes in fluxes and see if this were observed with the active transport of any metabolites.  
The flux data and its corresponding heat map showed a reduction of MRP3 transport and loss 
of MRP4 transport, along with increased flux through MRP2 and this indicates a shift from 
basolateral to apical transport of estradiol 17 beta glucuronide in presence of these flavonoids.  
This again confirms that there is capacity within the system to cope with a reduction or loss of 
function of an active process such as ABC protein transport. 
 
Due to the low nanomolar levels of endogenous compounds such as estradiol, it is likely that 
no change in metabolic activity is required to alter the fluxes though state transitions, just 
changes in the flux through active transport pathways (Davison S. L, 2005). The use of 
transport rather than metabolism is favoured as it is both energetically less costly and removes 
the potential to produce excess levels of bioactive/biotoxic compounds. Even at these low 
levels of required capacity, the model predicted a biologically-relevant impact of flavonoid 
intake on estradiol metabolism. However, this impact could be amplified if one considers the 
system capacity required to handle micormolar dosages of therapeutic compounds compared 
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to the nanomolar levels of endogenous chemicals such as estradiol. Under such circumstance, 
an increase of a thousand-fold could see the influence of flavonoids being far more significant 
when looking again at the fluxes through metabolic and transport processes.  The work carried 
out by Erluand et al., 2001 showed ingestion of 8ml/kg of body weight, of grapefruit juice, 
generated naringenin plasma concentrations of 60,000nM with variation as much as ± 
54,000nM however; the study also indicated a short half-life of these compounds within the 
plasma of 1.3 – 2.2 hours.  This indicates the influence of flavonoids on ADME is probably 
short term with intake, and on further development of the model the half-life of the compound 
could be taken into account.  Flavonoids have been well studied for their anti-carcinogenic role, 
such as the role of soy isoflavone as safe functional ingredients for replacement of traditional 
estrogen therapy (Song et al., 2007), and have been determined to be estrogenic in nature. By 
mimicking estrogens and they have been shown to impair activation of signalling pathways 
from estrogen receptors and could reduce estrogen induced proliferation (Virgili et al., 2004) 
and possibly influence estrogen homeostasis.  This work, therefore, further strengthens the need 
to study and incorporate drug transport in predictive models of ADME. 
 
The model as developed takes into account inhibition of active efflux processes by flavonoids 
and therefore it may under-represent the state transitions observed in vivo.  In a real human 
situation the flavonoids may not just impact upon transport but could also influence enzyme 
activity. To assess these kinetic assays would need to be carried out and aimed at specific state 
transitions.  This could then be analysed under the same flavonoid conditions as with the 
transporter experiments and applied to the estradiol model to assess the overall impact on 
estradiol ADME.  Flavonoids could also be impacting upon nuclear receptor activity which 
would in turn influence the metabolic enzyme and transporter expression. Once such an 
integrated model of the impact of flavonoids on drug transporters and drug metabolising 
enzymes is created, their true impact on xenobiotic metabolism will be predicted. It can, 
therefore, be seen that to create truly useful, predictive models of drug metabolism it is vital 
that small models are combined to form multi-scale models that represent more complex 
biological organisations (e.g, tissues, organs), until ultimately the digital human is 
reconstructed (Kolodkin et al., 2012) 
 
In contrast to the described adverse DDIs associated with flavonoids (Kane and Lipsky, 2000), 
and increasing body of evidence also supports their role in protection against toxic xenobiotics 
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and slowing/preventing disease progression (Middleton et al., 2000). One real potential in the 
field of systems biology (and systems toxicology) is the ability to use computational models to 
examine a large set of scenarios. Thus, the creation of these smaller models, and their 
maturation into digital organisms, will aid the resolution of the risk:benefit analysis of dietary 
flavonoid consumption (Lambert et al., 2007). 
 
The potential influence and health benefits offered by flavonoids are also contested due to the 
level of intestinal metabolism they undergo, potentially limiting their concentration before they 
are absorbed into the circulation (Chen et al., 2003).  Due to this first-pass effect, flavonoids 
are found in tissues in low micromolar to high nanomolar concentrations, and due to the 
lipophilic nature of the parent compounds are, generally, found circulating in their o-
methylated and glucuronidated forms (Ross and Kasum, 2002).  Within plant cells, flavonoids 
are also predominantly in their conjugated forms, to increase their solubility in the aqueous 
cellular milieu and enable their protective role(s) within the plant (Brunetti et al., 2013).  Given 
the conjugated nature of the main proportion of flavonoids in plants, these flavonoids will be 
predominantly consumed through our diets in their conjugated form, which will reduce the 
level of flavonoid obtainable from our diet. This makes the option of supplementation with 
these parent compounds more desirable for individuals wanting the health benefits associated 
with their consumption, such as cancer prevention (Middleton et al., 2000).  However, the 
potential benefits of flavonoid supplementation must be weighed against the fact that they, 
along with all food constituents, are regulated as food components and not therapeutic agents. 
As such they are not subject to the same rigorous examination of potential DDIs. As 
demonstrated in this thesis, there is a real concern of negative DDIs, with alterations to fluxes 
predicted in in this model where the ADME properties of only a single chemical is considered.  
It is possible that on applying this to a multi-scale system, which takes into account multiple 
chemicals as seen in the in vivo system, would show a greater influence of flavonoids on drug 
metabolism and a larger risk of drug toxicity. 
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6.0 Discussion and Future Work 
6.1 Discussion 
At the beginning of this project it was hypothesised that the transport and metabolism processes 
in ADME, are balanced to allow for the efficient handling of both endogenous and xenobiotics 
substrates into the excreta and systemic circulation. To address this hypothesis this project 
investigated the influence of ABC transporters on ADME of estradiol, and has utilised both 
computational and wet lab experiments. This has been achieved in two stages the first being 
the development of an in silico model to represent the metabolism and transport of estradiol 
within a hepatocyte. The second being analysis of the transporters MRP3 and MRP4 in over 
expressing cell lines and the inhibitory potential of dietary flavonoids and their impact on 
ADME of estradiol. 
It is now well recognised that the ADME properties of a chemical entity in-vitro don’t 
extrapolate accurately to an in-vivo model, and that the animal species used in-vivo do not 
robustly extrapolate to what is seen with humans.  We also see large intra-model variability, 
producing further problems when extrapolating drug ADME data into a human model (Yu and 
Adedoyin, 2003). Given the large volumes of data collected from the analysis of individual 
enzymes and transporters from different in-vitro and in-vivo experiments, often referred to as 
the ‘data deluge’, one of the most efficient methods for analysing the ADME properties of any 
chemical will be computational models.  For example, it has become common practice in drug 
discovery to use PBPK models to predict a drug candidates pharmacokinetic parameters, along 
with the plasma and tissue concentration-time profiles which can be used to assess the 
therapeutic dosage levels.  With such models already in place, increasing their scope to be able 
to predict potential ADME-toxicities during the initial development phases could help decrease 
attrition rates and costs (Smith, 2013). A significant advantage of in silico model approaches 
is the removal (or reduction) of time consuming in vivo and in vitro biological screening, and 
better direction of the biological work that is carried out.  With high throughput screening 
methods available, generated data could be entered into multi-scale models and these could in-
turn become sophisticated replacements for these other experimental models (van de 
Waterbeemd and Gifford, 2003). 
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In the first phase of the study an ODE-based model of estradiol disposition in the liver was 
generated, capable of recapitulating the fate of estradiol in vivo.  Experimentally-derived data 
from the literature was used to populate the kinetic parameters for the model. The generated 
system was validated using an LC-MS/MS analysis of in-vitro samples, demonstrating that the 
model was able to reproduce changes in the levels of estradiol and estrone seen over an eight 
hour time course.  To enable this work an LC-MS/MS method for analysis of estrone and 
estradiol in cell culture samples was also developed, which removed the need of sample 
derivitisation, reducing the safety risk associated with carrying out the procedure.  For the 
purposes of this study there was sufficient sensitivity to detect the changing levels of these 
estrogens in cell samples; however, with more time and funding the scope of this methodology 
could have been improved making it fully quantitative and capable of detecting other 
metabolites of interest from the model, such as estrone 3 sulphate which has shown to be a key 
pathway in estradiol elimination.  
With this model a robust identification of key pathways of flux in the metabolic and transport 
processes of estradiol could be generated.  Crucially, it has been possible to look at the 
influence of the individual enzymes and transporters on the system, and it is clear that both 
metabolism and transport work together to allow efficient response to changes in protein levels, 
without compromising estradiol elimination.  In addition, this has also been shown in the 
presence of flavonoid compounds, where there is loss of MRP4-mediated transport for the 
estradiol glucuronide, with fluxes directed elsewhere. 
With a much better quality of public health, and increased knowledge of medical conditions 
and how to treat them, life expectancy has now increased dramatically. This is leading to a 
large, ageing population with a range of health challenges, and increasingly subject to 
polypharmacy. For example, people of age of 65 and over are often taking a multitude of 
prescribed drugs such as statins, blood pressure medications, and we are also seeing a rise in 
metabolic disorders such as diabetes, leading to more people taking insulin sensitising 
medications. It has been reported that on average a person aged 65 and over are taking at least 
six prescribed medications, along with common self-prescription of vitamin supplements taken 
to help support a healthy diet, making the issue of drug-drug interactions a prevalent one 
(Gallagher and O’Mahony, 2008).  It is thus imperative that we build comprehensive predictive 
models underpinned by the extensive knowledge base to allow for the robust examination of 
the potential impact of polypharmacy.  
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Analysis of the impact of dietary flavonoids on transport of estradiol in this model, suggests a 
selective impact on drug transport processes. Essentially, there is a complete loss of MRP4-
mediated transport, while MRP2, 3, MDR1 and BCRP-mediated transport is unaffected.  This 
imbalance in transport is compensated for by flux being re-directed through the apical 
transporters. Such a re-direction of flux has been observed in previous experimental models, 
such as the work by Hirouchi et al. (2009) with triple transfected cells with OATP1B1, MRP2 
and MRP3 and loss of MRP2 seeing fluxes re-directed through MRP3 transport. This flavonoid 
impact could become more significant when there ae a multitude of chemicals present able to 
influence other potential DDIs or those also requiring clearance from the system. Together, 
these data are consistent with our hypothesis that the metabolism-transport system is robust, 
being able to compensate for reduction/loss of any single component. While this may not hold 
for proteins with high control coefficients, such as HMGCoA reductase (cc=0.5), for the 
majority of proteins, which have low control coefficients, this clearly demonstrates the 
designed redundancy within biological networks. Such redundancy may well be an essential 
part of biological survival, enabling organisms to survive in an ever-changing chemical soup.   
 
6.2 Future Work 
One of the routes to be followed on from this project would firstly be continuing the expansion 
of the model.  As this model stands it provides a simple snapshot of ADME transitions 
providing guidance in predicting estradiol fate, whilst not being completely accurate. In this 
work the influence of non-drug chemicals, flavonoids, were measured on  transport efficiency 
of MRP2, 3 and 4, with complete loss of MRP4 being observed at high naringin and hesperidin 
levels, which could be achieved with additional  dietary supplementation.  Adding further scale 
to the model will aid in the improvement of the predictive response possible and better analysis 
of flavonoid impact on whole cell ADME.  The same flavonoid analysis applied to calculate 
IC50 values for transport activity, could also be carried out in metabolic enzyme assays, to 
measure for inhibition of activity and applied to the model.  To improve the dynamics of the 
model addition of nuclear receptor function could be used to allow the inclusion of up-
regulation of ADME genes by both endogenous and exogenous signals, for example the 
induction of PXR by rifampicin and its influence of CYP enzymes, allowing a more realistic 
cellular response.  It could also provide the opportunity to look at scenarios of multiple drug 
use where DDIs and CDIs are a more significant concern, however such a model may be better 
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achieved using programmes such as hepatonet1 or Quasi-Steady State Petri Nets (QSSPN).  
These both enable study of metabolic processes at steady state conditions, as has been carried 
out in this work with cell designer, however it enables development of a more powerful model 
with multiple levels and many more species and reactions. This genome scale metabolic 
reconstruction allows development of a model to achieve analysis of not only basic metabolic 
and transport flux, but both nuclear receptor and gene regulation and the resulting fluxes 
through their stimulation and inhibition (Fisher et al., 2013).  
As mentioned in chapter 5, due to time constraints construction of the Rattus norvegicus MRP3 
and MRP4 was not completed.  The second aspect of the project which could be continued with 
more time, is the generation of stable transfects to carry out a species comparison of human 
and this regularly used animal model.  A result of this work showed us a loss of human MRP4 
transport activity when in silico simulations were run in the presence of these flavonoids, 
however it is unknown if the same response would be seen with rat MRP4. Studies have shown 
that MRP2 substrate efflux can be fourfold higher in rat hepatocytes compared to human 
hepatocytes, attributed to the species specific functional differences. The same work also 
showed that BCRP efflux of pheophorbide A in human and dog hepatocytes was similar but 
appears limited in monkey and rat hepatocytes (Li et al., 2008).  With these differences 
documented within apical transporters, it can be expected similar differences in activities for 
MRP3 and MRP4 transporters would also be observed between species and therefore potential 
drug toxicities may not get detected in the pre-clinical stages.  This leaves us with the same 
issues currently experienced by the pharmaceutical industry, where potential DDIs or CDIs 
may not get picked up till human trials or until the drug has received market authorisation.  
With these supplements unregulated by drug authorities and no guidance provided for safe use 
they present a viable threat to drug safety, which could be addressed earlier with the use of a 
dynamic ADME model and fall in line with a reduction, refinement and replacement of animal 
models during the design process.  
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8.0 Appendix 
8.1  Primer Design 
 
 
 
 
 
 
 
 
Table 8.1. 1 Primers designed, whilst using Vector NTi, to amplify the three fragments for 
Abcc3 and Abcc4 decided upon in the cloning strategy in 2.1.1; Forward (FWD) and Reverse 
(REV) primer sequences are shown along with their percentages of GC content and the TM (oC), 
primer length and their position within the gene sequence, which was obtained from the NCBI 
database. There are also nested PCR primers indicated with (N). 
  Primer Length Sequence 
Gene 
Position GC TM 
Abcc3          %  oC 
Fragment 1  FWD  22 TGAACTGAATTCCCAAGACCAG  10-31 45.5 58.4 
  REV  18 GACAGGTACCCGAAGGCC   1746-1763 66.7 60.5 
Fragment 2  FWD   20 GGTGACCCTGATCACCCTCG  1680-1699 65 63.5 
  REV  20 GGGCGTCGTTTCGAAGAAGG 3209-3228 60 61.4 
Fragment 3  FWD  22 GGACCAATGATGTGGAGGAACA 3020-3044 50 60.3 
  REV   18 TCCATGCGGCCGCTACTT 4664-4681 61.1 58.2 
Abcc4             
Fragment 1 FWD   20 ATGCTGCCGGTGCACACCGA 1-20 65 63.5 
  REV  24 GCGGTGAATTCTTGCACGTGAACG 1227-1250 54.2 64.4 
Fragment 2  FWD  21 GTCAGCGTTCGGAGGATCAAG 1141-1161 57.1 56.1 
  REV  20 CCGATGTCCTTGGAGAAACG  2470-2489 55 54.4 
Fragment 3  
  
FWD(N)  20 GTCCTTGTGAATGCTTCCCA   50 52.3 
  REV(N) 18 TCCAAAGACGCCGGTCTC   61.1 53.2 
  FWD  25 CTGAAGGCACCGGTGTTGTTCTTCG 2416-2440 56 66.3 
  REV  24 TAAGAAGTGCGGCCGCCTTGTTGG 4022-4045 58.3 66.1 
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8.2  p.TriEx 1.1 
 
 
 
Figure 8.1. 1 pTriEx1.1 Cloning Vector: The pTriEx1.1 cloning vector has a malleable 
multiple cloning site and has also a gene for ampicillin resistance, allowing for growth of 
competent cells containing the plasmid, on LB agar and ampicillin plates. 
 
 
 
 
 
 
 
pTriEx1.1
5301 bp
ampicil lin
MCS
CMV Enh ancer
His tag
HSV tag
lac operator
lef-2
1629
pTriEx-Down
T7 promoter primer
chicken actin  promoter
T7 promoter
p10 promoterT7 termin ator
rab bit g lobin  terminator exon 2
exon 1
NsiI (185)
NsiI (1446)
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8.3  pCR Blunt II TOPO 
 
 
Figure 8.1. 2 Zero Blunt TOPO PCR Cloning Vector: The pCR Blunt II Topo vector is 
provided in its linearised form and the blunt cloning site, where the fragment is inserted, is at 
the StuI site between two EcoRI sites as shown above.  When a fragment is inserted into the 
site it disrupts the interaction between the LacZα and ccdB genes, it also has a kanamycin 
resistance gene and these factors allow for its growth, producing a colony on the LB and 
Kanamycin Plate. 
 
 
 
 
 
 
 
 
